
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="152544D18AF30D330544D10001BD084E.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="fsn">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Food Science &amp; Nutrition">
<meta name="citation_title" content="Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review">
<meta name="citation_author" content="Mohammad Yasin Zamanian">
<meta name="citation_author_institution" content="Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran">
<meta name="citation_author_institution" content="Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran">
<meta name="citation_author" content="Klavdiya A Turkadze">
<meta name="citation_author_institution" content="Department of Infectious Diseases of Institute of Public Health Named After F.F. Erisman, I.M. Sechenov First Moscow State Medical University of the Russian Federation (Sechenov University), Moscow, Russia">
<meta name="citation_author" content="Mehraveh Sadeghi Ivraghi">
<meta name="citation_author_institution" content="School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran">
<meta name="citation_author" content="Maryam Golmohammadi">
<meta name="citation_author_institution" content="School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran">
<meta name="citation_author" content="Maryam Sharifi">
<meta name="citation_author_institution" content="MPH, American International University Bangladesh (AIUB), Dhaka, Bangladesh">
<meta name="citation_author" content="Zahra Keshtpour Amlashi">
<meta name="citation_author_institution" content="Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran">
<meta name="citation_publication_date" content="2025 Aug 25">
<meta name="citation_volume" content="13">
<meta name="citation_issue" content="9">
<meta name="citation_firstpage" content="e70829">
<meta name="citation_doi" content="10.1002/fsn3.70829">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/pdf/FSN3-13-e70829.pdf">
<meta name="description" content="Lung cancer, primarily consisting of nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant health challenge despite advancements in treatment. This comprehensive review investigates the therapeutic potential of ...">
<meta name="og:title" content="Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Lung cancer, primarily consisting of nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant health challenge despite advancements in treatment. This comprehensive review investigates the therapeutic potential of ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12376182">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/fsn3.70829"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/FSN3-13-e70829.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12376182%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12376182/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12376182/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-fsn.gif" alt="Food Science &amp; Nutrition logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Food Science &amp; Nutrition" title="Link to Food Science &amp; Nutrition" shape="default" href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%292048-7177" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Food Sci Nutr</button></div>. 2025 Aug 25;13(9):e70829. doi: <a href="https://doi.org/10.1002/fsn3.70829" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/fsn3.70829</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Food%20Sci%20Nutr%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Food%20Sci%20Nutr%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Food%20Sci%20Nutr%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Food%20Sci%20Nutr%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zamanian%20MY%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mohammad Yasin Zamanian</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Mohammad Yasin Zamanian</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zamanian%20MY%22%5BAuthor%5D" class="usa-link"><span class="name western">Mohammad Yasin Zamanian</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Turkadze%20KA%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Klavdiya A Turkadze</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Klavdiya A Turkadze</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Infectious Diseases of Institute of Public Health Named After F.F. Erisman, I.M. Sechenov First Moscow State Medical University of the Russian Federation (Sechenov University), Moscow, Russia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Turkadze%20KA%22%5BAuthor%5D" class="usa-link"><span class="name western">Klavdiya A Turkadze</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sadeghi%20Ivraghi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Mehraveh Sadeghi Ivraghi</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Mehraveh Sadeghi Ivraghi</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sadeghi%20Ivraghi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mehraveh Sadeghi Ivraghi</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Golmohammadi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Maryam Golmohammadi</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Maryam Golmohammadi</span></h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Golmohammadi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maryam Golmohammadi</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sharifi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Maryam Sharifi</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Maryam Sharifi</span></h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>MPH, American International University Bangladesh (AIUB), Dhaka, Bangladesh</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sharifi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maryam Sharifi</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Keshtpour%20Amlashi%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Zahra Keshtpour Amlashi</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Zahra Keshtpour Amlashi</span></h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Keshtpour%20Amlashi%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zahra Keshtpour Amlashi</span></a>
</div>
</div>
<sup>7,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="fsn370829-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran</div>
<div id="fsn370829-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran</div>
<div id="fsn370829-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Infectious Diseases of Institute of Public Health Named After F.F. Erisman, I.M. Sechenov First Moscow State Medical University of the Russian Federation (Sechenov University), Moscow, Russia</div>
<div id="fsn370829-aff-0004">
<sup>
<sup>4</sup>
</sup>School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran</div>
<div id="fsn370829-aff-0005">
<sup>
<sup>5</sup>
</sup>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</div>
<div id="fsn370829-aff-0006">
<sup>
<sup>6</sup>
</sup>MPH, American International University Bangladesh (AIUB), Dhaka, Bangladesh</div>
<div id="fsn370829-aff-0007">
<sup>
<sup>7</sup>
</sup>Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Mohammad Yasin Zamanian (<span>m.zamanian@umsha.ac.ir</span>; <span>mzamaniyan66@yahoo.com</span>), 
Zahra Keshtpour Amlashi (<span>z.keshtpour@edu.umsha.ac.ir</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 22; Received 2025 Mar 31; Accepted 2025 Aug 12; Collection date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Food Science &amp; Nutrition</em> published by Wiley Periodicals LLC.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12376182</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Lung cancer, primarily consisting of nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant health challenge despite advancements in treatment. This comprehensive review investigates the therapeutic potential of natural compounds curcumin (CUR) and resveratrol (RES) in targeting the STAT3 signaling pathway, which plays a crucial role in lung cancer progression and metastasis. Specifically, CUR inhibits STAT3 phosphorylation and activation in lung cancer cells, leading to a 40%–60% reduction in tumor size and a significant decrease in the expression of STAT3 target genes such as cyclin D1, VEGF, MMP2, and MMP9. RES demonstrates similar effects by suppressing STAT3 signaling, resulting in a 30%–50% reduction in tumor growth and a marked decrease in the M2 polarization of tumor‐associated macrophages, thereby disrupting the communication between cancer cells and the tumor microenvironment. CUR analogues, such as L48H37 and compound 5 k, also exhibit anticancer effects by blocking the STAT3 pathway. L48H37 suppresses the motility, migration, and invasion of human osteosarcoma cells by inhibiting the JAK/STAT pathway and urokinase plasminogen activator (uPA) expression. Compound 5 k inhibits NSCLC cell growth by regulating the NF‐κB/STAT3 signaling pathways. RES inhibits STAT3 activation and downstream signaling in NSCLC cells, reducing cell migration and invasion while increasing apoptosis by 20%–30%. In vivo studies show that RES can suppress tumor growth by 40%–50% by inhibiting the STAT3/HIF‐1α/VEGF axis. RES also shows promise in overcoming drug resistance in SCLC by inhibiting the STAT3/VEGF pathway and P‐glycoprotein function, potentially resensitizing resistant cells to chemotherapy. These findings underscore the potential of CUR and RES as promising therapeutic agents against lung cancer by targeting the STAT3 signaling pathway and related processes such as angiogenesis, metastasis, and drug resistance. Further research is needed to optimize their bioavailability, understand their molecular mechanisms, and assess their clinical efficacy in combination with standard therapies.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> curcumin, JAK2/STAT3 signaling pathway, lung cancer, resveratrol, STAT3</p></section></section><section class="abstract" id="abstract2"><hr class="headless">
<p>The STAT3 pathway plays a crucial role in lung cancer by regulating cell proliferation, survival, angiogenesis, invasion, and metastasis. CUR and RES have emerged as potential therapeutic agents due to their ability to inhibit the STAT3 pathway, reducing tumor growth, angiogenesis, migration, and invasion.</p>
<section class="bt xbox font-sm" id="fsn370829-blkfxd-0001"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6962/12376182/36c1d06caff2/FSN3-13-e70829-g001.jpg" loading="lazy" id="jats-graphic-1" height="226" width="331" alt="graphic file with name FSN3-13-e70829-g001.jpg"></p></section></section><hr class="headless">
<h3>Abbreviations</h3>
<dl class="def-list" id="fsn370829-dl-0001">
<dt id="fsn370829-li-0001">CD105</dt>
<dd id="fsn370829-li-0002"><p>cluster of differentiation 105</p></dd>
<dt id="fsn370829-li-0003">CD31</dt>
<dd id="fsn370829-li-0004"><p>cluster of differentiation 31</p></dd>
<dt id="fsn370829-li-0005">EGFR</dt>
<dd id="fsn370829-li-0006"><p>epidermal growth factor receptor</p></dd>
<dt id="fsn370829-li-0007">FGFR</dt>
<dd id="fsn370829-li-0008"><p>fibroblast growth factor receptor</p></dd>
<dt id="fsn370829-li-0009">GHET1</dt>
<dd id="fsn370829-li-0010"><p>gastric carcinoma proliferation enhancing transcript 1</p></dd>
<dt id="fsn370829-li-0011">HIF‐1α</dt>
<dd id="fsn370829-li-0012"><p>hypoxia‐inducible factor 1‐alpha</p></dd>
<dt id="fsn370829-li-0013">HOTAIR</dt>
<dd id="fsn370829-li-0014"><p>HOX transcript antisense RNA</p></dd>
<dt id="fsn370829-li-0015">ICAM‐1</dt>
<dd id="fsn370829-li-0016"><p>intercellular adhesion molecule 1</p></dd>
<dt id="fsn370829-li-0017">IGFR</dt>
<dd id="fsn370829-li-0018"><p>insulin‐like growth factor receptor</p></dd>
<dt id="fsn370829-li-0019">IL‐10R</dt>
<dd id="fsn370829-li-0020"><p>interleukin‐10 receptor</p></dd>
<dt id="fsn370829-li-0021">IL‐6</dt>
<dd id="fsn370829-li-0022"><p>interleukin‐6</p></dd>
<dt id="fsn370829-li-0023">MALAT1</dt>
<dd id="fsn370829-li-0024"><p>metastasis associated lung adenocarcinoma transcript 1</p></dd>
<dt id="fsn370829-li-0025">MMP2</dt>
<dd id="fsn370829-li-0026"><p>matrix metalloproteinase‐2</p></dd>
<dt id="fsn370829-li-0027">MMP9</dt>
<dd id="fsn370829-li-0028"><p>matrix metalloproteinase‐9</p></dd>
<dt id="fsn370829-li-0029">NF‐ĸB</dt>
<dd id="fsn370829-li-0030"><p>nuclear factor kappa B</p></dd>
<dt id="fsn370829-li-0031">PD‐1</dt>
<dd id="fsn370829-li-0032"><p>programmed cell death protein 1</p></dd>
<dt id="fsn370829-li-0033">PD‐L1</dt>
<dd id="fsn370829-li-0034"><p>programmed cell death ligand 1</p></dd>
<dt id="fsn370829-li-0035">PIAS</dt>
<dd id="fsn370829-li-0036"><p>protein inhibitor of activated STAT3</p></dd>
<dt id="fsn370829-li-0037">PTPs</dt>
<dd id="fsn370829-li-0038"><p>protein tyrosine phosphatases</p></dd>
<dt id="fsn370829-li-0039">SHP‐1</dt>
<dd id="fsn370829-li-0040"><p>SH2 domain‐containing protein tyrosine phosphatase 1</p></dd>
<dt id="fsn370829-li-0041">SOCS</dt>
<dd id="fsn370829-li-0042"><p>suppressor of cytokine signaling</p></dd>
<dt id="fsn370829-li-0043">VEGF</dt>
<dd id="fsn370829-li-0044"><p>vascular endothelial growth factor</p></dd>
</dl>
<section id="fsn370829-sec-0001"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Lung cancer is a significant public health concern due to its high mortality rate. The incidence of new lung cancer cases is substantially higher compared to other cancer types (Sung et al. <a href="#fsn370829-bib-0127" class="usa-link" aria-describedby="fsn370829-bib-0127">2021</a>). The age‐standardized incidence rate (ASIR) of lung cancer varies considerably across countries, ranging from 36.8 per 100,000 in Denmark to 5.9 per 100,000 in Mexico, with men generally having twice the incidence rate compared to women (Li et al. <a href="#fsn370829-bib-0073" class="usa-link" aria-describedby="fsn370829-bib-0073">2023</a>). Despite overall declining trends in many developed countries, lung cancer incidence is projected to reach 3.8 million annual cases globally by 2050, largely due to population growth and aging, as well as increasing tobacco use and air pollution in low‐ and middle‐income countries (Sharma <a href="#fsn370829-bib-0117" class="usa-link" aria-describedby="fsn370829-bib-0117">2022</a>).</p>
<p>Smoking is the primary etiological factor for lung cancer, accounting for approximately 80% of deaths associated with this disease. Other risk factors include exposure to radon and asbestos, as well as prolonged and cumulative exposure to air pollution, particularly emissions containing polycyclic aromatic hydrocarbons (PAHs). Additionally, a personal or family history of lung cancer further increases the risk associated with this disease (Brüske‐Hohlfeld <a href="#fsn370829-bib-0016" class="usa-link" aria-describedby="fsn370829-bib-0016"><sup>2009</sup></a>; Quazi and Malik <a href="#fsn370829-bib-0109" class="usa-link" aria-describedby="fsn370829-bib-0109"><sup>2022</sup></a>).</p>
<p>According to the World Health Organization (WHO), lung tumors are divided into two main types. Nonsmall cell lung cancer (NSCLC) accounts for 80%–85% of all lung cancer cases, while small cell lung cancer (SCLC) makes up the remaining 15% (Li, Yuan, et al. <a href="#fsn370829-bib-0076" class="usa-link" aria-describedby="fsn370829-bib-0076"><sup>2016</sup></a>; Molina et al. <a href="#fsn370829-bib-0094" class="usa-link" aria-describedby="fsn370829-bib-0094"><sup>2008</sup></a>; Travis et al. <a href="#fsn370829-bib-0135" class="usa-link" aria-describedby="fsn370829-bib-0135"><sup>2015</sup></a>). Current research indicates that more effective methods need to be developed to either cure or manage advanced‐stage lung cancers. This is necessary even with existing anticancer strategies such as surgery, chemotherapy, and radiation used for treating NSCLC and SCLC. Ongoing efforts are crucial to overcoming the challenges posed by advanced lung cancer and improving patient outcomes (Alexander et al. <a href="#fsn370829-bib-0002" class="usa-link" aria-describedby="fsn370829-bib-0002">2020</a>; Yasumoto et al. <a href="#fsn370829-bib-0161" class="usa-link" aria-describedby="fsn370829-bib-0161"><sup>2009</sup></a>). Despite significant medical advancements, resistance to important anticancer drugs, such as Paclitaxel (PTX), leads to treatment failure and recurrence of NSCLC (Sosa Iglesias et al. <a href="#fsn370829-bib-0123" class="usa-link" aria-describedby="fsn370829-bib-0123">2018</a>; Zhu and Chen <a href="#fsn370829-bib-0174" class="usa-link" aria-describedby="fsn370829-bib-0174"><sup>2019</sup></a>), presenting significant clinical challenges (Cui et al. <a href="#fsn370829-bib-0028" class="usa-link" aria-describedby="fsn370829-bib-0028">2020</a>). Immunotherapy, particularly immune checkpoint blockade (ICB), represents a new therapeutic approach with the potential to improve overall survival outcomes for individuals with lung cancer (Zhou, Qiao, and Zhou <a href="#fsn370829-bib-0171" class="usa-link" aria-describedby="fsn370829-bib-0171"><sup>2021</sup></a>). The urgent need for alternative strategies to enhance existing treatments or introduce new ones has become increasingly clear. Clinicians prioritize treatment goals to alleviate pain and improve the quality of life. In recent years, numerous plant extracts have been recognized as potential therapies for lung cancer, gaining greater increasing acceptance from patients. Curcumin (CUR), a polyphenolic compound derived from turmeric root, possesses various pharmacological properties, including antioxidant, anti‐inflammatory, and anticancer effects. These characteristics make it a promising candidate for treating cancer, neurodegenerative diseases, and cardiovascular diseases (Dehzad et al. <a href="#fsn370829-bib-0031" class="usa-link" aria-describedby="fsn370829-bib-0031">2023</a>; Peng et al. <a href="#fsn370829-bib-0103" class="usa-link" aria-describedby="fsn370829-bib-0103"><sup>2021</sup></a>; Wong et al. <a href="#fsn370829-bib-0148" class="usa-link" aria-describedby="fsn370829-bib-0148"><sup>2021</sup></a>; Lo Cascio et al. <a href="#fsn370829-bib-0083" class="usa-link" aria-describedby="fsn370829-bib-0083"><sup>2021</sup></a>; Cox et al. <a href="#fsn370829-bib-0027" class="usa-link" aria-describedby="fsn370829-bib-0027"><sup>2022</sup></a>). Other studies have shown that CUR inhibits cancer cell proliferation, metastasis, and promotes apoptosis, supporting its potential effectiveness as an anticancer agent (Man et al. <a href="#fsn370829-bib-0086" class="usa-link" aria-describedby="fsn370829-bib-0086">2018</a>; Wang et al. <a href="#fsn370829-bib-0145" class="usa-link" aria-describedby="fsn370829-bib-0145"><sup>2018</sup></a>).</p>
<p>Resveratrol (RES), a polyphenolic stilbene derivative found in grapes, red wine, and other plant sources, has garnered significant interest due to its antineoplastic properties (Ko et al. <a href="#fsn370829-bib-0065" class="usa-link" aria-describedby="fsn370829-bib-0065">2017</a>; Robertson et al. <a href="#fsn370829-bib-0112" class="usa-link" aria-describedby="fsn370829-bib-0112"><sup>2022</sup></a>). It exhibits a wide range of cellular and molecular effects, making it a promising candidate for the prevention and treatment of various cancers, including breast, prostate, lung, pancreatic, liver, and colorectal cancers, among others. Furthermore, it demonstrates antioxidant, anti‐inflammatory, and neuroprotective properties (Meng et al. <a href="#fsn370829-bib-0089" class="usa-link" aria-describedby="fsn370829-bib-0089">2020</a>; Honari et al. <a href="#fsn370829-bib-0051" class="usa-link" aria-describedby="fsn370829-bib-0051"><sup>2019</sup></a>; Kundu and Surh <a href="#fsn370829-bib-0067" class="usa-link" aria-describedby="fsn370829-bib-0067"><sup>2008</sup></a>; Yousef, Vlachogiannis, and Tsiani <a href="#fsn370829-bib-0163" class="usa-link" aria-describedby="fsn370829-bib-0163"><sup>2017</sup></a>). The interactions between RES and cellular signaling pathways involved in apoptosis, cell cycle regulation, inflammation, angiogenesis, and metastasis demonstrate its anticarcinogenic properties (Ko et al. <a href="#fsn370829-bib-0065" class="usa-link" aria-describedby="fsn370829-bib-0065">2017</a>; Athar et al. <a href="#fsn370829-bib-0012" class="usa-link" aria-describedby="fsn370829-bib-0012"><sup>2009</sup></a>). For example, it inhibits the expression of oncogenes, activates tumor growth‐limiting genes, and regulates the functioning of transcription factors (Xu, Deng, et al. <a href="#fsn370829-bib-0158" class="usa-link" aria-describedby="fsn370829-bib-0158"><sup>2021</sup></a>; Zhang et al. <a href="#fsn370829-bib-0168" class="usa-link" aria-describedby="fsn370829-bib-0168"><sup>2022</sup></a>).</p>
<p>The majority of NSCLC patients exhibit abnormally high levels of signal transducer and activator of transcription 3 (STAT3) overexpression, which is an essential component of the JAK–STAT pathway (Mohrherr et al. <a href="#fsn370829-bib-0092" class="usa-link" aria-describedby="fsn370829-bib-0092">2020</a>). STAT3 can be phosphorylated by various inflammatory mediators and subsequently translocate to the nucleus, where it regulates the transcription of specific genes (Johnson et al. <a href="#fsn370829-bib-0059" class="usa-link" aria-describedby="fsn370829-bib-0059">2018</a>).</p>
<p>Overactivation of STAT3 is also attributed to the presence of cancer stem cells (CSCs) or tumor‐initiating cells (TICs), which contribute to drug resistance, tumor metastasis, and recurrence (Prasetyanti and Medema <a href="#fsn370829-bib-0107" class="usa-link" aria-describedby="fsn370829-bib-0107">2017</a>). Both CUR and RES have been found to suppress STAT3 activity, suggesting their potential as therapeutic agents against lung cancer (Yousef, Vlachogiannis, and Tsiani <a href="#fsn370829-bib-0163" class="usa-link" aria-describedby="fsn370829-bib-0163"><sup>2017</sup></a>; Wan Mohd Tajuddin et al. <a href="#fsn370829-bib-0140" class="usa-link" aria-describedby="fsn370829-bib-0140"><sup>2019</sup></a>; Ashrafizadeh, Najafi, et al. <a href="#fsn370829-bib-0010" class="usa-link" aria-describedby="fsn370829-bib-0010"><sup>2020</sup></a>). Yang et al. noted that CUR can inhibit IL‐6‐inducible STAT3 phosphorylation in a dose‐ and time‐dependent manner, further suggesting its potential as a therapeutic agent for targeting the IL‐6/JAK/STAT3 pathway in treating SCLC (Yang et al. <a href="#fsn370829-bib-0159" class="usa-link" aria-describedby="fsn370829-bib-0159">2012</a>). Another study showed that CUR can reduce tumors by blocking the JAK2/STAT3 signaling pathway, indicating its potential for lung cancer treatment (Wu et al. <a href="#fsn370829-bib-0150" class="usa-link" aria-describedby="fsn370829-bib-0150">2015</a>). Additionally, RES exerts anticancer effects by inhibiting STAT3 signaling, further indicating its potential as a therapeutic agent for NSCLC (Li, Wang, et al. <a href="#fsn370829-bib-0077" class="usa-link" aria-describedby="fsn370829-bib-0077"><sup>2016</sup></a>).</p>
<p>It is crucial to emphasize that CUR and RES are not proposed as replacements for established anticancer drugs, but rather as complementary agents that could potentially enhance treatment efficacy, reduce side effects, and help address the challenge of drug resistance. The aim of this comprehensive review is to elucidate the therapeutic potential of CUR and RES as dual modulators of the STAT3 pathway in lung cancer. By synthesizing current evidence, we seek to provide insights into the molecular mechanisms, anticancer effects, and future directions for leveraging these natural compounds in lung cancer prevention and treatment strategies.</p></section><section id="fsn370829-sec-0002"><h2 class="pmc_sec_title">2. Methodology</h2>
<p>The methodology consisted of several key steps, beginning with a thorough literature search conducted using multiple electronic databases, including PubMed, Scopus, Google Scholar, ScienceDirect, and the Cochrane Library. The search strategy utilized a combination of appropriate keywords and Medical Subject Headings (MeSH) terms, such as “Curcumin,” “Resveratrol,” “Lung cancer,” “Nonsmall cell lung cancer,” “Small cell lung cancer,” “STAT3,” “Signal Transducer and Activator of Transcription 3,” and “JAK/STAT pathway.” Inclusion criteria for the review encompassed original research articles published in peer‐reviewed journals, studies focusing on curcumin or resveratrol in lung cancer, investigations examining the effects on STAT3 signaling, in vitro, in vivo, and clinical studies, and articles published in English. Exclusion criteria included studies not directly related to lung cancer or STAT3 signaling, conference abstracts, case reports, opinion pieces, and articles not available in full text.</p></section><section id="fsn370829-sec-0003"><h2 class="pmc_sec_title">3. Overview of Current Lung Cancer Treatments</h2>
<p>Lung cancer is the leading cause of oncological mortality globally, with NSCLC accounting for 85% of all diagnosed cases (Petrella et al. <a href="#fsn370829-bib-0104" class="usa-link" aria-describedby="fsn370829-bib-0104">2023</a>). Stage III NSCLC is a heterogeneous group characterized by varying tumor volumes, local diffusion, and lymph node involvement, requiring multimodal treatment approaches (Petrella et al. <a href="#fsn370829-bib-0104" class="usa-link" aria-describedby="fsn370829-bib-0104">2023</a>). The primary treatment modalities include surgery, radiotherapy, and systemic therapies, with radical surgery indicated for hilar or single‐station mediastinal lymph node involvement, potentially following neoadjuvant chemotherapy (Petrella et al. <a href="#fsn370829-bib-0104" class="usa-link" aria-describedby="fsn370829-bib-0104">2023</a>).</p>
<p>Surgery remains a crucial component in the multimodal treatment approach for stage III NSCLC, particularly for cases with hilar or single‐station mediastinal lymph node involvement (Petrella et al. <a href="#fsn370829-bib-0104" class="usa-link" aria-describedby="fsn370829-bib-0104">2023</a>).</p>
<p>Radical surgery is often indicated after neoadjuvant chemotherapy to improve resectability and outcomes. However, the optimal treatment strategy for multistation mediastinal lymph node involvement is still debated, with ongoing research exploring the role of surgery in this setting (Saw et al. <a href="#fsn370829-bib-0116" class="usa-link" aria-describedby="fsn370829-bib-0116">2021</a>; Sinn et al. <a href="#fsn370829-bib-0121" class="usa-link" aria-describedby="fsn370829-bib-0121"><sup>2022</sup></a>). Advancements in imaging techniques and surgical approaches have aided in the resection of early‐stage lesions, potentially improving outcomes for operable cases (Yang et al. <a href="#fsn370829-bib-0160" class="usa-link" aria-describedby="fsn370829-bib-0160">2017</a>).</p>
<p>However, the optimal treatment for multistation mediastinal lymph node involvement remains debated (Petrella et al. <a href="#fsn370829-bib-0104" class="usa-link" aria-describedby="fsn370829-bib-0104">2023</a>). For brain metastases, a common complication in lung cancer, modern stereotactic radiotherapy combined with targeted therapies is changing the therapeutic landscape (Levis et al. <a href="#fsn370829-bib-0072" class="usa-link" aria-describedby="fsn370829-bib-0072">2023</a>).</p>
<p>Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have revolutionized the management of NSCLC by targeting specific genetic mutations, resulting in improved progression‐free survival and personalized treatment approaches (Kaur et al. <a href="#fsn370829-bib-0063" class="usa-link" aria-describedby="fsn370829-bib-0063">2024</a>). However, the development of drug resistance remains a significant challenge, necessitating the exploration of new strategies to overcome this obstacle.</p>
<p>Chemotherapy continues to be a fundamental aspect of lung cancer management, especially in the case of NSCLC. The use of cytotoxic chemotherapy, whether administered as a monotherapy or in conjunction with other therapeutic approaches such as targeted therapies or immunotherapy, has shown significant clinical advantages in enhancing both survival rates and quality of life for patients diagnosed with early‐stage and advanced NSCLC (Lee <a href="#fsn370829-bib-0068" class="usa-link" aria-describedby="fsn370829-bib-0068">2019</a>). Platinum‐based chemotherapy regimens, such as cisplatin or carboplatin combined with drugs like pemetrexed, paclitaxel, or nab‐paclitaxel, are commonly used in the neoadjuvant, adjuvant, and metastatic settings (Forde et al. <a href="#fsn370829-bib-0039" class="usa-link" aria-describedby="fsn370829-bib-0039">2022</a>; Gandhi et al. <a href="#fsn370829-bib-0040" class="usa-link" aria-describedby="fsn370829-bib-0040"><sup>2018</sup></a>). Chemotherapy is advised as a standard treatment option for patients who have experienced disease progression following the administration of targeted therapies, such as tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) (Lee <a href="#fsn370829-bib-0068" class="usa-link" aria-describedby="fsn370829-bib-0068">2019</a>). Combination strategies involving chemotherapy and other treatment modalities, such as immunotherapy (e.g., pembrolizumab plus chemotherapy), are actively being explored to enhance therapeutic efficacy and overcome resistance mechanisms (Gandhi et al. <a href="#fsn370829-bib-0040" class="usa-link" aria-describedby="fsn370829-bib-0040">2018</a>). Neoadjuvant chemotherapy combined with immunotherapy (e.g., nivolumab plus chemotherapy) has shown promising results in improving pathological complete response rates and event‐free survival in resectable NSCLC (Forde et al. <a href="#fsn370829-bib-0039" class="usa-link" aria-describedby="fsn370829-bib-0039">2022</a>). Researchers are investigating new drug delivery systems and combination approaches with photodynamic therapy (PDT) to address drug resistance and enhance the efficacy of chemotherapy in lung cancer treatment (El‐Hussein et al. <a href="#fsn370829-bib-0036" class="usa-link" aria-describedby="fsn370829-bib-0036"><sup>2021</sup></a>). Immunotherapy has significantly altered the therapeutic landscape for advanced or metastatic NSCLC owing to its sustained effectiveness and tolerable side effects (Xu et al. <a href="#fsn370829-bib-0156" class="usa-link" aria-describedby="fsn370829-bib-0156">2023</a>).</p>
<p>ICIs like anti‐PD‐1 (nivolumab, pembrolizumab) and anti‐PD‐L1 (atezolizumab, durvalumab) have become cornerstones in NSCLC treatment, significantly improving patient survival and quality of life (Shen et al. <a href="#fsn370829-bib-0118" class="usa-link" aria-describedby="fsn370829-bib-0118">2023</a>). Anti‐CTLA‐4 inhibitors (ipilimumab) are also being utilized, often in combination with anti‐PD‐1/PD‐L1 agents (Shen et al. <a href="#fsn370829-bib-0118" class="usa-link" aria-describedby="fsn370829-bib-0118">2023</a>; Roque et al. <a href="#fsn370829-bib-0113" class="usa-link" aria-describedby="fsn370829-bib-0113"><sup>2023</sup></a>).</p>
<p>While targeted therapies and immunotherapy have revolutionized lung cancer treatment, chemotherapy remains a fundamental component, particularly in combination strategies, and continues to expand its clinical implications in the era of precision medicine.</p>
<p>Polyphenols, which are compounds naturally found in plants, have demonstrated significant potential as chemopreventive and therapeutic agents for lung cancer (Suvarna et al. <a href="#fsn370829-bib-0129" class="usa-link" aria-describedby="fsn370829-bib-0129">2018</a>). Studies have indicated a negative correlation between the consumption of fruits and vegetables rich in polyphenols and the risk of lung cancer, particularly in high‐risk populations (Amararathna et al. <a href="#fsn370829-bib-0005" class="usa-link" aria-describedby="fsn370829-bib-0005">2016</a>; Wang, Yang, et al. <a href="#fsn370829-bib-0141" class="usa-link" aria-describedby="fsn370829-bib-0141"><sup>2019</sup></a>). These polyphenols possess antioxidant, anti‐inflammatory, and antimutagenic properties, effectively safeguarding against lung carcinogenesis caused by carcinogens and oxidative stress (Amararathna et al. <a href="#fsn370829-bib-0005" class="usa-link" aria-describedby="fsn370829-bib-0005">2016</a>). In addition, they can modulate the activity of phase I and II metabolic enzymes, promoting the detoxification of carcinogens and preventing DNA damage (Amararathna et al. <a href="#fsn370829-bib-0005" class="usa-link" aria-describedby="fsn370829-bib-0005">2016</a>). In both in vitro and in vivo studies, polyphenols have exhibited anticancer effects against lung cancer cells by inhibiting cell proliferation, inducing apoptosis, and regulating cell cycle progression (Amararathna et al. <a href="#fsn370829-bib-0005" class="usa-link" aria-describedby="fsn370829-bib-0005">2016</a>). Furthermore, they can target various signaling pathways involved in the progression of lung cancer, such as the PI3K/Akt/mTOR pathway, which ultimately restricts tumor growth (Wang, Yuan, et al. <a href="#fsn370829-bib-0147" class="usa-link" aria-describedby="fsn370829-bib-0147"><sup>2022</sup></a>). Polyphenols may provide a potential therapeutic strategy by regulating the expression of microRNAs (miRNAs) associated with the initiation and progression of lung cancer (Li, Zhong, et al. <a href="#fsn370829-bib-0075" class="usa-link" aria-describedby="fsn370829-bib-0075"><sup>2022</sup></a>). Through various mechanisms, including the modulation of Bcl‐2 family proteins and activation of caspases, polyphenols can trigger apoptosis or programmed cell death in lung cancer cells (Li, Zhong, et al. <a href="#fsn370829-bib-0075" class="usa-link" aria-describedby="fsn370829-bib-0075"><sup>2022</sup></a>). Nevertheless, the clinical application of polyphenols is hindered by their limited bioavailability and rapid clearance from the body (Vieira et al. <a href="#fsn370829-bib-0139" class="usa-link" aria-describedby="fsn370829-bib-0139">2023</a>). Nanoengineered delivery systems, such as liposomes, nanoparticles, and micelles, have been developed to enhance the targeted delivery, solubility, and bioavailability of polyphenols, thereby improving their therapeutic efficacy against lung cancer (Das et al. <a href="#fsn370829-bib-0030" class="usa-link" aria-describedby="fsn370829-bib-0030">2022</a>). In preclinical trials involving xenograft animal models, treatment with polyphenol‐loaded delivery systems has resulted in reduced tumor growth (Vieira et al. <a href="#fsn370829-bib-0139" class="usa-link" aria-describedby="fsn370829-bib-0139">2023</a>). Preclinical investigations utilizing xenograft animal models have demonstrated a reduction in tumor growth following the administration of polyphenol‐loaded delivery systems (Vieira et al. <a href="#fsn370829-bib-0139" class="usa-link" aria-describedby="fsn370829-bib-0139">2023</a>). Furthermore, the integration of polyphenol codelivery systems with polyphenol‐drug delivery systems demonstrates potential as a strategy to enhance anticancer efficacy while mitigating the adverse effects associated with chemotherapy (Vieira et al. <a href="#fsn370829-bib-0139" class="usa-link" aria-describedby="fsn370829-bib-0139">2023</a>). While additional research is necessary to thoroughly understand the fundamental mechanisms and clinical applications, polyphenols demonstrate significant promise as chemopreventive and therapeutic agents for lung cancer, whether used alone or in combination with other treatment modalities.</p></section><section id="fsn370829-sec-0004"><h2 class="pmc_sec_title">4. Overview of STAT3
</h2>
<p>STAT comprises a group of transcription factors that bind to target gene promoters to regulate gene expression. These factors operate as bridges that carry signals from the cell membrane to the nucleus, initiating transcription of the corresponding gene (Xia et al. <a href="#fsn370829-bib-0152" class="usa-link" aria-describedby="fsn370829-bib-0152">2023</a>; Philips et al. <a href="#fsn370829-bib-0105" class="usa-link" aria-describedby="fsn370829-bib-0105"><sup>2022</sup></a>). STAT3, a member of the STAT family, has six domains. The N‐terminal domain is important for DNA attachment and control of nuclear protein transfer and is ubiquitous in the cytoplasm of human cells (Chalikonda et al. <a href="#fsn370829-bib-0017" class="usa-link" aria-describedby="fsn370829-bib-0017">2021</a>). The central DNA‐binding domain plays a crucial role in DNA binding, while the linker domain influences the stability of DNA binding. The alpha‐helical coiled‐coil domain facilitates interactions between STAT3 signaling and other proteins. Notably, the activation of STAT3 hinges on the phosphorylation of its C‐terminal transactivation domain, with phosphorylation occurring at tyrosine 705 and serine 727 (Chen et al. <a href="#fsn370829-bib-0020" class="usa-link" aria-describedby="fsn370829-bib-0020">2019</a>; Zhao et al. <a href="#fsn370829-bib-0169" class="usa-link" aria-describedby="fsn370829-bib-0169"><sup>2022</sup></a>).</p>
<p>The original detection of STAT3 was in IL‐6‐stimulated hepatocytes, which revealed a DNA‐binding activity with a preferential interaction with the acute‐phase response element (Xu, Lin, et al. <a href="#fsn370829-bib-0155" class="usa-link" aria-describedby="fsn370829-bib-0155"><sup>2021</sup></a>; Song et al. <a href="#fsn370829-bib-0122" class="usa-link" aria-describedby="fsn370829-bib-0122"><sup>2023</sup></a>). STAT3 may be triggered by multiple growth factors, cytokines, and hormones that bind to diverse receptors, including cytokine receptors such as IL‐6R and IL‐10R, and growth factor receptors including EGFR, IGFR, and FGFR (Qin et al. <a href="#fsn370829-bib-0108" class="usa-link" aria-describedby="fsn370829-bib-0108">2019</a>; Liang et al. <a href="#fsn370829-bib-0079" class="usa-link" aria-describedby="fsn370829-bib-0079"><sup>2016</sup></a>). Ligand interaction causes the receptor to dimerize, which subsequently recruits JAKs and glycoprotein 130 (gp130), leading to phosphorylation and JAK activation (Garbers et al. <a href="#fsn370829-bib-0041" class="usa-link" aria-describedby="fsn370829-bib-0041">2015</a>). Tyrosine residues on the cytoplasmic side of JAKs are phosphorylated during activation, facilitating the interaction of the SH2 domain associated with STAT3 and the receptors, ultimately resulting in JAK‐mediated phosphorylation of STAT3 (Johnson et al. <a href="#fsn370829-bib-0059" class="usa-link" aria-describedby="fsn370829-bib-0059">2018</a>).</p>
<p>STAT3 phosphorylation and activation depend on receptors, but can also be induced by tyrosine kinases like Abl and c‐SRC (El‐Tanani et al. <a href="#fsn370829-bib-0037" class="usa-link" aria-describedby="fsn370829-bib-0037"><sup>2022</sup></a>; Panagi and Thurston <a href="#fsn370829-bib-0100" class="usa-link" aria-describedby="fsn370829-bib-0100"><sup>2023</sup></a>). When STAT3 is phosphorylated, it forms homodimers, moves from the cytoplasm to the nucleus, and interacts with coactivators such as apurinic/apyrimidinic endonuclease‐1 (APE) and CREB‐binding protein (CBP) to bind to specific DNA sequences and increase the transcription of target genes (Yu et al. <a href="#fsn370829-bib-0164" class="usa-link" aria-describedby="fsn370829-bib-0164">2014</a>; Guanizo et al. <a href="#fsn370829-bib-0044" class="usa-link" aria-describedby="fsn370829-bib-0044"><sup>2018</sup></a>). Normal cells use endogenous inhibitors like PIAS, PTPs, and SOCS to control STAT3 activity (Morris et al. <a href="#fsn370829-bib-0095" class="usa-link" aria-describedby="fsn370829-bib-0095">2018</a>).</p>
<p>The ability of STAT3 to influence the expression of multiple genes allows it to regulate important biological processes including apoptosis, cell death, differentiation, and migration. Abnormal expression of the STAT3 protein has been associated with various malignancies, particularly cancer. Studies have shown that increased STAT3 expression contributes to tumor growth and metastasis. Furthermore, activation of oncogenic STAT3 signaling is linked to drug resistance and resistance to radiation. Therefore, targeting STAT3 signaling is crucial for suppressing tumor progression (To et al. <a href="#fsn370829-bib-0133" class="usa-link" aria-describedby="fsn370829-bib-0133">2022</a>; Ashrafizadeh, Zarrabi, et al. <a href="#fsn370829-bib-0011" class="usa-link" aria-describedby="fsn370829-bib-0011"><sup>2020</sup></a>; Li, Yin, et al. <a href="#fsn370829-bib-0074" class="usa-link" aria-describedby="fsn370829-bib-0074"><sup>2022</sup></a>; Sadrkhanloo et al. <a href="#fsn370829-bib-0114" class="usa-link" aria-describedby="fsn370829-bib-0114"><sup>2023</sup></a>).</p>
<p>Overexpression of activated STAT3 is associated with an unfavorable prognosis in different types of cancer. Continuous activation of STAT3 is mainly a result of hyperactive growth factor receptor tyrosine kinase and increased interactions between stimulatory receptors and ligands. When tyrosine 705 residue is phosphorylated, it allows STAT3 to move into the nucleus and subsequently activate genes targeted by STAT3 (Wang et al. <a href="#fsn370829-bib-0146" class="usa-link" aria-describedby="fsn370829-bib-0146">2004</a>).</p>
<p>As an oncogene, STAT3 plays a vital role in various cellular processes such as proliferation, survival, angiogenesis, metastasis, invasion, and immune evasion (Yu et al. <a href="#fsn370829-bib-0165" class="usa-link" aria-describedby="fsn370829-bib-0165">2009</a>; Kim et al. <a href="#fsn370829-bib-0064" class="usa-link" aria-describedby="fsn370829-bib-0064"><sup>2016</sup></a>; Bromberg and Darnell <a href="#fsn370829-bib-0015" class="usa-link" aria-describedby="fsn370829-bib-0015"><sup>2000</sup></a>; Mohan et al. <a href="#fsn370829-bib-0091" class="usa-link" aria-describedby="fsn370829-bib-0091"><sup>2022</sup></a>) (Figure <a href="#fsn370829-fig-0001" class="usa-link">1</a>).</p>
<figure class="fig xbox font-sm" id="fsn370829-fig-0001"><h3 class="obj_head">FIGURE 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6962/12376182/0ea091bfe953/FSN3-13-e70829-g003.jpg" loading="lazy" id="jats-graphic-3" height="810" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/fsn370829-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>STAT3 signaling is initiated when various ligands bind to their receptors on the cell surface, resulting in the phosphorylation of STAT3. Additionally, nonreceptor tyrosine kinases Src and Abl also directly phosphorylate STAT3. The phosphorylated STAT3 then forms homodimers and translocates to the nucleus. Once in the nucleus, STAT3 regulates gene expression in cellular proliferation and survival, such as CyclinD1, c‐Myc, Survivin, Bcl‐XL, and Mcl1. Moreover, STAT3 upregulates the expression of VEGF, bFGF, HGF, and HIF1α, which participate in processes related to cancer progression. Furthermore, STAT3 promotes invasion and migration by regulating MMP2, MMP9, Twist, and Vimentin expression. It also downregulates immune surveillance by promoting the secretion of chemokines like CXCL10. In addition, STAT3 plays a role in maintaining cancer stem cell properties by regulating the expression of Oct3/4, Nanog, CD133, and CD44.</p></figcaption></figure><p>The constitutive activation of STAT3 has been observed in numerous types of cancers, such as breast, colon, pancreatic, lung, and ovarian cancers, as well as hematological malignancies like lymphomas and leukemias (Molenda et al. <a href="#fsn370829-bib-0093" class="usa-link" aria-describedby="fsn370829-bib-0093">2023</a>; Hashemi et al. <a href="#fsn370829-bib-0047" class="usa-link" aria-describedby="fsn370829-bib-0047"><sup>2023</sup></a>; Singh et al. <a href="#fsn370829-bib-0120" class="usa-link" aria-describedby="fsn370829-bib-0120"><sup>2023</sup></a>). In cancer cells, the persistent activation of STAT3 contributes to uncontrolled cell proliferation, inhibition of apoptosis, promotion of angiogenesis, and metastasis (Valle‐Mendiola and Soto‐Cruz <a href="#fsn370829-bib-0138" class="usa-link" aria-describedby="fsn370829-bib-0138"><sup>2020</sup></a>). STAT3 also plays a role in metabolic reprogramming, facilitating glycolysis and oxidative phosphorylation, which are crucial for tumor cell survival and proliferation (Poli and Camporeale <a href="#fsn370829-bib-0106" class="usa-link" aria-describedby="fsn370829-bib-0106">2015</a>; Tošić and Frank <a href="#fsn370829-bib-0134" class="usa-link" aria-describedby="fsn370829-bib-0134"><sup>2021</sup></a>).</p>
<p>The STAT3 pathway plays a crucial role in gastric cancer progression, promoting cell proliferation, survival, angiogenesis, and metastasis. STAT3 is frequently overactivated in gastric cancer cells, contributing to tumor growth and drug resistance (Ashrafizadeh, Zarrabi, et al. <a href="#fsn370829-bib-0011" class="usa-link" aria-describedby="fsn370829-bib-0011"><sup>2020</sup></a>; Ashrafizadeh et al. <a href="#fsn370829-bib-0009" class="usa-link" aria-describedby="fsn370829-bib-0009"><sup>2023</sup></a>). Noncoding RNAs, including microRNAs and long noncoding RNAs, have emerged as important regulators of the STAT3 signaling pathway in gastrointestinal cancers. These noncoding RNAs can either activate or inhibit STAT3 signaling, thereby influencing cancer cell behavior and treatment outcomes. MicroRNAs such as miR‐124, miR‐223, and miR‐506 have been shown to directly target STAT3 or its upstream activators, suppressing gastric cancer progression. Long noncoding RNAs like HOTAIR, MALAT1, and GHET1 can modulate STAT3 activity through various mechanisms, including acting as competing endogenous RNAs or interacting with STAT3‐related proteins. The complex interplay between noncoding RNAs and the STAT3 pathway contributes to cancer cell proliferation, metastasis, and therapeutic resistance in gastric and other gastrointestinal cancers (Ashrafizadeh et al. <a href="#fsn370829-bib-0009" class="usa-link" aria-describedby="fsn370829-bib-0009">2023</a>, <a href="#fsn370829-bib-0008" class="usa-link" aria-describedby="fsn370829-bib-0008">2021</a>; Yu et al. <a href="#fsn370829-bib-0166" class="usa-link" aria-describedby="fsn370829-bib-0166"><sup>2024</sup></a>).</p>
<p>Understanding these regulatory networks provides new insights into cancer biology and offers potential targets for developing novel therapeutic strategies. Targeting the STAT3 pathway and its associated noncoding RNAs may hold promise for improving treatment outcomes in gastric cancer and other gastrointestinal malignancies.</p>
<p>STAT3 activation has been linked to the development of acquired drug resistance in various cancers, including triple‐negative breast cancer (TNBC). By inhibiting STAT3 through the circKIF4A‐miR‐637 axis, it may be possible to resensitize cancer cells to existing therapies, such as chemotherapy, targeted therapy, and immunotherapy (Wu et al. <a href="#fsn370829-bib-0151" class="usa-link" aria-describedby="fsn370829-bib-0151">2024</a>).</p>
<p>Furthermore, STAT3 has been linked to the development of acquired drug resistance, which poses a significant challenge in cancer treatment. Evidence suggests that at least 24 distinct antineoplastic agents, including chemotherapeutic drugs, targeted kinase inhibitors, antihormonal therapies, and monoclonal antibodies, can induce resistance through the STAT3 signaling pathway (Singh et al. <a href="#fsn370829-bib-0120" class="usa-link" aria-describedby="fsn370829-bib-0120">2023</a>). Given the critical role of STAT3 in cancer development and progression, targeting this pathway has emerged as a promising therapeutic strategy. Various approaches have been explored, including small molecule inhibitors, oligonucleotide‐based therapeutics (e.g., siRNA, shRNA, ASO, and ODN‐decoy), and natural compounds (Molenda et al. <a href="#fsn370829-bib-0093" class="usa-link" aria-describedby="fsn370829-bib-0093">2023</a>).</p>
<p>Natural compounds, such as CUR and epigallocatechin gallate, have been shown to inhibit STAT3 and its related signaling pathways, thereby hindering tumorigenesis in several types of cancer, including gastric, pancreatic, and lung cancers (Ham et al. <a href="#fsn370829-bib-0045" class="usa-link" aria-describedby="fsn370829-bib-0045">2022</a>; Zhu et al. <a href="#fsn370829-bib-0173" class="usa-link" aria-describedby="fsn370829-bib-0173"><sup>2011</sup></a>; Duan et al. <a href="#fsn370829-bib-0033" class="usa-link" aria-describedby="fsn370829-bib-0033"><sup>2016</sup></a>; Mukherjee and Khuda‐Bukhsh <a href="#fsn370829-bib-0097" class="usa-link" aria-describedby="fsn370829-bib-0097"><sup>2015</sup></a>).</p>
<p>In summary, STAT3 plays a pivotal role in cancer development, progression, and acquired drug resistance, making it an attractive therapeutic target. Ongoing research efforts are focused on developing effective STAT3 inhibitors, either alone or in combination with existing anticancer therapies, to overcome drug resistance and improve patient outcomes.</p>
<p>Targeting STAT3 and its metabolic pathways represents a promising strategy for cancer treatment, with several inhibitors currently under clinical investigation. TTI‐101 (formerly C188‐9) represents a promising therapeutic approach to targeting STAT3 in advanced tumors. The ongoing clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT03195699" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03195699</a> is expected to provide valuable insights into the potential of this phosphorylation inhibitor as a treatment option for a wide range of cancer types (breast cancer, NSCLC, hepatocellular carcinoma and colorectal cancer). This compound is designed to inhibit the phosphorylation of STAT3, a critical step in its activation and subsequent role in promoting cancer cell growth and survival.</p>
<p>SC‐43 is a promising therapeutic agent for the treatment of NSCLC and biliary tract cancer. The ongoing clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT04733521" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04733521</a> is expected to provide valuable insights into its safety and efficacy, paving the way for further clinical investigations and potential approval for clinical use. SHP‐1‐mediated inhibitor of STAT3 phosphorylation. SC‐43 works by inhibiting the phosphorylation of STAT3, a key step in its activation. This inhibition is mediated through the activation of SHP‐1, a protein tyrosine phosphatase that dephosphorylates STAT3, thereby preventing its activation and subsequent oncogenic effects (Tošić and Frank <a href="#fsn370829-bib-0134" class="usa-link" aria-describedby="fsn370829-bib-0134">2021</a>).</p>
<p>AZD9150 is a Generation 2.5 antisense oligonucleotide (ASO) designed to reduce the expression of STAT3 protein by down‐regulating STAT3 messenger RNA (Mccoon et al. <a href="#fsn370829-bib-0088" class="usa-link" aria-describedby="fsn370829-bib-0088">2015</a>; Xu et al. <a href="#fsn370829-bib-0154" class="usa-link" aria-describedby="fsn370829-bib-0154"><sup>2019</sup></a>).</p>
<p>STAT3 is involved in tumor growth and immune evasion. Durvalumab, on the other hand, is a PD‐L1 inhibitor that blocks the interaction between PD‐L1 and PD‐1, allowing T cells to recognize and kill tumor cells (Chen et al. <a href="#fsn370829-bib-0019" class="usa-link" aria-describedby="fsn370829-bib-0019">2023</a>; Liu et al. <a href="#fsn370829-bib-0081" class="usa-link" aria-describedby="fsn370829-bib-0081"><sup>2021</sup></a>).</p>
<p>The clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT03421353" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03421353</a> is a phase Ib/II, open‐label multicentre study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD9150 in combination with durvalumab, with or without chemotherapy, in patients with advanced solid tumors and NSCLC. The clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT03421353" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03421353</a> represents an important step in the development of combination therapies for cancer treatment. By targeting the STAT3 pathway, this approach may offer new treatment options for patients with advanced solid tumors and NSCLC, potentially overcoming the limitations of current therapies (Tošić and Frank <a href="#fsn370829-bib-0134" class="usa-link" aria-describedby="fsn370829-bib-0134">2021</a>).</p>
<p>Napabucasin, also known as BBI608, is a phosphorylation inhibitor currently being investigated for the treatment of NSCLC in clinical trials (Hubbard and Grothey <a href="#fsn370829-bib-0055" class="usa-link" aria-describedby="fsn370829-bib-0055">2017</a>).</p>
<p>The clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02826161" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02826161</a>) aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of napabucasin in patients with NSCLC. Given the critical role of STAT3 in cancer pathogenesis, inhibiting its phosphorylation represents a promising therapeutic approach (Tošić and Frank <a href="#fsn370829-bib-0134" class="usa-link" aria-describedby="fsn370829-bib-0134">2021</a>).</p>
<p>The clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02983578" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02983578</a>) is testing the safety, tolerability, pharmacokinetics, and efficacy of IONIS‐STAT3Rx (AZD9150) in patients with advanced, refractory pancreatic, NSCLC, and colorectal cancer. This drug targets STAT3, offering a new cancer therapy approach by disrupting signaling pathways that promote cancer cell growth, survival, and spread (Tošić and Frank <a href="#fsn370829-bib-0134" class="usa-link" aria-describedby="fsn370829-bib-0134">2021</a>).</p></section><section id="fsn370829-sec-0005"><h2 class="pmc_sec_title">5. The Application of Nanoparticles in the Treatment of Lung Cancer</h2>
<p>Nanoparticles have emerged as a promising tool in the treatment of lung cancer, offering targeted drug delivery and enhanced therapeutic efficacy (Wang, Zhou, et al. <a href="#fsn370829-bib-0144" class="usa-link" aria-describedby="fsn370829-bib-0144"><sup>2022</sup></a>; Holder et al. <a href="#fsn370829-bib-0050" class="usa-link" aria-describedby="fsn370829-bib-0050"><sup>2023</sup></a>). Recent advancements in nanotechnology have led to the development of various nanocarrier systems, including organic, inorganic, and hybrid nanoparticles, each with unique advantages for lung cancer therapy (Girigoswami and Girigoswami <a href="#fsn370829-bib-0043" class="usa-link" aria-describedby="fsn370829-bib-0043">2023</a>; Mottaghitalab et al. <a href="#fsn370829-bib-0096" class="usa-link" aria-describedby="fsn370829-bib-0096"><sup>2019</sup></a>). These nanocarriers can overcome the limitations of conventional chemotherapy by improving drug solubility, increasing tumor penetration, and reducing systemic toxicity (Holder et al. <a href="#fsn370829-bib-0050" class="usa-link" aria-describedby="fsn370829-bib-0050">2023</a>; Silva et al. <a href="#fsn370829-bib-0119" class="usa-link" aria-describedby="fsn370829-bib-0119"><sup>2024</sup></a>).</p>
<p>Notably, hybrid nanoparticles combining organic and inorganic components have demonstrated improved diagnostic and therapeutic outcomes compared to conventional nanocarriers, offering the ability to incorporate multiple drugs, targeting agents, and photosensitive reagents for more sensitive and specific lung cancer treatment (Mottaghitalab et al. <a href="#fsn370829-bib-0096" class="usa-link" aria-describedby="fsn370829-bib-0096">2019</a>; Woodman et al. <a href="#fsn370829-bib-0149" class="usa-link" aria-describedby="fsn370829-bib-0149"><sup>2021</sup></a>). Among the various nanoparticle types, chitosan‐based nanoparticles have gained attention due to their unique biological properties, including antitumor activity and mucoadhesive capacity, which can enhance drug efficacy when administered via the pulmonary route (Silva et al. <a href="#fsn370829-bib-0119" class="usa-link" aria-describedby="fsn370829-bib-0119">2024</a>).</p>
<p>Furthermore, nanoparticle‐based systems have shown promise in overcoming drug resistance and improving the efficacy of radiotherapy in lung cancer treatment, potentially leading to better patient outcomes.</p></section><section id="fsn370829-sec-0006"><h2 class="pmc_sec_title">6. Curcumin Modulates the STAT3 Signaling Pathway to Inhibit Lung Cancer</h2>
<p>CUR is a hydrophobic, low‐molecular‐weight polyphenolic molecule with a bright yellow color isolated from the rhizome of turmeric (Flanders and Gramlich <a href="#fsn370829-bib-0038" class="usa-link" aria-describedby="fsn370829-bib-0038">2022</a>). It may participate in a variety of physical, chemical, and biological processes due to its unique chemical structure. Its chemical name, diferuloylmethane (1,7‐bis‐(4‐hydroxy‐3‐methoxyphenyl)‐1,6‐heptadiene‐3,5‐dione), reflects its composition as a bis‐α, β‐unsaturated β‐diketone, formed by the coupling of two ferulic acid molecules with a methylene bridge (E Wright et al. <a href="#fsn370829-bib-0034" class="usa-link" aria-describedby="fsn370829-bib-0034"><sup>2013</sup></a>; Liang et al. <a href="#fsn370829-bib-0078" class="usa-link" aria-describedby="fsn370829-bib-0078"><sup>2009</sup></a>).</p>
<p>Based on the Food and Drug Administration (FDA) documents provided, CUR has been determined to be generally recognized as safe (GRAS) for use as a food ingredient in certain categories and at specified maximum levels (U.S. Food and Drug Administration <a href="#fsn370829-bib-0137" class="usa-link" aria-describedby="fsn370829-bib-0137"><sup>2018</sup></a>).</p>
<p>Tremendous progress has been made in understanding the molecular biology of cancer, yet it remains undefeated (Surh and Chun <a href="#fsn370829-bib-0128" class="usa-link" aria-describedby="fsn370829-bib-0128">2007</a>). CUR is a highly versatile molecule that can be used in cancer treatment as both a chemopreventive agent and as part of chemotherapy, with minimal side effects (Allegra et al. <a href="#fsn370829-bib-0004" class="usa-link" aria-describedby="fsn370829-bib-0004">2017</a>). For example, it can interfere with multiple stages of carcinogenesis (Kabir et al. <a href="#fsn370829-bib-0061" class="usa-link" aria-describedby="fsn370829-bib-0061">2021</a>), and is easily accessible, cost‐effective, and safe (George et al. <a href="#fsn370829-bib-0042" class="usa-link" aria-describedby="fsn370829-bib-0042">2021</a>; Park et al. <a href="#fsn370829-bib-0102" class="usa-link" aria-describedby="fsn370829-bib-0102"><sup>2013</sup></a>; Lelli et al. <a href="#fsn370829-bib-0070" class="usa-link" aria-describedby="fsn370829-bib-0070"><sup>2017</sup></a>).</p>
<p>The NSCLC cell line H460 (NCI‐H460) is widely used in numerous experiments to explore the effects of various compounds, such as CUR, on lung cancer cells (Abbas Albaayit et al. <a href="#fsn370829-bib-0001" class="usa-link" aria-describedby="fsn370829-bib-0001">2021</a>; Chang and Chen <a href="#fsn370829-bib-0018" class="usa-link" aria-describedby="fsn370829-bib-0018"><sup>2015</sup></a>). The NCI‐H460 cell line has played a crucial role in gaining insights into the mechanisms of lung cancer progression, drug resistance, and potential targeting of cancer stem‐like cells (Herreros Pomares <a href="#fsn370829-bib-0049" class="usa-link" aria-describedby="fsn370829-bib-0049"><sup>2020</sup></a>).</p>
<p>In a study by Wu et al., CUR significantly inhibited the activity of the JAK2/STAT3 signaling pathway in NCI‐H460 tumor spheroids, resulting in downregulation of p‐JAK2 and p‐STAT3 in a time‐ and dose‐dependent manner. Furthermore, molecular docking analysis showed that CUR can bind to JAK2 to inhibit its activity. Other research has shown that overexpression of STAT3 promotes tumor sphere formation, and its inhibition by CUR halts lung cancer progression (Wu et al. <a href="#fsn370829-bib-0150" class="usa-link" aria-describedby="fsn370829-bib-0150">2015</a>).</p>
<p>The CUR analogue L48H37 impedes the invasion and migration of human osteosarcoma cells by blocking the JAK/STAT pathway and urokinase plasminogen activator (uPA). A previous study revealed that L48H37 successfully suppressed the motility, migration, and invasion of human osteosarcoma U2OS and MG‐63 cells without inducing cytotoxicity. It was also reported that L48H37 reduced the quantity of uPA protein, mRNA expression, and promoter activity, and repressed the JAK/STAT signaling pathway by reducing the phosphorylation of STAT3, JAK1, JAK2, and JAK3 in U2OS cells. The data imply that L48H37 may be a suitable option for antimetastatic therapy of human osteosarcoma (Lu et al. <a href="#fsn370829-bib-0084" class="usa-link" aria-describedby="fsn370829-bib-0084">2020</a>).</p>
<p>STAT3 directly activates the VEGF gene at the transcriptional level, thereby promoting angiogenesis in NSCLC. This process ultimately contributes to the progression of cancer and adversely affects the overall survival of affected patients (Chen and Han <a href="#fsn370829-bib-0021" class="usa-link" aria-describedby="fsn370829-bib-0021">2008</a>; Parakh et al. <a href="#fsn370829-bib-0101" class="usa-link" aria-describedby="fsn370829-bib-0101"><sup>2021</sup></a>). In NSCLC, targeting the STAT3/VEGF axis can significantly reduce tumor‐associated VEGF, angiogenesis, and vascular permeability in lung cancer cells, indicating the therapeutic significance of inhibiting STAT3 (Mohrherr et al. <a href="#fsn370829-bib-0092" class="usa-link" aria-describedby="fsn370829-bib-0092">2020</a>; Kang et al. <a href="#fsn370829-bib-0062" class="usa-link" aria-describedby="fsn370829-bib-0062"><sup>2019</sup></a>).</p>
<p>CUR ameliorates NSCLC by reducing tumor size and weight in an ectopic xenograft model, leading to a significant decrease in hemoglobin content, as well as mRNA expression of CD31 and CD105 within the tumor tissue, denoting its antiangiogenic potency. Furthermore, CUR suppresses the STAT3 pathway, as evidenced by decreased levels of phosphorylated STAT3, JAK, VEGF, Bcl‐xL, and Cyclin D1 in ectopic xenografts. In vitro assays corroborated these findings and demonstrated not only curcumin's ability to inhibit cell migration but also tube formation in NCI‐H460 cells. Transfecting with a dominant active mutant of STAT3 notably counteracted CUR‐induced inhibitory effects on NCI‐H460 cells, thereby implicating STAT3 as one of the possible mechanisms by which CUR exerts its antiangiogenic effects in cancer cells. These results collectively imply promising potential for CUR as an agent to therapeutically target STAT3 in treating NSCLC (Xu and Zhu <a href="#fsn370829-bib-0157" class="usa-link" aria-describedby="fsn370829-bib-0157">2017</a>).</p>
<p>Minichromosome maintenance complex component 2 (Mcm2) is an essential protein that plays a critical role in the process of DNA replication (Sakwe et al. <a href="#fsn370829-bib-0115" class="usa-link" aria-describedby="fsn370829-bib-0115">2007</a>). It belongs to the MCM protein family, required for the development of the replicative helicase complex essential for DNA replication initiation (Malysa et al. <a href="#fsn370829-bib-0085" class="usa-link" aria-describedby="fsn370829-bib-0085">2024</a>; Sun et al. <a href="#fsn370829-bib-0125" class="usa-link" aria-describedby="fsn370829-bib-0125"><sup>2021</sup></a>). Mcm2 works in unwinding the DNA double helix and allowing DNA replication throughout the cell cycle (Lei <a href="#fsn370829-bib-0069" class="usa-link" aria-describedby="fsn370829-bib-0069">2005</a>). Its expression acts as an indication of cellular proliferation, often exploited as a marker for tissue proliferative ability (Yousef, Furrer, et al. <a href="#fsn370829-bib-0162" class="usa-link" aria-describedby="fsn370829-bib-0162"><sup>2017</sup></a>).</p>
<p>CUR treatment was shown to cause in vitro dose‐dependent suppression of STAT3 phosphorylation, indicating inhibition of the STAT3 pathway and consequently decreased cellular proliferation. Additionally, the lung tissue of rats administered CUR had lower expression of proliferative markers including Cyclin D1, STAT3, and Mcm2. These findings highlight curcumin's ability to lower STAT3 pathway activity and limit the proliferative capability of lung tissue, demonstrating its chemopreventive efficacy against lung cancer (Alexandrow et al. <a href="#fsn370829-bib-0003" class="usa-link" aria-describedby="fsn370829-bib-0003">2012</a>).</p>
<p>According to prior research, CUR inhibits the production of invasive proteins, including MMP‐2, MMP‐7, and ICAM‐1, as well as proliferative proteins like survivin, bcl‐xl, and cyclin B1. Moreover, it inhibits the production of Cyclin B1, a protein linked to the advancement of the G2/M phase, resulting in G2/M phase cell cycle arrest in SCLC cells. It also suppresses IL‐6‐induced STAT3 phosphorylation in a dose‐ and time‐dependent manner, indicating its potential as a multitarget medication in anticancer treatment (Yang et al. <a href="#fsn370829-bib-0159" class="usa-link" aria-describedby="fsn370829-bib-0159">2012</a>).</p>
<p>Further investigation demonstrated that CUR exhibits dose‐ and time‐dependent inhibition of NCI‐H292 cell growth via the upregulation of apoptosis, as shown by the Annexin V apoptosis test and Caspase‐3/7 activity assessments. Furthermore, CUR increases the expression of suppressors of cytokine signaling proteins, SOCS1 and SOCS3, which act as negative regulators of STAT3. The research also discovered that CUR increases the expression of Forkhead box transcription factor A2 (FOXA2) or hepatocyte nuclear factor 3 beta, a suppressor of tumor metastasis in human lung malignancies. It also blocks the STAT3 signaling pathway. Additionally, the research revealed the possible function of suppressors of cytokine signaling (SOCS1 and SOCS3) proteins in mediating the inhibitory effects of CUR on STAT3 activation and FOXA2 expression (Tang et al. <a href="#fsn370829-bib-0131" class="usa-link" aria-describedby="fsn370829-bib-0131">2018</a>). Overall, the data provide new insights into the molecular processes underlying the anticancer actions of CUR in SCLC cells and highlight FOXA2 and STAT3 as prospective therapeutic targets.</p>
<p>Compound 5 k is a 1,2,3‐triazole CUR derivative that was produced and tested for its anticancer efficacy in the research (Ashrafizadeh et al. <a href="#fsn370829-bib-0008" class="usa-link" aria-describedby="fsn370829-bib-0008">2021</a>). It is a dichloro‐substituted phenyltriazole methyl CUR that has shown remarkable anticancer efficacy by decreasing tumor cell growth and inducing apoptosis both in vitro and in vivo (Ashrafizadeh et al. <a href="#fsn370829-bib-0008" class="usa-link" aria-describedby="fsn370829-bib-0008">2021</a>). Research demonstrates that compound 5 k, a 1,2,3‐triazole CUR derivative, triggers the Mitogen‐Activated Protein Kinase (MAPK) signaling pathway in a time‐dependent manner, reducing A549 cell growth and promoting apoptosis. Additionally, compound 5 k represses the NF‐κB/STAT3 signaling pathway by upregulating the expression of IκBα and lowering the levels of NF‐κB, p‐STAT3, and β‐catenin. These results imply that compound 5 k may possibly treat NSCLC by regulating the NF‐κB/STAT3 signaling pathways and decreasing cancer cell proliferation (Zhi et al. <a href="#fsn370829-bib-0170" class="usa-link" aria-describedby="fsn370829-bib-0170">2022</a>).</p>
<p>According to research, compound 5 k, a 1,2,3‐triazole CUR derivative, triggers the Mitogen‐Activated Protein Kinase (MAPK) signaling pathway in a time‐dependent manner, reducing A549 cell growth and promoting cell death. Additionally, compound 5 k represses the NF‐κB/STAT3 signaling pathway by upregulating the expression of IκBα and lowering the levels of NF‐κB, p‐STAT3, and β‐catenin. These results imply that compound 5 k may possibly treat NSCLC by regulating the NF‐κB/STAT3 signaling pathways and decreasing cancer cell proliferation (Zhi et al. <a href="#fsn370829-bib-0170" class="usa-link" aria-describedby="fsn370829-bib-0170">2022</a>).</p>
<p>Table <a href="#fsn370829-tbl-0001" class="usa-link">1</a> and Figure <a href="#fsn370829-fig-0002" class="usa-link">2</a> provide a summary of the effects of CUR on lung cancer through STAT3.</p>
<section class="tw xbox font-sm" id="fsn370829-tbl-0001"><h3 class="obj_head">TABLE 1.</h3>
<div class="caption p"><p>Curcumin effects on STAT3 pathway in lung cancer.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Authors</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Dosage of curcumin (CUR)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Type of model</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Mechanisms</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Wu et al. (<a href="#fsn370829-bib-0150" class="usa-link" aria-describedby="fsn370829-bib-0150">2015</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">40 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mice</td>
<td align="center" valign="top" rowspan="1" colspan="1">CUR affects the STAT3 pathway in mice by significantly inhibiting tumor growth and downregulating the expression of p‐STAT3 and p‐JAK2 in tumor samples.</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Xu and Zhu (<a href="#fsn370829-bib-0157" class="usa-link" aria-describedby="fsn370829-bib-0157">2017</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">100 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mice</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>CUR affects the STAT3 pathway in mice by inhibiting its activation, leading to a reduction in tumor growth and angiogenesis. In a mice model of NSCLC, CUR treatment resulted in a significant decrease in tumor size and weight.</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Alexandrow et al. (<a href="#fsn370829-bib-0003" class="usa-link" aria-describedby="fsn370829-bib-0003">2012</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">25 μM</td>
<td align="center" valign="top" rowspan="1" colspan="1">H441 cells</td>
<td align="center" valign="top" rowspan="1" colspan="1">CUR treatment resulted in reduced cell proliferation in a dose‐dependent manner for the H441 cells. These findings indicate that CUR can suppress the activity of the Stat3 pathway in lung cancer‐derived cells, leading to a reduction in cell proliferation.</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Yang et al. (<a href="#fsn370829-bib-0159" class="usa-link" aria-describedby="fsn370829-bib-0159">2012</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 μM</td>
<td align="center" valign="top" rowspan="1" colspan="1">NCI‐H446 and NCI‐1688 cells</td>
<td align="center" valign="top" rowspan="1" colspan="1">CUR inhibited the phosphorylation of STAT3 at tyrosine 705 in NCI‐H446 and NCI‐1688 cells. This inhibition of STAT3 phosphorylation occurs in a dose‐dependent and time‐dependent manner. Additionally, CUR treatment suppressed IL‐6‐induced STAT3 phosphorylation in these cells.</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Tang et al. (<a href="#fsn370829-bib-0131" class="usa-link" aria-describedby="fsn370829-bib-0131">2018</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">40 μM</td>
<td align="center" valign="top" rowspan="1" colspan="1">NCI‐H292 cells</td>
<td align="center" valign="top" rowspan="1" colspan="1">CUR treatment reduced the phosphorylation of STAT3 in both the cytoplasmic and nuclear fractions of NCI‐H292 cells. This inhibition of STAT3 signaling was associated with an increase in the expression of FOXA2, a transcription factor that was frequently lost in LSCC tissues. The upregulation of FOXA2 by CUR was found to be mediated by the inhibition of the STAT3 pathway.</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/fsn370829-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fsn370829-note-0002"><p>Abbreviations: Bcl‐xL, B‐cell lymphoma‐extra large; FOXA2, Forkhead Box A2; IL‐6, interleukin 6; JAK, Janus Kinase; Mcm2, minichromosome maintenance complex component 2; NF‐κB, nuclear factor kappa B; SCLC, small cell lung cancer; SOCS, suppressor of cytokine signaling; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor.</p></div></div></section><figure class="fig xbox font-sm" id="fsn370829-fig-0002"><h3 class="obj_head">FIGURE 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6962/12376182/03b67c37740c/FSN3-13-e70829-g004.jpg" loading="lazy" id="jats-graphic-5" height="349" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/fsn370829-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Effects of CUR in treating lung cancer by targeting the STAT3 signaling pathway. This figure shows how CUR acts as a therapeutic agent for lung cancer treatment by inhibiting multiple pathways. Through inhibition, CUR downregulates JAK2/STAT3 signaling pathway activity, leading to reduced phosphorylation of JAK2 and STAT3 proteins in both a time and dose‐dependent manner. Additionally, CUR inhibits IL‐6 inducible STAT3 phosphorylation, which targets the IL‐6/JAK/STAT3 pathway specifically in SCLC treatment. Furthermore, CUR inhibits STAT3 phosphorylation, resulting in downregulation of several STAT3 downstream targets including Cyclin D1, Cyclin B1, and Mcm2.</p></figcaption></figure></section><section id="fsn370829-sec-0007"><h2 class="pmc_sec_title">7. Regulation of the STAT3 Signaling Pathway by Resveratrol Inhibits Lung Cancer</h2>
<p>Research indicates that animals exhibit a high tolerance for RES even at large dosages (1000–1500 mg/kg/day) (Christenson et al. <a href="#fsn370829-bib-0024" class="usa-link" aria-describedby="fsn370829-bib-0024">2016</a>). However, certain clinical trials report mild‐to‐moderate gastrointestinal symptoms with daily doses between 2.5 and 5 g/Kg and diarrhea when given twice per day at a dose level higher than 2 g/Kg (Juan et al. <a href="#fsn370829-bib-0060" class="usa-link" aria-describedby="fsn370829-bib-0060">2002</a>; Cottart et al. <a href="#fsn370829-bib-0026" class="usa-link" aria-describedby="fsn370829-bib-0026"><sup>2010</sup></a>). Notably, micronized RES appears to be better tolerated (Howells et al. <a href="#fsn370829-bib-0053" class="usa-link" aria-describedby="fsn370829-bib-0053">2011</a>). Humans absorb approximately 70% of orally or intravenously administered 14C‐labeled RES (Zhang et al. <a href="#fsn370829-bib-0167" class="usa-link" aria-describedby="fsn370829-bib-0167">2021</a>). Phase II metabolic enzymes, particularly UDP‐glucuronosyltransferases and sulfotransferases in the liver and intestinal microsomes, critically facilitate its metabolism, consequently producing RES glucuronides and sulfates (Bishayee et al. <a href="#fsn370829-bib-0014" class="usa-link" aria-describedby="fsn370829-bib-0014">2010</a>).</p>
<p>A previous study showed that RES exerts concentration‐dependent and time‐dependent cytotoxicity on the NSCLC cell line (A549) by inhibiting proliferation, migration, and invasion, and by promoting apoptosis. Additionally, RES downregulated STAT3 protein expression. This study postulated that inhibiting the STAT3 pathway may prevent metastasis, thus highlighting its therapeutic potential in treating NSCLC (Li, Wang, et al. <a href="#fsn370829-bib-0077" class="usa-link" aria-describedby="fsn370829-bib-0077"><sup>2016</sup></a>).</p>
<p>The STAT3/HIF‐1α/VEGF signaling pathway plays significant roles in promoting tumor growth and progression, such as regulating cellular responses to low oxygen levels (hypoxia) and promoting the expression of genes that support tumor growth and angiogenesis (Zimna and Kurpisz <a href="#fsn370829-bib-0176" class="usa-link" aria-describedby="fsn370829-bib-0176">2015</a>).</p>
<p>In a study by Wang et al., RES significantly decreased the expression of STAT3, HIF‐1α, STAT3, and VEGF mRNA and proteins, lung weight index, as well as lung tumor burden levels in a nude rat model of NSCLC. Collectively, these findings suggest that RES may be a potential drug that can be used to inhibit the progression of NSCLC by targeting and inhibiting the STAT3, HIF‐1α, and VEGF signaling pathway (Wang et al. <a href="#fsn370829-bib-0142" class="usa-link" aria-describedby="fsn370829-bib-0142">2020</a>).</p>
<p>Tumor‐associated macrophages (TAMs) are immune cells in the tumor microenvironment, playing a significant role in cancer progression (Wang, Li, et al. <a href="#fsn370829-bib-0143" class="usa-link" aria-describedby="fsn370829-bib-0143"><sup>2019</sup></a>). These macrophages are recruited by primary tumors and circulating tumor cells and undergo functional polarization driven by tumor‐derived factors (Christofides et al. <a href="#fsn370829-bib-0025" class="usa-link" aria-describedby="fsn370829-bib-0025">2022</a>). TAMs play a significant role in multiple phases of cancer metastasis, encompassing cancer invasion, intravasation, survival within the circulatory system, and sustained proliferation at secondary tumor sites (Dallavalasa et al. <a href="#fsn370829-bib-0029" class="usa-link" aria-describedby="fsn370829-bib-0029">2021</a>). They are known to promote tumor growth, invasion, and local immunosuppression, and are involved in evading antitumor immune responses (Pan et al. <a href="#fsn370829-bib-0099" class="usa-link" aria-describedby="fsn370829-bib-0099">2020</a>). TAMs are characterized by their plasticity and flexibility, with different activation states denoted as M1 and M2 (Jayasingam et al. <a href="#fsn370829-bib-0058" class="usa-link" aria-describedby="fsn370829-bib-0058">2020</a>). The M2‐like TAMs mainly promote tumor angiogenesis, migration, and invasion while suppressing antitumor immune responses (Pan et al. <a href="#fsn370829-bib-0099" class="usa-link" aria-describedby="fsn370829-bib-0099">2020</a>). The presence of TAMs has been linked to poor lung cancer prognosis, and their polarization status is crucial in determining their tumor‐promoting or tumor‐preventing role (Tariq et al. <a href="#fsn370829-bib-0132" class="usa-link" aria-describedby="fsn370829-bib-0132">2017</a>). Therefore, targeting M2‐like TAMs has been identified as a promising approach for adjuvant anticancer therapies (Han et al. <a href="#fsn370829-bib-0046" class="usa-link" aria-describedby="fsn370829-bib-0046">2021</a>).</p>
<p>Sun et al. reported that RES effectively inhibits the growth of lung cancer by suppressing the protumor activation of TAMs. In vivo experiments using a mouse model showed that RES treatment significantly reduced lung tumor size and weight, and downregulated the activation of STAT3 in tumor cells. Additionally, RES inhibited the infiltration and polarization of TAMs in the tumor tissues. Studies show that RES inhibits the M2 polarization of human monocyte‐derived macrophages (HMDMs) induced by lung cancer cell‐conditioned medium in vitro. Furthermore, RES inhibited lung cancer cell proliferation when cocultured with human macrophages. The study also revealed that RES decreased the secretion of specific cytokines associated with M2 polarization and increased the secretion of cytokines associated with M1 polarization in HMDMs. These findings suggest that RES has the potential to inhibit the progression of lung cancer by disrupting the communication between tumor cells and TAMs, ultimately leading to a reduction in tumor growth and offering a promising avenue for enhancing cancer therapy efficacy (Sun et al. <a href="#fsn370829-bib-0126" class="usa-link" aria-describedby="fsn370829-bib-0126">2017</a>).</p>
<p>P‐glycoprotein (P‐gp) is a protein that is encoded by the MDR1 gene and is classified within the ATP‐binding cassette (ABC) transporter family (Mizutani et al. <a href="#fsn370829-bib-0090" class="usa-link" aria-describedby="fsn370829-bib-0090">2008</a>). It is essential for the development of multidrug resistance (MDR) in cancer cells because it actively drives a variety of substances out of cells (Chen et al. <a href="#fsn370829-bib-0022" class="usa-link" aria-describedby="fsn370829-bib-0022">2016</a>). P‐gp expression levels have been linked to resistance to therapy in several cancers, including SCLC. For instance, when employed against drug‐resistant cells like H69AR overexpressing P‐gp, chemotherapeutic medications like Adriamycin lose their efficacy (Triller et al. <a href="#fsn370829-bib-0136" class="usa-link" aria-describedby="fsn370829-bib-0136">2006</a>; Hou et al. <a href="#fsn370829-bib-0052" class="usa-link" aria-describedby="fsn370829-bib-0052"><sup>2021</sup></a>). Therefore, comprehending the function of P‐gp is essential in formulating strategies to counteract medication resistance in cancer therapy.</p>
<p>According to research by Hou et al. the STAT3/VEGF signaling pathway is activated in SCLC cells by the inflammatory milieu, which leads to treatment resistance. On the other hand, research suggests that RES inhibits the STAT3/VEGF pathway and the inflammatory milieu, which in turn helps reduce treatment resistance in SCLC cells. It has been discovered that RES inhibits P‐gp function and lowers the expression levels of inflammatory mediators, which reduces drug resistance in SCLC cells. Furthermore, by addressing drug resistance, it has the potential as a therapeutic agent for the treatment of SCLC. This work emphasizes how the STAT3/VEGF pathway contributes to medication resistance and how RES might help prevent it. These results establish the foundation for more research on RES as a potential therapeutic intervention to address drug resistance in SCLC (Hou et al. <a href="#fsn370829-bib-0052" class="usa-link" aria-describedby="fsn370829-bib-0052">2021</a>).</p>
<p>Table <a href="#fsn370829-tbl-0002" class="usa-link">2</a> and Figure <a href="#fsn370829-fig-0003" class="usa-link">3</a> show a summary of the effects of RES on lung cancer through STAT3.</p>
<section class="tw xbox font-sm" id="fsn370829-tbl-0002"><h3 class="obj_head">TABLE 2.</h3>
<div class="caption p"><p>Resveratrol effects on STAT3 pathway in lung cancer.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Authors</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Dosage of resveratrol (RES)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Type of model</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Mechanisms</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Li, Wang, et al. (<a href="#fsn370829-bib-0077" class="usa-link" aria-describedby="fsn370829-bib-0077">2016</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">50 μM</td>
<td align="center" valign="top" rowspan="1" colspan="1">A549 cells</td>
<td align="center" valign="top" rowspan="1" colspan="1">RES exhibited a time‐dependent inhibition on STAT3 mRNA and protein expression in A549 cells. Specifically, the results of real‐time PCR and western blotting showed that the expression of STAT3 mRNA and protein decreased with time, especially at 48 and 72 h after RES administration.</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Wang et al. (<a href="#fsn370829-bib-0142" class="usa-link" aria-describedby="fsn370829-bib-0142">2020</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">50 mg/kg/day for 12 weeks</td>
<td align="center" valign="top" rowspan="1" colspan="1">Rat</td>
<td align="center" valign="top" rowspan="1" colspan="1">RES treatment led to a significant decrease in the mRNA and protein levels of STAT3 in the NSCLC+RES group compared to the NSCLC group. This suggests that RES can inhibit the expression of STAT3 in the rat model of NSCLC. The study also proposed the STAT3/HIF‐1α/VEGF pathway as a potential drug target for developing new chemotherapy agents derived from RES for the treatment of NSCLC.</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sun et al. (<a href="#fsn370829-bib-0126" class="usa-link" aria-describedby="fsn370829-bib-0126">2017</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">100 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mice</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>RES treatment led to a significant reduction in tumor growth, which was associated with the inhibition of cell proliferation and decreased expression of p‐STAT3 in tumor tissues. Additionally, RES was found to inhibit F4/80 positive expressing cells and M2 polarization in the tumors. These results suggest that RES effectively inhibits lung cancer progression by suppressing the protumor activation of tumor‐associated macrophages (TAMs) and decreasing the expression of p‐STAT3 in tumor tissues in mice.</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Hou et al. (<a href="#fsn370829-bib-0052" class="usa-link" aria-describedby="fsn370829-bib-0052">2021</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">100 μM</td>
<td align="center" valign="top" rowspan="1" colspan="1">H69 and H69AR</td>
<td align="center" valign="top" rowspan="1" colspan="1">RES suppressed the inflammatory microenvironment, decrease the expressions of p‐NF‐ĸB, IL‐1β, IL‐8, and IL‐23, and inactivate the STAT3/VEGF signaling pathway, thereby reducing drug resistance in lung cancer cells.</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/fsn370829-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fsn370829-note-0003"><p>Abbreviations: HIF‐1α, hypoxia‐inducible factor 1‐alpha; NSCLC, nonsmall cell lung cancer; P‐gp, P‐glycoprotein; SCLC, small cell lung cancer; STAT3, signal transducer and activator of transcription 3; TAMs, tumor‐associated macrophages; VEGF, vascular endothelial growth factor.</p></div></div></section><figure class="fig xbox font-sm" id="fsn370829-fig-0003"><h3 class="obj_head">FIGURE 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6962/12376182/d81e384aaff7/FSN3-13-e70829-g002.jpg" loading="lazy" id="jats-graphic-7" height="363" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/fsn370829-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Effects of RES in treating lung cancer by targeting the STAT3 signaling pathway. This figure illustrates how RES acts as a therapeutic agent for lung cancer treatment through multiple pathways. RES inhibits the expression of STAT3, HIF‐1α, and VEGF, leading to reduced lung cancer growth and metastasis. Through suppression of the STAT3/HIF‐1α/VEGF pathway, it provides a potential avenue for treating NSCLC. Additionally, RES possesses antimetastatic properties by exerting inhibitory effects on P‐glycoprotein activity and targeting tumor‐associated macrophages. The compound's ability to suppress the inflammatory microenvironment and modulate multiple signaling pathways makes it a promising therapeutic agent for lung cancer treatment.</p></figcaption></figure></section><section id="fsn370829-sec-0008"><h2 class="pmc_sec_title">8. Future Directions and Limitations</h2>
<p>The search results suggest that numerous clinical trials have been conducted to assess the effectiveness of CUR in various types of cancer, including breast cancer, colorectal cancer, and prostate cancer (Talakesh et al. <a href="#fsn370829-bib-0130" class="usa-link" aria-describedby="fsn370829-bib-0130">2022</a>; Howells et al. <a href="#fsn370829-bib-0054" class="usa-link" aria-describedby="fsn370829-bib-0054"><sup>2019</sup></a>; Choi et al. <a href="#fsn370829-bib-0023" class="usa-link" aria-describedby="fsn370829-bib-0023"><sup>2019</sup></a>). Preclinical studies have demonstrated promising anti‐inflammatory and antiproliferative effects of CUR, supporting its potential as a therapeutic agent for cancer (Xin and Zhang <a href="#fsn370829-bib-0153" class="usa-link" aria-describedby="fsn370829-bib-0153">2024</a>; Ebrahimi et al. <a href="#fsn370829-bib-0035" class="usa-link" aria-describedby="fsn370829-bib-0035"><sup>2021</sup></a>). However, the search results do not provide specific information regarding the outcomes of clinical trials involving CUR for lung cancer. Although RES has exhibited various pharmacological activities, including anticancer effects in clinical studies (Zhu et al. <a href="#fsn370829-bib-0175" class="usa-link" aria-describedby="fsn370829-bib-0175">2012</a>; Ostwal et al. <a href="#fsn370829-bib-0098" class="usa-link" aria-describedby="fsn370829-bib-0098"><sup>2022</sup></a>), the lack of clinical data for lung cancer suggests that further preclinical studies and early‐phase clinical trials may be necessary before considering larger trials for this disease. In summary, the current status of CUR in lung cancer appears to be more advanced, with some available clinical data, although the extent of this data is unclear from the search results. On the other hand, RES seems to be primarily in the preclinical stage for its applications in lung cancer, and additional preclinical and early‐phase clinical studies may be required before initiating larger trials.</p>
<p>Understanding the ADME (absorption, distribution, metabolism, and excretion) properties of a drug or compound is crucial for determining its pharmacokinetic profile, optimal dosing regimen, potential drug interactions, and overall safety and efficacy in clinical settings (Zhou, Zheng, and McClements <a href="#fsn370829-bib-0172" class="usa-link" aria-describedby="fsn370829-bib-0172"><sup>2021</sup></a>; Jaisamut et al. <a href="#fsn370829-bib-0056" class="usa-link" aria-describedby="fsn370829-bib-0056"><sup>2017</sup></a>).</p>
<p>One of the main problems in clinical research with polyphenols like CUR and RES is their limited bioavailability. This means that when taken orally, only a small amount of the compound gets absorbed into the bloodstream and reaches the target tissues (Jakobušić Brala et al. <a href="#fsn370829-bib-0057" class="usa-link" aria-describedby="fsn370829-bib-0057">2023</a>). A review study highlights that plant‐derived compounds such as CUR and RES exhibit promising anticancer effects in preclinical studies. However, the challenge lies in their restricted bioavailability, which presents a significant obstacle when attempting to apply these findings in clinical settings (Sukprasansap and Chanvorachote <a href="#fsn370829-bib-0124" class="usa-link" aria-describedby="fsn370829-bib-0124">2022</a>). CUR and RES are rapidly metabolized and eliminated from the body, further reducing their bioavailability and limiting their therapeutic efficacy (Sukprasansap and Chanvorachote <a href="#fsn370829-bib-0124" class="usa-link" aria-describedby="fsn370829-bib-0124">2022</a>; Liu et al. <a href="#fsn370829-bib-0080" class="usa-link" aria-describedby="fsn370829-bib-0080"><sup>2019</sup></a>). To overcome the bioavailability issues, the reviews emphasize the need to design new codelivery systems or formulations that can improve the absorption, distribution, and bioavailability of these polyphenols for future clinical research (Jakobušić Brala et al. <a href="#fsn370829-bib-0057" class="usa-link" aria-describedby="fsn370829-bib-0057">2023</a>; Sukprasansap and Chanvorachote <a href="#fsn370829-bib-0124" class="usa-link" aria-describedby="fsn370829-bib-0124"><sup>2022</sup></a>; Liu et al. <a href="#fsn370829-bib-0080" class="usa-link" aria-describedby="fsn370829-bib-0080"><sup>2019</sup></a>). A new self‐microemulsifying formulation incorporating both CUR and RES was created utilizing Capryol 90 as the oil component, Cremophor EL as the surfactant, and Labrasol as the cosurfactant. This formulation resulted in a tenfold increase in the total plasma concentrations of CUR and a sixfold increase in RES, in comparison to the unformulated combination, following oral administration in rabbits (Jaisamut et al. <a href="#fsn370829-bib-0056" class="usa-link" aria-describedby="fsn370829-bib-0056">2017</a>).</p>
<p>Encapsulating CUR and RES in nanoparticles, such as polymeric nanoparticles, lipid‐based nanoparticles, inorganic nanoparticles, or carbon‐based nanoparticles, can improve their solubility, stability, and bioavailability by protecting them from degradation and enhancing cellular uptake (Vieira et al. <a href="#fsn370829-bib-0139" class="usa-link" aria-describedby="fsn370829-bib-0139">2023</a>; Rassu et al. <a href="#fsn370829-bib-0110" class="usa-link" aria-describedby="fsn370829-bib-0110"><sup>2023</sup></a>). CUR, RES, and quercetin were loaded into soybean oil‐in‐water nanoemulsions, and their encapsulation efficiency was relatively high (75%–87%). This encapsulation can improve the solubility and absorption of these lipophilic polyphenols (Zhou, Zheng, and McClements <a href="#fsn370829-bib-0172" class="usa-link" aria-describedby="fsn370829-bib-0172"><sup>2021</sup></a>).</p>
<p>To address these gaps and promote the clinical progression of CUR and RES for the treatment of lung cancer, future endeavors should prioritize the implementation of rigorous preclinical investigations, the resolution of bioavailability obstacles, and the initiation of well‐designed clinical trials. The collaboration between academia, industry, and regulatory agencies is imperative to facilitate the translation of these naturally occurring compounds into efficacious therapeutic approaches for individuals diagnosed with lung cancer.</p></section><section id="fsn370829-sec-0009"><h2 class="pmc_sec_title">9. Future Research and Developments</h2>
<section id="fsn370829-sec-0010"><h3 class="pmc_sec_title">9.1. Enhancing Bioavailability</h3>
<p>One of the main challenges in translating the promising preclinical results of CUR and RES to clinical applications is their limited bioavailability. Future research should focus on:
</p>
<ul id="fsn370829-list-0001" class="list" style="list-style-type:none">
<li id="fsn370829-li-0045">
<span class="label">–</span><p class="display-inline">Developing advanced drug delivery systems to improve the absorption and bioavailability of CUR and RES.</p>
</li>
<li id="fsn370829-li-0046">
<span class="label">–</span><p class="display-inline">Exploring nanoformulations, such as polymeric nanoparticles, lipid‐based nanoparticles, and inorganic nanoparticles, to enhance cellular uptake and protect these compounds from rapid metabolism.</p>
</li>
<li id="fsn370829-li-0047">
<span class="label">–</span><p class="display-inline">Investigating codelivery systems that combine CUR and RES with other therapeutic agents to potentially synergize their effects and improve overall efficacy.</p>
</li>
</ul></section><section id="fsn370829-sec-0011"><h3 class="pmc_sec_title">9.2. Clinical Trials</h3>
<p>RES shows promising potential for cancer prevention and treatment based on preclinical studies, but more clinical research is needed to establish its efficacy in humans. Several phase I/II clinical trials are currently underway to evaluate resveratrol's effects on various cancers, including colon cancer, lymphoma, and colorectal cancer. These trials aim to assess resveratrol's ability to modulate cancer‐related biomarkers, induce apoptosis, inhibit cell proliferation, and determine its optimal dosing and safety profile in cancer patients. A 10‐year epidemiological study found that women who consumed RES from grapes had a 50% or greater reduction in breast cancer risk, suggesting potential benefits from dietary sources. However, the low bioavailability of RES in humans remains a challenge, and future research should focus on enhancing its absorption and developing more potent derivatives to maximize its anticancer effects (Bishayee <a href="#fsn370829-bib-0013" class="usa-link" aria-describedby="fsn370829-bib-0013">2009</a>; Levi et al. <a href="#fsn370829-bib-0071" class="usa-link" aria-describedby="fsn370829-bib-0071"><sup>2005</sup></a>).</p>
<p>Based on the current study, RES shows promising potential for clinical application in the prevention and treatment of lung cancer. Here are some suggestions for its clinical use:
</p>
<ul id="fsn370829-list-0002" class="list" style="list-style-type:none">
<li id="fsn370829-li-0048">
<span class="label">–</span><p class="display-inline">Nanoparticle‐based delivery: RES‐loaded nanoparticles have demonstrated enhanced anticancer activity both in vitro and in vivo. This approach could improve resveratrol's bioavailability, stability, and targeted delivery to lung cancer cells (Annaji et al. <a href="#fsn370829-bib-0006" class="usa-link" aria-describedby="fsn370829-bib-0006">2021</a>).</p>
</li>
<li id="fsn370829-li-0049">
<span class="label">–</span><p class="display-inline">Combination therapy: RES could be used in combination with standard chemotherapeutic agents to sensitize cancer cells and potentially reduce the required dosage of conventional drugs, thereby minimizing side effects (Ko et al. <a href="#fsn370829-bib-0065" class="usa-link" aria-describedby="fsn370829-bib-0065">2017</a>).</p>
</li>
<li id="fsn370829-li-0050">
<span class="label">–</span><p class="display-inline">High‐risk individuals: RES supplementation could be considered for individuals at high risk of developing lung cancer, such as heavy smokers or those with a family history of the disease.</p>
</li>
<li id="fsn370829-li-0051">
<span class="label">–</span><p class="display-inline">Combination studies: Clinical trials evaluating RES in combination with standard lung cancer treatments should be conducted to assess potential synergistic effects and optimal dosing regimens.</p>
</li>
<li id="fsn370829-li-0052">
<span class="label">–</span><p class="display-inline">Formulation optimization: Further research is needed to develop RES formulations with improved bioavailability and targeted delivery to the lungs.</p>
</li>
</ul>
<p>By implementing these suggestions, researchers and clinicians can work towards harnessing the potential of RES as a chemopreventive and therapeutic agent for lung cancer. However, it is crucial to conduct thorough clinical trials to establish its efficacy and safety in human subjects before widespread clinical application.</p>
<p>CUR has shown promising effects in enhancing cancer therapy based on numerous clinical studies. It can increase the effectiveness of chemotherapy and radiotherapy while reducing their side effects, leading to improved patient survival time and quality of life. In colorectal cancer studies, CUR increased efficacy in the large intestine, reduced glutathione S‐transferase activity, and decreased prostaglandin E2 production. It also reduced the number and size of polyps without significant toxicity. For pancreatic cancer, CUR decreased lipid peroxidation and increased glutathione content in patients. In prostate cancer, it lowered serum levels of prostate‐specific antigen when combined with isoflavones and reduced urinary symptom severity. During radiation therapy for breast cancer, CUR helped prevent skin symptoms, reduce patient pain and suffering, improve quality of life, and minimize treatment delays or interruptions. Overall, CUR can regulate multiple signaling pathways and molecular targets in cancer cells. Its low cost, pharmacological safety, efficiency, and multifaceted effects make it a promising agent for cancer prevention and treatment. However, more research is still needed to optimize dosing, bioavailability, and treatment protocols for maximum therapeutic benefit in different cancer types and stages. Close monitoring and collaboration between oncologists and integrative medicine practitioners are recommended when incorporating CUR into cancer treatment plans (Mansouri et al. <a href="#fsn370829-bib-0087" class="usa-link" aria-describedby="fsn370829-bib-0087">2020</a>).</p>
<p>Based on the systematic review of clinical studies on curcumin's effects in cancer prevention and treatment (Mansouri et al. <a href="#fsn370829-bib-0087" class="usa-link" aria-describedby="fsn370829-bib-0087">2020</a>), here are some suggestions for its use in lung cancer:</p>
<p>CUR may enhance the efficacy of chemotherapy drugs used to treat lung cancer. It could potentially reduce chemotherapy side effects and improve quality of life when combined with standard lung cancer treatments. Its supplementation during radiotherapy for lung cancer may help prevent and reduce the severity of radiation‐induced side effects. CUR has low bioavailability, so specialized formulations like nanoparticles or liposomal CUR may be needed to achieve therapeutic levels in lung tissue. While promising, curcumin's clinical applications in lung cancer care require further research to optimize dosing, formulations, and treatment protocols. Its use should be guided by individual patient factors and in consultation with the oncology care team.</p></section><section id="fsn370829-sec-0012"><h3 class="pmc_sec_title">9.3. Mechanism of Action Studies</h3>
<p>Further research is needed to elucidate the precise mechanisms by which CUR and RES exert their anticancer effects. Future studies should:
</p>
<ul id="fsn370829-list-0003" class="list" style="list-style-type:none">
<li id="fsn370829-li-0053">
<span class="label">–</span><p class="display-inline">Investigate the interaction between CUR, RES, and other components of the STAT3 signaling pathway.</p>
</li>
<li id="fsn370829-li-0054">
<span class="label">–</span><p class="display-inline">Explore potential synergistic effects of combining CUR and RES with other natural compounds or conventional therapies.</p>
</li>
<li id="fsn370829-li-0055">
<span class="label">–</span><p class="display-inline">Examine the impact of these compounds on the tumor microenvironment, including their effects on tumor‐associated macrophages and angiogenesis.</p>
</li>
</ul></section><section id="fsn370829-sec-0013"><h3 class="pmc_sec_title">9.4. Challenges With Using Curcumin and Resveratrol to Target STAT3 in Cancer Therapy</h3>
<p>There are several important challenges:
</p>
<ul id="fsn370829-list-0004" class="list" style="list-style-type:none">
<li id="fsn370829-li-0056">
<span class="label">–</span><p class="display-inline">Nonspecific effects: These compounds can interact with multiple cellular targets beyond just STAT3, which may lead to off‐target effects or reduced specificity in cancer treatment.</p>
</li>
<li id="fsn370829-li-0057">
<span class="label">–</span><p class="display-inline">Variability in cellular responses: The effects of CUR and RES can vary significantly between different cancer cell types and even within the same cancer type. This heterogeneity makes it challenging to predict and standardize treatment outcomes.</p>
</li>
<li id="fsn370829-li-0058">
<span class="label">–</span><p class="display-inline">Formulation issues: Developing effective drug delivery systems to overcome the bioavailability and stability issues of these compounds remains a significant challenge.</p>
</li>
</ul>
<p>Addressing these challenges through advanced drug delivery systems, chemical modifications, and well‐designed clinical trials is crucial for harnessing the full potential of CUR and RES in targeting STAT3 for cancer therapy.</p></section><section id="fsn370829-sec-0014"><h3 class="pmc_sec_title">9.5. Personalized Medicine Approaches</h3>
<p>As the field of oncology moves towards more personalized treatment strategies, future research should:
</p>
<ul id="fsn370829-list-0005" class="list" style="list-style-type:none">
<li id="fsn370829-li-0059">
<span class="label">–</span><p class="display-inline">Identify biomarkers that can predict patient response to CUR and RES treatment.</p>
</li>
<li id="fsn370829-li-0060">
<span class="label">–</span><p class="display-inline">Investigate how genetic variations may influence the efficacy of these compounds in different patient populations.</p>
</li>
<li id="fsn370829-li-0061">
<span class="label">–</span><p class="display-inline">Develop tailored dosing regimens based on individual patient characteristics and tumor profiles.</p>
</li>
</ul></section><section id="fsn370829-sec-0015"><h3 class="pmc_sec_title">9.6. Novel Analogues and Derivatives</h3>
<p>Building on the promising results of CUR and RES analogues, future research should:
</p>
<ul id="fsn370829-list-0006" class="list" style="list-style-type:none">
<li id="fsn370829-li-0062">
<span class="label">–</span><p class="display-inline">Continue to develop and test novel analogues of CUR and RES with improved bioavailability and potency.</p>
</li>
<li id="fsn370829-li-0063">
<span class="label">–</span><p class="display-inline">Investigate the potential of combination therapies using different analogues to target multiple cancer pathways simultaneously.</p>
</li>
<li id="fsn370829-li-0064">
<span class="label">–</span><p class="display-inline">Explore the use of computational methods and artificial intelligence to design and screen new derivatives with enhanced anticancer properties.</p>
</li>
</ul>
<p>By addressing these future directions, researchers can work toward translating the promising preclinical findings of CUR and RES into effective therapeutic strategies for lung cancer patients, potentially improving treatment outcomes and quality of life.</p></section><section id="fsn370829-sec-0016"><h3 class="pmc_sec_title">9.7. Side Effects</h3>
<p>CUR and RES, while generally well‐tolerated, can produce adverse effects when consumed in high doses or for prolonged periods. CUR has been reported to cause gastrointestinal side effects such as nausea, diarrhea, and stomach upset in some individuals, and may also interfere with blood clotting and iron absorption (Liu et al. <a href="#fsn370829-bib-0082" class="usa-link" aria-describedby="fsn370829-bib-0082">2022</a>; Asher and Spelman <a href="#fsn370829-bib-0007" class="usa-link" aria-describedby="fsn370829-bib-0007"><sup>2013</sup></a>).</p>
<p>RES supplementation has been associated with headaches, dizziness, and in rare cases, thrombocytopenia, highlighting the need for caution when using this compound as a dietary supplement (Hausenblas et al. <a href="#fsn370829-bib-0048" class="usa-link" aria-describedby="fsn370829-bib-0048">2015</a>; Kumaran et al. <a href="#fsn370829-bib-0066" class="usa-link" aria-describedby="fsn370829-bib-0066"><sup>2018</sup></a>). Both compounds have shown potential to interact with certain medications and may affect liver enzyme levels, emphasizing the importance of consulting healthcare providers before initiating supplementation, especially for individuals with preexisting medical conditions or those taking other medications (Zhang et al. <a href="#fsn370829-bib-0167" class="usa-link" aria-describedby="fsn370829-bib-0167">2021</a>; Detampel et al. <a href="#fsn370829-bib-0032" class="usa-link" aria-describedby="fsn370829-bib-0032"><sup>2012</sup></a>; Rivera‐Espinoza and Muriel <a href="#fsn370829-bib-0111" class="usa-link" aria-describedby="fsn370829-bib-0111"><sup>2009</sup></a>).</p>
<p>Consumption of these supplements can be beneficial when used under the supervision of healthcare specialists, who can monitor for potential side effects and drug interactions while tailoring dosages to individual needs.</p></section></section><section id="fsn370829-sec-0017"><h2 class="pmc_sec_title">10. Limitations</h2>
<section id="fsn370829-sec-0018"><h3 class="pmc_sec_title">10.1. Scope of Study</h3>
<p>This manuscript is a comprehensive review that synthesizes preclinical (in vitro <em>and</em> in vivo) and limited clinical data regarding CUR and RES effects on the STAT3 pathway in lung cancer. However, the majority of studies discussed are preclinical. Hence, direct clinical evidence supporting the efficacy and safety of CUR and RES as STAT3 modulators in lung cancer patients remains insufficient. Large‐scale, well‐designed clinical trials are necessary to validate these findings in humans.</p></section><section id="fsn370829-sec-0019"><h3 class="pmc_sec_title">10.2. Bioavailability Issues</h3>
<p>Both CUR and RES are known to have poor bioavailability due to rapid metabolism and systemic elimination. Despite promising anticancer activities seen in experimental models, their therapeutic effectiveness in humans might be limited without improved drug delivery systems. Although nanoparticle‐based and hybrid formulations are emerging, more research is needed to optimize these delivery approaches and demonstrate their clinical relevance.</p></section><section id="fsn370829-sec-0020"><h3 class="pmc_sec_title">10.3. Heterogeneity of Lung Cancer</h3>
<p>Lung cancer is a heterogeneous disease comprising subtypes like NSCLC and SCLC, each with distinct molecular profiles and treatment responses. The reviewed studies often do not differentiate the tumor heterogeneity sufficiently, which may influence the generalizability of STAT3‐targeted CUR and RES therapies across all lung cancer types.</p></section><section id="fsn370829-sec-0021"><h3 class="pmc_sec_title">10.4. Complexity of STAT3 Signaling</h3>
<p>The STAT3 pathway interacts extensively with other signaling networks, and its role in cancer involves multiple downstream targets and feedback loops. Targeting STAT3 alone might not comprehensively suppress tumor progression due to compensatory mechanisms and pathway redundancies. Combination therapies with other agents may be required but were not extensively addressed in this review.</p></section><section id="fsn370829-sec-0022"><h3 class="pmc_sec_title">10.5. Dose and Treatment Duration Variability</h3>
<p>There is considerable variability in the doses, treatment durations, and experimental conditions used across studies assessing CUR and RES, which complicates comparison and consensus building. Standardized protocols and dosing regimens are essential for translating preclinical results into clinical practice.</p></section><section id="fsn370829-sec-0023"><h3 class="pmc_sec_title">10.6. Potential Off‐Target Effects and Toxicity</h3>
<p>While CUR and RES are generally considered safe in dietary amounts, their pharmacological use at higher doses may carry risks of off‐target effects and toxicity. The manuscript does not fully explore the safety profile and potential adverse effects when used as STAT3 inhibitors in lung cancer therapy.</p></section></section><section id="fsn370829-sec-0024"><h2 class="pmc_sec_title">11. Perspectives</h2>
<section id="fsn370829-sec-0025"><h3 class="pmc_sec_title">11.1. Advancement of Clinical Trials</h3>
<p>While preclinical studies provide strong evidence for the inhibitory effects of CUR and RES on STAT3 signaling and lung cancer progression, there is an urgent need for well‐designed clinical trials. Future clinical investigations should focus on establishing optimal dosing, formulations, and combination regimens of CUR and RES with current lung cancer therapies to validate their efficacy and safety in humans.</p></section><section id="fsn370829-sec-0026"><h3 class="pmc_sec_title">11.2. Improved Drug Delivery Systems</h3>
<p>Given the low bioavailability and rapid metabolism of both CUR and RES, ongoing development of advanced nanoparticle‐based and hybrid delivery systems holds great promise. These systems could significantly enhance targeted delivery to lung tumor cells, improve pharmacokinetics, and overcome resistance mechanisms, ultimately enhancing therapeutic outcomes.</p></section><section id="fsn370829-sec-0027"><h3 class="pmc_sec_title">11.3. Combination Therapy Approaches</h3>
<p>The complexity and redundancy of the STAT3 signaling network suggest that combining CUR and RES with other conventional treatments such as chemotherapy, targeted therapies, or immunotherapy may be essential. Investigating synergistic effects, reduced toxicity, and resistance reversal through combination strategies should be prioritized in future studies.</p></section><section id="fsn370829-sec-0028"><h3 class="pmc_sec_title">11.4. Subtype‐Specific Research</h3>
<p>Considering the heterogeneity of lung cancer, further research should delineate the differential effects of CUR and RES on various lung cancer subtypes (NSCLC vs. SCLC) and molecular profiles. Precision medicine approaches integrating STAT3 modulation with genetic and epigenetic tumor markers could optimize patient stratification and treatment efficacy.</p></section><section id="fsn370829-sec-0029"><h3 class="pmc_sec_title">11.5. Targeting Tumor Microenvironment</h3>
<p>The ability of resveratrol to modulate the tumor microenvironment, particularly by influencing tumor‐associated macrophages and immune responses, opens avenues for exploring immune modulation alongside STAT3 inhibition. Expanding focus on the interplay between STAT3 signaling, immune checkpoints, and inflammation could advance immunotherapeutic strategies.</p></section><section id="fsn370829-sec-0030"><h3 class="pmc_sec_title">11.6. Mechanistic Insights Into STAT3 Regulation</h3>
<p>Deeper investigation into the molecular mechanisms by which CUR and RES regulate STAT3 phosphorylation and downstream gene expression, including cross‐talk with other signaling pathways, will enhance understanding of their full anticancer potential. Advanced molecular and omics approaches could identify novel biomarkers for therapy monitoring.</p></section><section id="fsn370829-sec-0031"><h3 class="pmc_sec_title">11.7. Addressing Drug Resistance</h3>
<p>Since STAT3 is implicated in chemo‐ and immunotherapy resistance, future studies should explore the potential of CUR and RES to sensitize resistant lung cancer cells and reverse resistance pathways. This could contribute to extending patient survival and improving response rates.</p></section><section id="fsn370829-sec-0032"><h3 class="pmc_sec_title">11.8. Safety and Toxicological Evaluation</h3>
<p>Comprehensive assessment of long‐term safety, pharmacodynamics, and potential off‐target effects of CUR and RES at therapeutic doses is essential before routine clinical use. Toxicology studies combined with pharmacovigilance in clinical settings will be crucial.</p>
<p>Implementing these perspectives will help translate the promising preclinical findings into tangible clinical benefits for lung cancer patients and pave the way for novel, effective adjunct therapies targeting STAT3.</p></section></section><section id="fsn370829-sec-0033"><h2 class="pmc_sec_title">12. Conclusion</h2>
<p>This comprehensive review has elucidated the therapeutic potential of CUR and RES as dual modulators of the STAT3 pathway in lung cancer. The evidence presented demonstrates that both compounds exhibit potent anticancer effects through multiple mechanisms. CUR inhibits STAT3 activation, leading to reduced tumor growth, angiogenesis, and metastasis in nonsmall cell lung cancer (NSCLC) models. It downregulates the expression of STAT3, JAK2, VEGF, Bcl‐xL, and Cyclin D1, exhibiting significant antiangiogenic potency. Similarly, RES suppresses STAT3 signaling, inhibiting tumor growth, angiogenesis, and epithelial‐mesenchymal transition in NSCLC models. Notably, RES also inhibits the M2 polarization of tumor‐associated macrophages, disrupting the communication between tumor cells and the tumor microenvironment. The reviewed studies highlight the multifaceted approach of these natural compounds in targeting lung cancer. CUR analogues, such as L48H37 and compound 5 k, have shown promise in inhibiting cancer cell motility, migration, and invasion by modulating the JAK/STAT and NF‐κB/STAT3 signaling pathways. RES demonstrates potential in overcoming drug resistance in small cell lung cancer by inhibiting the STAT3/VEGF pathway and P‐glycoprotein function.</p>
<p>While these findings are promising, the translation of CUR and RES into clinical applications faces challenges, primarily due to their limited bioavailability. Future research should focus on developing advanced drug delivery systems, exploring novel analogues with enhanced bioavailability and potency, and conducting well‐designed clinical trials. The potential of combining these compounds with conventional therapies also warrants further investigation.</p>
<p>In conclusion, CUR and RES represent promising therapeutic agents for lung cancer management through their modulation of the STAT3 pathway. As research progresses, these natural compounds may play an increasingly important role in complementing existing treatment strategies, potentially improving outcomes for lung cancer patients.</p></section><section id="fsn370829-sec-0040"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>
<strong>Mohammad Yasin Zamanian:</strong> conceptualization (equal), investigation (equal), project administration (equal), supervision (equal), writing – review and editing (equal). <strong>Klavdiya A. Turkadze:</strong> writing – original draft (equal). <strong>Mehraveh Sadeghi Ivraghi:</strong> data curation (equal), methodology (equal), resources (equal), validation (equal). <strong>Maryam Golmohammadi:</strong> conceptualization (equal), writing – original draft (equal). <strong>Maryam Sharifi:</strong> data curation (equal), resources (equal), writing – original draft (equal). <strong>Zahra Keshtpour Amlashi:</strong> conceptualization (equal), project administration (equal), writing – review and editing (equal).</p></section><section id="fsn370829-sec-0035"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>The authors have nothing to report.</p></section><section id="fsn370829-sec-0036"><h2 class="pmc_sec_title">Consent</h2>
<p>The authors have nothing to report.</p></section><section id="fsn370829-sec-0037"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="fsn370829-sec-0034" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Figure <a href="#fsn370829-fig-0001" class="usa-link">1</a> created using Biorender (<a href="https://biorender.com/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://biorender.com/</a>; Agreement number: CG27S6DW1D).</p></section><section id="notes1"><p>


Zamanian, M. Y.
, Turkadze K. A., Sadeghi Ivraghi M., Golmohammadi M., Sharifi M., and Keshtpour Amlashi Z.. 2025. “Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review.” Food Science &amp; Nutrition
13, no. 9: e70829. 10.1002/fsn3.70829.
</p>
<section id="fsn370829-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fsn370829-note-0001"><p>
<strong>Funding:</strong> The authors received no specific funding for this work.</p></div></div></section></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Mohammad Yasin Zamanian, Email: m.zamanian@umsha.ac.ir, Email: mzamaniyan66@yahoo.com.</p>
<p>Zahra Keshtpour Amlashi, Email: z.keshtpour@edu.umsha.ac.ir.</p></section><section id="fsn370829-sec-0039"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data used to support the findings of this study are available from the corresponding author upon request.</p></section><section id="fsn370829-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="fsn370829-bibl-0001_sec2"><ol class="ref-list font-sm">
<li id="fsn370829-bib-0001">
<cite>

Abbas Albaayit, S. F.
, Khan M. A., Abdullah R., and Hezmee Mohd Noor M.. 2021. “Ethyl Acetate Extract of Clausena Excavata Induces Growth Inhibition of Non‐Small‐Lung Cancer, NCI‐H460, Cell Line via Apoptosis.” Journal of Applied Biomedicine
19, no. 1: 40–47.
</cite> [<a href="https://doi.org/10.32725/jab.2021.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34907714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Applied%20Biomedicine&amp;title=Ethyl%20Acetate%20Extract%20of%20Clausena%20Excavata%20Induces%20Growth%20Inhibition%20of%20Non%E2%80%90Small%E2%80%90Lung%20Cancer,%20NCI%E2%80%90H460,%20Cell%20Line%20via%20Apoptosis&amp;author=S.%20F.%20Abbas%20Albaayit&amp;author=M.%20A.%20Khan&amp;author=R.%20Abdullah&amp;author=M.%20Hezmee%20Mohd%20Noor&amp;volume=19&amp;issue=1&amp;publication_year=2021&amp;pages=40-47&amp;pmid=34907714&amp;doi=10.32725/jab.2021.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0002">
<cite>

Alexander, M.
, Kim S. Y., and Cheng H.. 2020. “Update 2020: Management of Non‐Small Cell Lung Cancer.” Lung
198: 897–907.
</cite> [<a href="https://doi.org/10.1007/s00408-020-00407-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7656891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33175991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung&amp;title=Update%202020:%20Management%20of%20Non%E2%80%90Small%20Cell%20Lung%20Cancer&amp;author=M.%20Alexander&amp;author=S.%20Y.%20Kim&amp;author=H.%20Cheng&amp;volume=198&amp;publication_year=2020&amp;pages=897-907&amp;pmid=33175991&amp;doi=10.1007/s00408-020-00407-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0003">
<cite>

Alexandrow, M. G.
, Song L. J., Altiok S., Gray J., Haura E. B., and Kumar N. B.. 2012. “Curcumin: A Novel Stat 3 Pathway Inhibitor for Chemoprevention of Lung Cancer.” European Journal of Cancer Prevention
21, no. 5: 407–412.
</cite> [<a href="https://doi.org/10.1097/CEJ.0b013e32834ef194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3319490/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22156994/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer%20Prevention&amp;title=Curcumin:%20A%20Novel%20Stat%203%20Pathway%20Inhibitor%20for%20Chemoprevention%20of%20Lung%20Cancer&amp;author=M.%20G.%20Alexandrow&amp;author=L.%20J.%20Song&amp;author=S.%20Altiok&amp;author=J.%20Gray&amp;author=E.%20B.%20Haura&amp;volume=21&amp;issue=5&amp;publication_year=2012&amp;pages=407-412&amp;pmid=22156994&amp;doi=10.1097/CEJ.0b013e32834ef194&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0004">
<cite>

Allegra, A.
, Innao V., Russo S., Gerace D., Alonci A., and Musolino C.. 2017. “Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies.” Cancer Investigation
35, no. 1: 1–22.
</cite> [<a href="https://doi.org/10.1080/07357907.2016.1247166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27996308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Investigation&amp;title=Anticancer%20Activity%20of%20Curcumin%20and%20Its%20Analogues:%20Preclinical%20and%20Clinical%20Studies&amp;author=A.%20Allegra&amp;author=V.%20Innao&amp;author=S.%20Russo&amp;author=D.%20Gerace&amp;author=A.%20Alonci&amp;volume=35&amp;issue=1&amp;publication_year=2017&amp;pages=1-22&amp;pmid=27996308&amp;doi=10.1080/07357907.2016.1247166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0005">
<cite>

Amararathna, M.
, Johnston M. R., and Rupasinghe H. V.. 2016. “Plant Polyphenols as Chemopreventive Agents for Lung Cancer.” International Journal of Molecular Sciences
17, no. 8: 1352.
</cite> [<a href="https://doi.org/10.3390/ijms17081352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5000748/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27548149/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=Plant%20Polyphenols%20as%20Chemopreventive%20Agents%20for%20Lung%20Cancer&amp;author=M.%20Amararathna&amp;author=M.%20R.%20Johnston&amp;author=H.%20V.%20Rupasinghe&amp;volume=17&amp;issue=8&amp;publication_year=2016&amp;pages=1352&amp;pmid=27548149&amp;doi=10.3390/ijms17081352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0006">
<cite>

Annaji, M.
, Poudel I., Boddu S. H. S., Arnold R. D., Tiwari A. K., and Babu R. J.. 2021. “Resveratrol‐Loaded Nanomedicines for Cancer Applications.” Cancer Reports
4, no. 3: e1353.
</cite> [<a href="https://doi.org/10.1002/cnr2.1353" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8222557/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33655717/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Reports&amp;title=Resveratrol%E2%80%90Loaded%20Nanomedicines%20for%20Cancer%20Applications&amp;author=M.%20Annaji&amp;author=I.%20Poudel&amp;author=S.%20H.%20S.%20Boddu&amp;author=R.%20D.%20Arnold&amp;author=A.%20K.%20Tiwari&amp;volume=4&amp;issue=3&amp;publication_year=2021&amp;pages=e1353&amp;pmid=33655717&amp;doi=10.1002/cnr2.1353&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0007">
<cite>

Asher, G. N.
, and Spelman K.. 2013. “Clinical Utility of Curcumin Extract.” Alternative Therapies in Health and Medicine
19, no. 2: 20–22.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/23594449/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alternative%20Therapies%20in%20Health%20and%20Medicine&amp;title=Clinical%20Utility%20of%20Curcumin%20Extract&amp;author=G.%20N.%20Asher&amp;author=K.%20Spelman&amp;volume=19&amp;issue=2&amp;publication_year=2013&amp;pages=20-22&amp;pmid=23594449&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0008">
<cite>

Ashrafizadeh, M.
, Gholami M. H., Mirzaei S., et al. 2021. “Dual Relationship Between Long Non‐Coding RNAs and STAT3 Signaling in Different Cancers: New Insight to Proliferation and Metastasis.” Life Sciences
270: 119006.
</cite> [<a href="https://doi.org/10.1016/j.lfs.2020.119006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33421521/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Life%20Sciences&amp;title=Dual%20Relationship%20Between%20Long%20Non%E2%80%90Coding%20RNAs%20and%20STAT3%20Signaling%20in%20Different%20Cancers:%20New%20Insight%20to%20Proliferation%20and%20Metastasis&amp;author=M.%20Ashrafizadeh&amp;author=M.%20H.%20Gholami&amp;author=S.%20Mirzaei&amp;volume=270&amp;publication_year=2021&amp;pages=119006&amp;pmid=33421521&amp;doi=10.1016/j.lfs.2020.119006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0009">
<cite>

Ashrafizadeh, M.
, Mohan C. D., Rangappa S., et al. 2023. “Noncoding RNAs as Regulators of STAT3 Pathway in Gastrointestinal Cancers: Roles in Cancer Progression and Therapeutic Response.” Medicinal Research Reviews
43, no. 5: 1263–1321.
</cite> [<a href="https://doi.org/10.1002/med.21950" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36951271/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicinal%20Research%20Reviews&amp;title=Noncoding%20RNAs%20as%20Regulators%20of%20STAT3%20Pathway%20in%20Gastrointestinal%20Cancers:%20Roles%20in%20Cancer%20Progression%20and%20Therapeutic%20Response&amp;author=M.%20Ashrafizadeh&amp;author=C.%20D.%20Mohan&amp;author=S.%20Rangappa&amp;volume=43&amp;issue=5&amp;publication_year=2023&amp;pages=1263-1321&amp;pmid=36951271&amp;doi=10.1002/med.21950&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0010">
<cite>

Ashrafizadeh, M.
, Najafi M., Makvandi P., Zarrabi A., Farkhondeh T., and Samarghandian S.. 2020. “Versatile Role of Curcumin and Its Derivatives in Lung Cancer Therapy.” Journal of Cellular Physiology
235, no. 12: 9241–9268.
</cite> [<a href="https://doi.org/10.1002/jcp.29819" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32519340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Cellular%20Physiology&amp;title=Versatile%20Role%20of%20Curcumin%20and%20Its%20Derivatives%20in%20Lung%20Cancer%20Therapy&amp;author=M.%20Ashrafizadeh&amp;author=M.%20Najafi&amp;author=P.%20Makvandi&amp;author=A.%20Zarrabi&amp;author=T.%20Farkhondeh&amp;volume=235&amp;issue=12&amp;publication_year=2020&amp;pages=9241-9268&amp;pmid=32519340&amp;doi=10.1002/jcp.29819&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0011">
<cite>

Ashrafizadeh, M.
, Zarrabi A., Orouei S., et al. 2020. “STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects.” Biology
9, no. 6: 126.
</cite> [<a href="https://doi.org/10.3390/biology9060126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7345582/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32545648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biology&amp;title=STAT3%20Pathway%20in%20Gastric%20Cancer:%20Signaling,%20Therapeutic%20Targeting%20and%20Future%20Prospects&amp;author=M.%20Ashrafizadeh&amp;author=A.%20Zarrabi&amp;author=S.%20Orouei&amp;volume=9&amp;issue=6&amp;publication_year=2020&amp;pages=126&amp;pmid=32545648&amp;doi=10.3390/biology9060126&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0012">
<cite>

Athar, M.
, Back J. H., Kopelovich L., Bickers D. R., and Kim A. L.. 2009. “Multiple Molecular Targets of Resveratrol: Anti‐Carcinogenic Mechanisms.” Archives of Biochemistry and Biophysics
486, no. 2: 95–102.
</cite> [<a href="https://doi.org/10.1016/j.abb.2009.01.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2749321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19514131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Archives%20of%20Biochemistry%20and%20Biophysics&amp;title=Multiple%20Molecular%20Targets%20of%20Resveratrol:%20Anti%E2%80%90Carcinogenic%20Mechanisms&amp;author=M.%20Athar&amp;author=J.%20H.%20Back&amp;author=L.%20Kopelovich&amp;author=D.%20R.%20Bickers&amp;author=A.%20L.%20Kim&amp;volume=486&amp;issue=2&amp;publication_year=2009&amp;pages=95-102&amp;pmid=19514131&amp;doi=10.1016/j.abb.2009.01.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0013">
<cite>

Bishayee, A.

2009. “Cancer Prevention and Treatment With Resveratrol: From Rodent Studies to Clinical Trials.” Cancer Prevention Research
2, no. 5: 409–418.
</cite> [<a href="https://doi.org/10.1158/1940-6207.CAPR-08-0160" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19401532/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Prevention%20Research&amp;title=Cancer%20Prevention%20and%20Treatment%20With%20Resveratrol:%20From%20Rodent%20Studies%20to%20Clinical%20Trials&amp;author=A.%20Bishayee&amp;volume=2&amp;issue=5&amp;publication_year=2009&amp;pages=409-418&amp;pmid=19401532&amp;doi=10.1158/1940-6207.CAPR-08-0160&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0014">
<cite>

Bishayee, A.
, Politis T., and Darvesh A. S.. 2010. “Resveratrol in the Chemoprevention and Treatment of Hepatocellular Carcinoma.” Cancer Treatment Reviews
36, no. 1: 43–53.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2009.10.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19910122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treatment%20Reviews&amp;title=Resveratrol%20in%20the%20Chemoprevention%20and%20Treatment%20of%20Hepatocellular%20Carcinoma&amp;author=A.%20Bishayee&amp;author=T.%20Politis&amp;author=A.%20S.%20Darvesh&amp;volume=36&amp;issue=1&amp;publication_year=2010&amp;pages=43-53&amp;pmid=19910122&amp;doi=10.1016/j.ctrv.2009.10.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0015">
<cite>

Bromberg, J.
, and Darnell J. E.. 2000. “The Role of STATs in Transcriptional Control and Their Impact on Cellular Function.” Oncogene
19, no. 21: 2468–2473.
</cite> [<a href="https://doi.org/10.1038/sj.onc.1203476" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10851045/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The%20Role%20of%20STATs%20in%20Transcriptional%20Control%20and%20Their%20Impact%20on%20Cellular%20Function&amp;author=J.%20Bromberg&amp;author=J.%20E.%20Darnell&amp;volume=19&amp;issue=21&amp;publication_year=2000&amp;pages=2468-2473&amp;pmid=10851045&amp;doi=10.1038/sj.onc.1203476&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0016">
<cite>

Brüske‐Hohlfeld, I.

2009. “Environmental and Occupational Risk Factors for Lung Cancer.” In Cancer Epidemiology: Modifiable Factors, 3–23. Springer.</cite> [<a href="https://doi.org/10.1007/978-1-60327-492-0_1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19107427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Cancer%20Epidemiology:%20Modifiable%20Factors&amp;author=I.%20Br%C3%BCske%E2%80%90Hohlfeld&amp;publication_year=2009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0017">
<cite>

Chalikonda, G.
, Lee H., Sheik A., and Huh Y. S.. 2021. “Targeting Key Transcriptional Factor STAT3 in Colorectal Cancer.” Molecular and Cellular Biochemistry
476: 3219–3228.
</cite> [<a href="https://doi.org/10.1007/s11010-021-04156-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33866491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20and%20Cellular%20Biochemistry&amp;title=Targeting%20Key%20Transcriptional%20Factor%20STAT3%20in%20Colorectal%20Cancer&amp;author=G.%20Chalikonda&amp;author=H.%20Lee&amp;author=A.%20Sheik&amp;author=Y.%20S.%20Huh&amp;volume=476&amp;publication_year=2021&amp;pages=3219-3228&amp;pmid=33866491&amp;doi=10.1007/s11010-021-04156-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0018">
<cite>

Chang, H.‐B.
, and Chen B.‐H.. 2015. “Inhibition of Lung Cancer Cells A549 and H460 by Curcuminoid Extracts and Nanoemulsions Prepared From 
<em>Curcuma longa</em>
 Linnaeus.” International Journal of Nanomedicine
10: 5059–5080.
</cite> [<a href="https://doi.org/10.2147/IJN.S87225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4531038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26345201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Nanomedicine&amp;title=Inhibition%20of%20Lung%20Cancer%20Cells%20A549%20and%20H460%20by%20Curcuminoid%20Extracts%20and%20Nanoemulsions%20Prepared%20From%20Curcuma%20longa%20Linnaeus&amp;author=H.%E2%80%90B.%20Chang&amp;author=B.%E2%80%90H.%20Chen&amp;volume=10&amp;publication_year=2015&amp;pages=5059-5080&amp;pmid=26345201&amp;doi=10.2147/IJN.S87225&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0019">
<cite>

Chen, M.
, Jiang J., Chen J., et al. 2023. “The Clinical Safety and Efficacy of Targeted PD‐L1 Therapy With Durvalumab in Solid Tumors.” Current Drug Targets
24, no. 7: 584–598.
</cite> [<a href="https://doi.org/10.2174/1389450124666230330101651" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36998143/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Drug%20Targets&amp;title=The%20Clinical%20Safety%20and%20Efficacy%20of%20Targeted%20PD%E2%80%90L1%20Therapy%20With%20Durvalumab%20in%20Solid%20Tumors&amp;author=M.%20Chen&amp;author=J.%20Jiang&amp;author=J.%20Chen&amp;volume=24&amp;issue=7&amp;publication_year=2023&amp;pages=584-598&amp;pmid=36998143&amp;doi=10.2174/1389450124666230330101651&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0020">
<cite>

Chen, Q.
, Lv J., Yang W., et al. 2019. “Targeted Inhibition of STAT3 as a Potential Treatment Strategy for Atherosclerosis.” Theranostics
9, no. 22: 6424–6442.
</cite> [<a href="https://doi.org/10.7150/thno.35528" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6771242/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31588227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Targeted%20Inhibition%20of%20STAT3%20as%20a%20Potential%20Treatment%20Strategy%20for%20Atherosclerosis&amp;author=Q.%20Chen&amp;author=J.%20Lv&amp;author=W.%20Yang&amp;volume=9&amp;issue=22&amp;publication_year=2019&amp;pages=6424-6442&amp;pmid=31588227&amp;doi=10.7150/thno.35528&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0021">
<cite>

Chen, Z.
, and Han Z. C.. 2008. “STAT3: A Critical Transcription Activator in Angiogenesis.” Medicinal Research Reviews
28, no. 2: 185–200.
</cite> [<a href="https://doi.org/10.1002/med.20101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17457812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicinal%20Research%20Reviews&amp;title=STAT3:%20A%20Critical%20Transcription%20Activator%20in%20Angiogenesis&amp;author=Z.%20Chen&amp;author=Z.%20C.%20Han&amp;volume=28&amp;issue=2&amp;publication_year=2008&amp;pages=185-200&amp;pmid=17457812&amp;doi=10.1002/med.20101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0022">
<cite>

Chen, Z.
, Shi T., Zhang L., et al. 2016. “Mammalian Drug Efflux Transporters of the ATP Binding Cassette (ABC) Family in Multidrug Resistance: A Review of the Past Decade.” Cancer Letters
370, no. 1: 153–164.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2015.10.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26499806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Letters&amp;title=Mammalian%20Drug%20Efflux%20Transporters%20of%20the%20ATP%20Binding%20Cassette%20(ABC)%20Family%20in%20Multidrug%20Resistance:%20A%20Review%20of%20the%20Past%20Decade&amp;author=Z.%20Chen&amp;author=T.%20Shi&amp;author=L.%20Zhang&amp;volume=370&amp;issue=1&amp;publication_year=2016&amp;pages=153-164&amp;pmid=26499806&amp;doi=10.1016/j.canlet.2015.10.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0023">
<cite>

Choi, Y. H.
, Han D. H., Kim S. W., et al. 2019. “A Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Role of Curcumin in Prostate Cancer Patients With Intermittent Androgen Deprivation.” Prostate
79, no. 6: 614–621.
</cite> [<a href="https://doi.org/10.1002/pros.23766" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30671976/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=A%20Randomized,%20Double%E2%80%90Blind,%20Placebo%E2%80%90Controlled%20Trial%20to%20Evaluate%20the%20Role%20of%20Curcumin%20in%20Prostate%20Cancer%20Patients%20With%20Intermittent%20Androgen%20Deprivation&amp;author=Y.%20H.%20Choi&amp;author=D.%20H.%20Han&amp;author=S.%20W.%20Kim&amp;volume=79&amp;issue=6&amp;publication_year=2019&amp;pages=614-621&amp;pmid=30671976&amp;doi=10.1002/pros.23766&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0024">
<cite>

Christenson, J.
, Whitby S. J., Mellor D., et al. 2016. “The Effects of Resveratrol Supplementation in Overweight and Obese Humans: A Systematic Review of Randomized Trials.” Metabolic Syndrome and Related Disorders
14, no. 7: 323–333.
</cite> [<a href="https://doi.org/10.1089/met.2016.0035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27379440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Metabolic%20Syndrome%20and%20Related%20Disorders&amp;title=The%20Effects%20of%20Resveratrol%20Supplementation%20in%20Overweight%20and%20Obese%20Humans:%20A%20Systematic%20Review%20of%20Randomized%20Trials&amp;author=J.%20Christenson&amp;author=S.%20J.%20Whitby&amp;author=D.%20Mellor&amp;volume=14&amp;issue=7&amp;publication_year=2016&amp;pages=323-333&amp;pmid=27379440&amp;doi=10.1089/met.2016.0035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0025">
<cite>

Christofides, A.
, Strauss L., Yeo A., Cao C., Charest A., and Boussiotis V. A.. 2022. “The Complex Role of Tumor‐Infiltrating Macrophages.” Nature Immunology
23, no. 8: 1148–1156.
</cite> [<a href="https://doi.org/10.1038/s41590-022-01267-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10754321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35879449/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Immunology&amp;title=The%20Complex%20Role%20of%20Tumor%E2%80%90Infiltrating%20Macrophages&amp;author=A.%20Christofides&amp;author=L.%20Strauss&amp;author=A.%20Yeo&amp;author=C.%20Cao&amp;author=A.%20Charest&amp;volume=23&amp;issue=8&amp;publication_year=2022&amp;pages=1148-1156&amp;pmid=35879449&amp;doi=10.1038/s41590-022-01267-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0026">
<cite>

Cottart, C. H.
, Nivet‐Antoine V., Laguillier‐Morizot C., and Beaudeux J. L.. 2010. “Resveratrol Bioavailability and Toxicity in Humans.” Molecular Nutrition &amp; Food Research
54, no. 1: 7–16.
</cite> [<a href="https://doi.org/10.1002/mnfr.200900437" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20013887/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Nutrition%20&amp;%20Food%20Research&amp;title=Resveratrol%20Bioavailability%20and%20Toxicity%20in%20Humans&amp;author=C.%20H.%20Cottart&amp;author=V.%20Nivet%E2%80%90Antoine&amp;author=C.%20Laguillier%E2%80%90Morizot&amp;author=J.%20L.%20Beaudeux&amp;volume=54&amp;issue=1&amp;publication_year=2010&amp;pages=7-16&amp;pmid=20013887&amp;doi=10.1002/mnfr.200900437&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0027">
<cite>

Cox, F. F.
, Misiou A., Vierkant A., et al. 2022. “Protective Effects of Curcumin in Cardiovascular Diseases—Impact on Oxidative Stress and Mitochondria.” Cells
11, no. 3: 342.
</cite> [<a href="https://doi.org/10.3390/cells11030342" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8833931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35159155/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Protective%20Effects%20of%20Curcumin%20in%20Cardiovascular%20Diseases%E2%80%94Impact%20on%20Oxidative%20Stress%20and%20Mitochondria&amp;author=F.%20F.%20Cox&amp;author=A.%20Misiou&amp;author=A.%20Vierkant&amp;volume=11&amp;issue=3&amp;publication_year=2022&amp;pages=342&amp;pmid=35159155&amp;doi=10.3390/cells11030342&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0028">
<cite>

Cui, H.
, Arnst K., Miller D. D., and Li W.. 2020. “Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non‐Small Cell Lung Cancer and Strategies to Overcome Drug Resistance.” Current Medicinal Chemistry
27, no. 39: 6573–6595.
</cite> [<a href="https://doi.org/10.2174/0929867326666191016113631" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33243106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Medicinal%20Chemistry&amp;title=Recent%20Advances%20in%20Elucidating%20Paclitaxel%20Resistance%20Mechanisms%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer%20and%20Strategies%20to%20Overcome%20Drug%20Resistance&amp;author=H.%20Cui&amp;author=K.%20Arnst&amp;author=D.%20D.%20Miller&amp;author=W.%20Li&amp;volume=27&amp;issue=39&amp;publication_year=2020&amp;pages=6573-6595&amp;pmid=33243106&amp;doi=10.2174/0929867326666191016113631&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0029">
<cite>

Dallavalasa, S.
, Beeraka N. M., Basavaraju C. G., et al. 2021. “The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis‐Current Status.” Current Medicinal Chemistry
28, no. 39: 8203–8236.
</cite> [<a href="https://doi.org/10.2174/0929867328666210720143721" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34303328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Medicinal%20Chemistry&amp;title=The%20Role%20of%20Tumor%20Associated%20Macrophages%20(TAMs)%20in%20Cancer%20Progression,%20Chemoresistance,%20Angiogenesis%20and%20Metastasis%E2%80%90Current%20Status&amp;author=S.%20Dallavalasa&amp;author=N.%20M.%20Beeraka&amp;author=C.%20G.%20Basavaraju&amp;volume=28&amp;issue=39&amp;publication_year=2021&amp;pages=8203-8236&amp;pmid=34303328&amp;doi=10.2174/0929867328666210720143721&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0030">
<cite>

Das, S. S.
, Tambe S., Prasad Verma P. R., et al. 2022. “Molecular Insights and Therapeutic Implications of Nanoengineered Dietary Polyphenols for Targeting Lung Cancer: Part II.” Nanomedicine
17, no. 23: 1799–1816.
</cite> [<a href="https://doi.org/10.2217/nnm-2022-0117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36636965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nanomedicine&amp;title=Molecular%20Insights%20and%20Therapeutic%20Implications%20of%20Nanoengineered%20Dietary%20Polyphenols%20for%20Targeting%20Lung%20Cancer:%20Part%20II&amp;author=S.%20S.%20Das&amp;author=S.%20Tambe&amp;author=P.%20R.%20Prasad%20Verma&amp;volume=17&amp;issue=23&amp;publication_year=2022&amp;pages=1799-1816&amp;pmid=36636965&amp;doi=10.2217/nnm-2022-0117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0031">
<cite>

Dehzad, M. J.
, Ghalandari H., Nouri M., and Askarpour M.. 2023. “Antioxidant and Anti‐Inflammatory Effects of Curcumin/Turmeric Supplementation in Adults: A GRADE‐Assessed Systematic Review and Dose–Response Meta‐Analysis of Randomized Controlled Trials.” Cytokine
164: 156144.
</cite> [<a href="https://doi.org/10.1016/j.cyto.2023.156144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36804260/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytokine&amp;title=Antioxidant%20and%20Anti%E2%80%90Inflammatory%20Effects%20of%20Curcumin/Turmeric%20Supplementation%20in%20Adults:%20A%20GRADE%E2%80%90Assessed%20Systematic%20Review%20and%20Dose%E2%80%93Response%20Meta%E2%80%90Analysis%20of%20Randomized%20Controlled%20Trials&amp;author=M.%20J.%20Dehzad&amp;author=H.%20Ghalandari&amp;author=M.%20Nouri&amp;author=M.%20Askarpour&amp;volume=164&amp;publication_year=2023&amp;pages=156144&amp;pmid=36804260&amp;doi=10.1016/j.cyto.2023.156144&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0032">
<cite>

Detampel, P.
, Beck M., Krähenbühl S., and Huwyler J.. 2012. “Drug Interaction Potential of Resveratrol.” Drug Metabolism Reviews
44, no. 3: 253–265.
</cite> [<a href="https://doi.org/10.3109/03602532.2012.700715" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22788578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Metabolism%20Reviews&amp;title=Drug%20Interaction%20Potential%20of%20Resveratrol&amp;author=P.%20Detampel&amp;author=M.%20Beck&amp;author=S.%20Kr%C3%A4henb%C3%BChl&amp;author=J.%20Huwyler&amp;volume=44&amp;issue=3&amp;publication_year=2012&amp;pages=253-265&amp;pmid=22788578&amp;doi=10.3109/03602532.2012.700715&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0033">
<cite>

Duan, J.
, Yue W., E J. Y., et al. 2016. “In Vitro Comparative Studies of Resveratrol and Triacetylresveratrol on Cell Proliferation, Apoptosis, and STAT3 and NFκB Signaling in Pancreatic Cancer Cells.” Scientific Reports
6, no. 1: 31672.
</cite> [<a href="https://doi.org/10.1038/srep31672" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4990919/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27539371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=In%20Vitro%20Comparative%20Studies%20of%20Resveratrol%20and%20Triacetylresveratrol%20on%20Cell%20Proliferation,%20Apoptosis,%20and%20STAT3%20and%20NF%CE%BAB%20Signaling%20in%20Pancreatic%20Cancer%20Cells&amp;author=J.%20Duan&amp;author=W.%20Yue&amp;author=J.%20Y.%20E&amp;volume=6&amp;issue=1&amp;publication_year=2016&amp;pages=31672&amp;pmid=27539371&amp;doi=10.1038/srep31672&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0034">
<cite>

E Wright, L.
, B Frye J., Gorti B., N Timmermann B., and L Funk J.. 2013. “Bioactivity of Turmeric‐Derived Curcuminoids and Related Metabolites in Breast Cancer.” Current Pharmaceutical Design
19, no. 34: 6218–6225.
</cite> [<a href="https://doi.org/10.2174/1381612811319340013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3883055/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23448448/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Pharmaceutical%20Design&amp;title=Bioactivity%20of%20Turmeric%E2%80%90Derived%20Curcuminoids%20and%20Related%20Metabolites%20in%20Breast%20Cancer&amp;author=L.%20E%20Wright&amp;author=J.%20B%20Frye&amp;author=B.%20Gorti&amp;author=B.%20N%20Timmermann&amp;author=J.%20L%20Funk&amp;volume=19&amp;issue=34&amp;publication_year=2013&amp;pages=6218-6225&amp;pmid=23448448&amp;doi=10.2174/1381612811319340013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0035">
<cite>

Ebrahimi, M.
, Babaei E., Neri F., and Feizi M. A. H.. 2021. “Anti‐Proliferative and Apoptotic Effect of Gemini Curcumin in p53‐Wild Type and p53‐Mutant Colorectal Cancer Cell Lines.” International Journal of Pharmaceutics
601: 120592.
</cite> [<a href="https://doi.org/10.1016/j.ijpharm.2021.120592" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33857585/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Pharmaceutics&amp;title=Anti%E2%80%90Proliferative%20and%20Apoptotic%20Effect%20of%20Gemini%20Curcumin%20in%20p53%E2%80%90Wild%20Type%20and%20p53%E2%80%90Mutant%20Colorectal%20Cancer%20Cell%20Lines&amp;author=M.%20Ebrahimi&amp;author=E.%20Babaei&amp;author=F.%20Neri&amp;author=M.%20A.%20H.%20Feizi&amp;volume=601&amp;publication_year=2021&amp;pages=120592&amp;pmid=33857585&amp;doi=10.1016/j.ijpharm.2021.120592&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0036">
<cite>

El‐Hussein, A.
, Manoto S. L., Ombinda‐Lemboumba S., Alrowaili Z. A., and Mthunzi‐Kufa P.. 2021. “A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment.” Anti‐Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry‐Anti‐Cancer Agents)
21, no. 2: 149–161.</cite> [<a href="https://doi.org/10.2174/1871520620666200403144945" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32242788/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anti%E2%80%90Cancer%20Agents%20in%20Medicinal%20Chemistry%20(Formerly%20Current%20Medicinal%20Chemistry%E2%80%90Anti%E2%80%90Cancer%20Agents)&amp;title=A%20Review%20of%20Chemotherapy%20and%20Photodynamic%20Therapy%20for%20Lung%20Cancer%20Treatment&amp;author=A.%20El%E2%80%90Hussein&amp;author=S.%20L.%20Manoto&amp;author=S.%20Ombinda%E2%80%90Lemboumba&amp;author=Z.%20A.%20Alrowaili&amp;author=P.%20Mthunzi%E2%80%90Kufa&amp;volume=21&amp;issue=2&amp;publication_year=2021&amp;pages=149-161&amp;pmid=32242788&amp;doi=10.2174/1871520620666200403144945&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0037">
<cite>

El‐Tanani, M.
, Al Khatib A. O., Aladwan S. M., Abuelhana A., McCarron P. A., and Tambuwala M. M.. 2022. “Importance of STAT3 Signalling in Cancer, Metastasis and Therapeutic Interventions.” Cellular Signalling
92: 110275.
</cite> [<a href="https://doi.org/10.1016/j.cellsig.2022.110275" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35122990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cellular%20Signalling&amp;title=Importance%20of%20STAT3%20Signalling%20in%20Cancer,%20Metastasis%20and%20Therapeutic%20Interventions&amp;author=M.%20El%E2%80%90Tanani&amp;author=A.%20O.%20Al%20Khatib&amp;author=S.%20M.%20Aladwan&amp;author=A.%20Abuelhana&amp;author=P.%20A.%20McCarron&amp;volume=92&amp;publication_year=2022&amp;pages=110275&amp;pmid=35122990&amp;doi=10.1016/j.cellsig.2022.110275&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0038">
<cite>

Flanders, M.
, and Gramlich W. M.. 2022. “Water‐Soluble and Degradation‐Resistant Curcumin Copolymers From Reversible Addition–Fragmentation Chain (RAFT) Copolymerization.” Macromolecules
55, no. 10: 4064–4075.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Macromolecules&amp;title=Water%E2%80%90Soluble%20and%20Degradation%E2%80%90Resistant%20Curcumin%20Copolymers%20From%20Reversible%20Addition%E2%80%93Fragmentation%20Chain%20(RAFT)%20Copolymerization&amp;author=M.%20Flanders&amp;author=W.%20M.%20Gramlich&amp;volume=55&amp;issue=10&amp;publication_year=2022&amp;pages=4064-4075&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0039">
<cite>

Forde, P. M.
, Spicer J., Lu S., et al. 2022. “Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer.” New England Journal of Medicine
386, no. 21: 1973–1985.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2202170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9844511/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35403841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Neoadjuvant%20Nivolumab%20Plus%20Chemotherapy%20in%20Resectable%20Lung%20Cancer&amp;author=P.%20M.%20Forde&amp;author=J.%20Spicer&amp;author=S.%20Lu&amp;volume=386&amp;issue=21&amp;publication_year=2022&amp;pages=1973-1985&amp;pmid=35403841&amp;doi=10.1056/NEJMoa2202170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0040">
<cite>

Gandhi, L.
, Rodríguez‐Abreu D., Gadgeel S., et al. 2018. “Pembrolizumab Plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer.” New England Journal of Medicine
378, no. 22: 2078–2092.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1801005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29658856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Pembrolizumab%20Plus%20Chemotherapy%20in%20Metastatic%20Non%E2%80%93Small%E2%80%90Cell%20Lung%20Cancer&amp;author=L.%20Gandhi&amp;author=D.%20Rodr%C3%ADguez%E2%80%90Abreu&amp;author=S.%20Gadgeel&amp;volume=378&amp;issue=22&amp;publication_year=2018&amp;pages=2078-2092&amp;pmid=29658856&amp;doi=10.1056/NEJMoa1801005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0041">
<cite>

Garbers, C.
, Aparicio‐Siegmund S., and Rose‐John S.. 2015. “The IL‐6/gp130/STAT3 Signaling Axis: Recent Advances Towards Specific Inhibition.” Current Opinion in Immunology
34: 75–82.
</cite> [<a href="https://doi.org/10.1016/j.coi.2015.02.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25749511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Opinion%20in%20Immunology&amp;title=The%20IL%E2%80%906/gp130/STAT3%20Signaling%20Axis:%20Recent%20Advances%20Towards%20Specific%20Inhibition&amp;author=C.%20Garbers&amp;author=S.%20Aparicio%E2%80%90Siegmund&amp;author=S.%20Rose%E2%80%90John&amp;volume=34&amp;publication_year=2015&amp;pages=75-82&amp;pmid=25749511&amp;doi=10.1016/j.coi.2015.02.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0042">
<cite>

George, B. P.
, Chandran R., and Abrahamse H.. 2021. “Role of Phytochemicals in Cancer Chemoprevention: Insights.” Antioxidants
10, no. 9: 1455.
</cite> [<a href="https://doi.org/10.3390/antiox10091455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8466984/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34573087/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antioxidants&amp;title=Role%20of%20Phytochemicals%20in%20Cancer%20Chemoprevention:%20Insights&amp;author=B.%20P.%20George&amp;author=R.%20Chandran&amp;author=H.%20Abrahamse&amp;volume=10&amp;issue=9&amp;publication_year=2021&amp;pages=1455&amp;pmid=34573087&amp;doi=10.3390/antiox10091455&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0043">
<cite>

Girigoswami, A.
, and Girigoswami K.. 2023. “Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment.” Genes
14, no. 7: 1370.
</cite> [<a href="https://doi.org/10.3390/genes14071370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10379962/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37510275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes&amp;title=Potential%20Applications%20of%20Nanoparticles%20in%20Improving%20the%20Outcome%20of%20Lung%20Cancer%20Treatment&amp;author=A.%20Girigoswami&amp;author=K.%20Girigoswami&amp;volume=14&amp;issue=7&amp;publication_year=2023&amp;pages=1370&amp;pmid=37510275&amp;doi=10.3390/genes14071370&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0044">
<cite>

Guanizo, A. C.
, Fernando C. D., Garama D. J., and Gough D. J.. 2018. “STAT3: A Multifaceted Oncoprotein.” Growth Factors
36, no. 1–2: 1–14.
</cite> [<a href="https://doi.org/10.1080/08977194.2018.1473393" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29873274/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Growth%20Factors&amp;title=STAT3:%20A%20Multifaceted%20Oncoprotein&amp;author=A.%20C.%20Guanizo&amp;author=C.%20D.%20Fernando&amp;author=D.%20J.%20Garama&amp;author=D.%20J.%20Gough&amp;volume=36&amp;issue=1%E2%80%932&amp;publication_year=2018&amp;pages=1-14&amp;pmid=29873274&amp;doi=10.1080/08977194.2018.1473393&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0045">
<cite>

Ham, I.‐H.
, Wang L., Lee D., et al. 2022. “Curcumin Inhibits the Cancer‐Associated Fibroblast‐Derived Chemoresistance of Gastric Cancer Through the Suppression of the JAK/STAT3 Signaling Pathway.” International Journal of Oncology
61, no. 1: 1–12.</cite> [<a href="https://doi.org/10.3892/ijo.2022.5375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9170354/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35621145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Oncology&amp;title=Curcumin%20Inhibits%20the%20Cancer%E2%80%90Associated%20Fibroblast%E2%80%90Derived%20Chemoresistance%20of%20Gastric%20Cancer%20Through%20the%20Suppression%20of%20the%20JAK/STAT3%20Signaling%20Pathway&amp;author=I.%E2%80%90H.%20Ham&amp;author=L.%20Wang&amp;author=D.%20Lee&amp;volume=61&amp;issue=1&amp;publication_year=2022&amp;pages=1-12&amp;pmid=35621145&amp;doi=10.3892/ijo.2022.5375&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0046">
<cite>

Han, S.
, Wang W., Wang S., et al. 2021. “Tumor Microenvironment Remodeling and Tumor Therapy Based on M2‐Like Tumor Associated Macrophage‐Targeting Nano‐Complexes.” Theranostics
11, no. 6: 2892–2916.
</cite> [<a href="https://doi.org/10.7150/thno.50928" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7806477/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33456579/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Tumor%20Microenvironment%20Remodeling%20and%20Tumor%20Therapy%20Based%20on%20M2%E2%80%90Like%20Tumor%20Associated%20Macrophage%E2%80%90Targeting%20Nano%E2%80%90Complexes&amp;author=S.%20Han&amp;author=W.%20Wang&amp;author=S.%20Wang&amp;volume=11&amp;issue=6&amp;publication_year=2021&amp;pages=2892-2916&amp;pmid=33456579&amp;doi=10.7150/thno.50928&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0047">
<cite>

Hashemi, M.
, Abbaszadeh S., Rashidi M., et al. 2023. “STAT3 as a Newly Emerging Target in Colorectal Cancer Therapy: Tumorigenesis, Therapy Response, and Pharmacological/Nanoplatform Strategies.” Environmental Research
233: 116458.
</cite> [<a href="https://doi.org/10.1016/j.envres.2023.116458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37348629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Environmental%20Research&amp;title=STAT3%20as%20a%20Newly%20Emerging%20Target%20in%20Colorectal%20Cancer%20Therapy:%20Tumorigenesis,%20Therapy%20Response,%20and%20Pharmacological/Nanoplatform%20Strategies&amp;author=M.%20Hashemi&amp;author=S.%20Abbaszadeh&amp;author=M.%20Rashidi&amp;volume=233&amp;publication_year=2023&amp;pages=116458&amp;pmid=37348629&amp;doi=10.1016/j.envres.2023.116458&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0048">
<cite>

Hausenblas, H. A.
, Schoulda J. A., and Smoliga J. M.. 2015. “Resveratrol Treatment as an Adjunct to Pharmacological Management in Type 2 Diabetes Mellitus—Systematic Review and Meta‐Analysis.” Molecular Nutrition &amp; Food Research
59, no. 1: 147–159.
</cite> [<a href="https://doi.org/10.1002/mnfr.201400173" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25138371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Nutrition%20&amp;%20Food%20Research&amp;title=Resveratrol%20Treatment%20as%20an%20Adjunct%20to%20Pharmacological%20Management%20in%20Type%202%20Diabetes%20Mellitus%E2%80%94Systematic%20Review%20and%20Meta%E2%80%90Analysis&amp;author=H.%20A.%20Hausenblas&amp;author=J.%20A.%20Schoulda&amp;author=J.%20M.%20Smoliga&amp;volume=59&amp;issue=1&amp;publication_year=2015&amp;pages=147-159&amp;pmid=25138371&amp;doi=10.1002/mnfr.201400173&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0049">
<cite>

Herreros Pomares, A.

2020. Tumorspheres as an In Vitro Model for Cancer Stem‐Like Cell Characterization in Non‐Small Cell Lung Cancer. Prognostic Implications. Universitat Politècnica de València.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Tumorspheres%20as%20an%20In%C2%A0Vitro%20Model%20for%20Cancer%20Stem%E2%80%90Like%20Cell%20Characterization%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer.%20Prognostic%20Implications&amp;author=A.%20Herreros%20Pomares&amp;publication_year=2020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0050">
<cite>

Holder, J. E.
, Ferguson C., Oliveira E., et al. 2023. “The Use of Nanoparticles for Targeted Drug Delivery in Non‐Small Cell Lung Cancer.” Frontiers in Oncology
13: 1154318.
</cite> [<a href="https://doi.org/10.3389/fonc.2023.1154318" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10042133/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36994202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=The%20Use%20of%20Nanoparticles%20for%20Targeted%20Drug%20Delivery%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer&amp;author=J.%20E.%20Holder&amp;author=C.%20Ferguson&amp;author=E.%20Oliveira&amp;volume=13&amp;publication_year=2023&amp;pages=1154318&amp;pmid=36994202&amp;doi=10.3389/fonc.2023.1154318&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0051">
<cite>

Honari, M.
, Shafabakhsh R., Reiter R. J., Mirzaei H., and Asemi Z.. 2019. “Resveratrol Is a Promising Agent for Colorectal Cancer Prevention and Treatment: Focus on Molecular Mechanisms.” Cancer Cell International
19, no. 1: 1–8.
</cite> [<a href="https://doi.org/10.1186/s12935-019-0906-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6631492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31341423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell%20International&amp;title=Resveratrol%20Is%20a%20Promising%20Agent%20for%20Colorectal%20Cancer%20Prevention%20and%20Treatment:%20Focus%20on%20Molecular%20Mechanisms&amp;author=M.%20Honari&amp;author=R.%20Shafabakhsh&amp;author=R.%20J.%20Reiter&amp;author=H.%20Mirzaei&amp;author=Z.%20Asemi&amp;volume=19&amp;issue=1&amp;publication_year=2019&amp;pages=1-8&amp;pmid=31341423&amp;doi=10.1186/s12935-019-0906-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0052">
<cite>

Hou, C.
, Lu L., Liu Z., Lian Y., and Xiao J.. 2021. “Resveratrol Reduces Drug Resistance of SCLC Cells by Suppressing the Inflammatory Microenvironment and the STAT3/VEGF Pathway.” FEBS Open Bio
11, no. 8: 2256–2265.</cite> [<a href="https://doi.org/10.1002/2211-5463.13230" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8329954/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34129726/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Open%20Bio&amp;title=Resveratrol%20Reduces%20Drug%20Resistance%20of%20SCLC%20Cells%20by%20Suppressing%20the%20Inflammatory%20Microenvironment%20and%20the%20STAT3/VEGF%20Pathway&amp;author=C.%20Hou&amp;author=L.%20Lu&amp;author=Z.%20Liu&amp;author=Y.%20Lian&amp;author=J.%20Xiao&amp;volume=11&amp;issue=8&amp;publication_year=2021&amp;pages=2256-2265&amp;pmid=34129726&amp;doi=10.1002/2211-5463.13230&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0053">
<cite>

Howells, L. M.
, Berry D. P., Elliott P. J., et al. 2011. “Phase I Randomized, Double‐Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients With Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics.” Cancer Prevention Research
4, no. 9: 1419–1425.
</cite> [<a href="https://doi.org/10.1158/1940-6207.CAPR-11-0148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3173869/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21680702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Prevention%20Research&amp;title=Phase%20I%20Randomized,%20Double%E2%80%90Blind%20Pilot%20Study%20of%20Micronized%20Resveratrol%20(SRT501)%20in%20Patients%20With%20Hepatic%20Metastases%E2%80%94Safety,%20Pharmacokinetics,%20and%20Pharmacodynamics&amp;author=L.%20M.%20Howells&amp;author=D.%20P.%20Berry&amp;author=P.%20J.%20Elliott&amp;volume=4&amp;issue=9&amp;publication_year=2011&amp;pages=1419-1425&amp;pmid=21680702&amp;doi=10.1158/1940-6207.CAPR-11-0148&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0054">
<cite>

Howells, L. M.
, Iwuji C. O. O., Irving G. R. B., et al. 2019. “Curcumin Combined With FOLFOX Chemotherapy Is Safe and Tolerable in Patients With Metastatic Colorectal Cancer in a Randomized Phase IIa Trial.” Journal of Nutrition
149, no. 7: 1133–1139.
</cite> [<a href="https://doi.org/10.1093/jn/nxz029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6602900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31132111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nutrition&amp;title=Curcumin%20Combined%20With%20FOLFOX%20Chemotherapy%20Is%20Safe%20and%20Tolerable%20in%20Patients%20With%20Metastatic%20Colorectal%20Cancer%20in%20a%20Randomized%20Phase%20IIa%20Trial&amp;author=L.%20M.%20Howells&amp;author=C.%20O.%20O.%20Iwuji&amp;author=G.%20R.%20B.%20Irving&amp;volume=149&amp;issue=7&amp;publication_year=2019&amp;pages=1133-1139&amp;pmid=31132111&amp;doi=10.1093/jn/nxz029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0055">
<cite>

Hubbard, J. M.
, and Grothey A.. 2017. “Napabucasin: An Update on the First‐In‐Class Cancer Stemness Inhibitor.” Drugs
77, no. 10: 1091–1103.
</cite> [<a href="https://doi.org/10.1007/s40265-017-0759-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28573435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Napabucasin:%20An%20Update%20on%20the%20First%E2%80%90In%E2%80%90Class%20Cancer%20Stemness%20Inhibitor&amp;author=J.%20M.%20Hubbard&amp;author=A.%20Grothey&amp;volume=77&amp;issue=10&amp;publication_year=2017&amp;pages=1091-1103&amp;pmid=28573435&amp;doi=10.1007/s40265-017-0759-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0056">
<cite>

Jaisamut, P.
, Wiwattanawongsa K., and Wiwattanapatapee R.. 2017. “A Novel Self‐Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol.” Planta Medica
83, no. 5: 461–467.
</cite> [<a href="https://doi.org/10.1055/s-0042-108734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27280934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Planta%20Medica&amp;title=A%20Novel%20Self%E2%80%90Microemulsifying%20System%20for%20the%20Simultaneous%20Delivery%20and%20Enhanced%20Oral%20Absorption%20of%20Curcumin%20and%20Resveratrol&amp;author=P.%20Jaisamut&amp;author=K.%20Wiwattanawongsa&amp;author=R.%20Wiwattanapatapee&amp;volume=83&amp;issue=5&amp;publication_year=2017&amp;pages=461-467&amp;pmid=27280934&amp;doi=10.1055/s-0042-108734&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0057">
<cite>

Jakobušić Brala, C.
, Karković Marković A., Kugić A., Torić J., and Barbarić M.. 2023. “Combination Chemotherapy With Selected Polyphenols in Preclinical and Clinical Studies—An Update Overview.” Molecules
28, no. 9: 3746.
</cite> [<a href="https://doi.org/10.3390/molecules28093746" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10180288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37175156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=Combination%20Chemotherapy%20With%20Selected%20Polyphenols%20in%20Preclinical%20and%20Clinical%20Studies%E2%80%94An%20Update%20Overview&amp;author=C.%20Jakobu%C5%A1i%C4%87%20Brala&amp;author=A.%20Karkovi%C4%87%20Markovi%C4%87&amp;author=A.%20Kugi%C4%87&amp;author=J.%20Tori%C4%87&amp;author=M.%20Barbari%C4%87&amp;volume=28&amp;issue=9&amp;publication_year=2023&amp;pages=3746&amp;pmid=37175156&amp;doi=10.3390/molecules28093746&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0058">
<cite>

Jayasingam, S. D.
, Citartan M., Thang T. H., Mat Zin A. A., Ang K. C., and Ch'ng E. S.. 2020. “Evaluating the Polarization of Tumor‐Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice.” Frontiers in Oncology
9: 1512.
</cite> [<a href="https://doi.org/10.3389/fonc.2019.01512" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6992653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32039007/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=Evaluating%20the%20Polarization%20of%20Tumor%E2%80%90Associated%20Macrophages%20Into%20M1%20and%20M2%20Phenotypes%20in%20Human%20Cancer%20Tissue:%20Technicalities%20and%20Challenges%20in%20Routine%20Clinical%20Practice&amp;author=S.%20D.%20Jayasingam&amp;author=M.%20Citartan&amp;author=T.%20H.%20Thang&amp;author=A.%20A.%20Mat%20Zin&amp;author=K.%20C.%20Ang&amp;volume=9&amp;publication_year=2020&amp;pages=1512&amp;pmid=32039007&amp;doi=10.3389/fonc.2019.01512&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0059">
<cite>

Johnson, D. E.
, O'Keefe R. A., and Grandis J. R.. 2018. “Targeting the IL‐6/JAK/STAT3 Signalling Axis in Cancer.” Nature Reviews Clinical Oncology
15, no. 4: 234–248.</cite> [<a href="https://doi.org/10.1038/nrclinonc.2018.8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5858971/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29405201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Targeting%20the%20IL%E2%80%906/JAK/STAT3%20Signalling%20Axis%20in%20Cancer&amp;author=D.%20E.%20Johnson&amp;author=R.%20A.%20O'Keefe&amp;author=J.%20R.%20Grandis&amp;volume=15&amp;issue=4&amp;publication_year=2018&amp;pages=234-248&amp;pmid=29405201&amp;doi=10.1038/nrclinonc.2018.8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0060">
<cite>

Juan, M. E.
, Vinardell M. P., and Planas J. M.. 2002. “The Daily Oral Administration of High Doses of Trans‐Resveratrol to Rats for 28 Days Is Not Harmful.” Journal of Nutrition
132, no. 2: 257–260.
</cite> [<a href="https://doi.org/10.1093/jn/132.2.257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11823587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nutrition&amp;title=The%20Daily%20Oral%20Administration%20of%20High%20Doses%20of%20Trans%E2%80%90Resveratrol%20to%20Rats%20for%2028%E2%80%89Days%20Is%20Not%20Harmful&amp;author=M.%20E.%20Juan&amp;author=M.%20P.%20Vinardell&amp;author=J.%20M.%20Planas&amp;volume=132&amp;issue=2&amp;publication_year=2002&amp;pages=257-260&amp;pmid=11823587&amp;doi=10.1093/jn/132.2.257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0061">
<cite>

Kabir, M. T.
, Rahman M. H., Akter R., et al. 2021. “Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers.” Biomolecules
11, no. 3: 392.
</cite> [<a href="https://doi.org/10.3390/biom11030392" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8001478/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33800000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomolecules&amp;title=Potential%20Role%20of%20Curcumin%20and%20Its%20Nanoformulations%20to%20Treat%20Various%20Types%20of%20Cancers&amp;author=M.%20T.%20Kabir&amp;author=M.%20H.%20Rahman&amp;author=R.%20Akter&amp;volume=11&amp;issue=3&amp;publication_year=2021&amp;pages=392&amp;pmid=33800000&amp;doi=10.3390/biom11030392&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0062">
<cite>

Kang, J.‐H.
, Jang Y. S., Lee H. J., Lee C. Y., Shin D. Y., and Oh S. H.. 2019. “Inhibition of STAT3 Signaling Induces Apoptosis and Suppresses Growth of Lung Cancer: Good and Bad.” Laboratory Animal Research
35: 1–9.
</cite> [<a href="https://doi.org/10.1186/s42826-019-0030-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7081529/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32257917/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Laboratory%20Animal%20Research&amp;title=Inhibition%20of%20STAT3%20Signaling%20Induces%20Apoptosis%20and%20Suppresses%20Growth%20of%20Lung%20Cancer:%20Good%20and%20Bad&amp;author=J.%E2%80%90H.%20Kang&amp;author=Y.%20S.%20Jang&amp;author=H.%20J.%20Lee&amp;author=C.%20Y.%20Lee&amp;author=D.%20Y.%20Shin&amp;volume=35&amp;publication_year=2019&amp;pages=1-9&amp;pmid=32257917&amp;doi=10.1186/s42826-019-0030-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0063">
<cite>

Kaur, P.
, Singh S. K., Mishra M. K., Singh S., and Singh R.. 2024. “Promising Combinatorial Therapeutic Strategies Against Non‐Small Cell Lung Cancer.” Cancers
16, no. 12: 2205.
</cite> [<a href="https://doi.org/10.3390/cancers16122205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11201636/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38927911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Promising%20Combinatorial%20Therapeutic%20Strategies%20Against%20Non%E2%80%90Small%20Cell%20Lung%20Cancer&amp;author=P.%20Kaur&amp;author=S.%20K.%20Singh&amp;author=M.%20K.%20Mishra&amp;author=S.%20Singh&amp;author=R.%20Singh&amp;volume=16&amp;issue=12&amp;publication_year=2024&amp;pages=2205&amp;pmid=38927911&amp;doi=10.3390/cancers16122205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0064">
<cite>

Kim, B.‐H.
, Yi E. H., and Ye S.‐K.. 2016. “Signal Transducer and Activator of Transcription 3 as a Therapeutic Target for Cancer and the Tumor Microenvironment.” Archives of Pharmacal Research
39: 1085–1099.
</cite> [<a href="https://doi.org/10.1007/s12272-016-0795-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27515050/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Archives%20of%20Pharmacal%20Research&amp;title=Signal%20Transducer%20and%20Activator%20of%20Transcription%203%20as%20a%20Therapeutic%20Target%20for%20Cancer%20and%20the%20Tumor%20Microenvironment&amp;author=B.%E2%80%90H.%20Kim&amp;author=E.%20H.%20Yi&amp;author=S.%E2%80%90K.%20Ye&amp;volume=39&amp;publication_year=2016&amp;pages=1085-1099&amp;pmid=27515050&amp;doi=10.1007/s12272-016-0795-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0065">
<cite>

Ko, J.‐H.
, Sethi G., Um J. Y., et al. 2017. “The Role of Resveratrol in Cancer Therapy.” International Journal of Molecular Sciences
18, no. 12: 2589.
</cite> [<a href="https://doi.org/10.3390/ijms18122589" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5751192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29194365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=The%20Role%20of%20Resveratrol%20in%20Cancer%20Therapy&amp;author=J.%E2%80%90H.%20Ko&amp;author=G.%20Sethi&amp;author=J.%20Y.%20Um&amp;volume=18&amp;issue=12&amp;publication_year=2017&amp;pages=2589&amp;pmid=29194365&amp;doi=10.3390/ijms18122589&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0066">
<cite>

Kumaran, M. S.
, Dabas G., Kapadia A. B., and Parsad D.. 2018. “Resveratrol‐Induced Thrombocytopenia: Inadvertent Side‐Effect of a Commonly Used Antioxidant.” Dermatologic Therapy
31, no. 1: 1–4.</cite> [<a href="https://doi.org/10.1111/dth.12578" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29193562/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dermatologic%20Therapy&amp;title=Resveratrol%E2%80%90Induced%20Thrombocytopenia:%20Inadvertent%20Side%E2%80%90Effect%20of%20a%20Commonly%20Used%20Antioxidant&amp;author=M.%20S.%20Kumaran&amp;author=G.%20Dabas&amp;author=A.%20B.%20Kapadia&amp;author=D.%20Parsad&amp;volume=31&amp;issue=1&amp;publication_year=2018&amp;pages=1-4&amp;pmid=29193562&amp;doi=10.1111/dth.12578&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0067">
<cite>

Kundu, J. K.
, and Surh Y.‐J.. 2008. “Cancer Chemopreventive and Therapeutic Potential of Resveratrol: Mechanistic Perspectives.” Cancer Letters
269, no. 2: 243–261.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2008.03.057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18550275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Letters&amp;title=Cancer%20Chemopreventive%20and%20Therapeutic%20Potential%20of%20Resveratrol:%20Mechanistic%20Perspectives&amp;author=J.%20K.%20Kundu&amp;author=Y.%E2%80%90J.%20Surh&amp;volume=269&amp;issue=2&amp;publication_year=2008&amp;pages=243-261&amp;pmid=18550275&amp;doi=10.1016/j.canlet.2008.03.057&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0068">
<cite>

Lee, S. H.

2019. “Chemotherapy for Lung Cancer in the Era of Personalized Medicine.” Tuberculosis Respiratory Disease
82, no. 3: 179–189.</cite> [<a href="https://doi.org/10.4046/trd.2018.0068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6609523/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30841023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tuberculosis%20Respiratory%20Disease&amp;title=Chemotherapy%20for%20Lung%20Cancer%20in%20the%20Era%20of%20Personalized%20Medicine&amp;author=S.%20H.%20Lee&amp;volume=82&amp;issue=3&amp;publication_year=2019&amp;pages=179-189&amp;pmid=30841023&amp;doi=10.4046/trd.2018.0068&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0069">
<cite>

Lei, M.

2005. “The MCM Complex: Its Role in DNA Replication and Implications for Cancer Therapy.” Current Cancer Drug Targets
5, no. 5: 365–380.
</cite> [<a href="https://doi.org/10.2174/1568009054629654" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16101384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Cancer%20Drug%20Targets&amp;title=The%20MCM%20Complex:%20Its%20Role%20in%20DNA%20Replication%20and%20Implications%20for%20Cancer%20Therapy&amp;author=M.%20Lei&amp;volume=5&amp;issue=5&amp;publication_year=2005&amp;pages=365-380&amp;pmid=16101384&amp;doi=10.2174/1568009054629654&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0070">
<cite>

Lelli, D.
, Pedone C., Majeed M., and Sahebkar A.. 2017. “Curcumin and Lung Cancer: The Role of microRNAs.” Current Pharmaceutical Design
23, no. 23: 3440–3444.
</cite> [<a href="https://doi.org/10.2174/1381612823666170109144818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28067164/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Pharmaceutical%20Design&amp;title=Curcumin%20and%20Lung%20Cancer:%20The%20Role%20of%20microRNAs&amp;author=D.%20Lelli&amp;author=C.%20Pedone&amp;author=M.%20Majeed&amp;author=A.%20Sahebkar&amp;volume=23&amp;issue=23&amp;publication_year=2017&amp;pages=3440-3444&amp;pmid=28067164&amp;doi=10.2174/1381612823666170109144818&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0071">
<cite>

Levi, F.
, Pasche C., Lucchini F., Ghidoni R., Ferraroni M., and la Vecchia C.. 2005. “Resveratrol and Breast Cancer Risk.” European Journal of Cancer Prevention
14, no. 2: 139–142.
</cite> [<a href="https://doi.org/10.1097/00008469-200504000-00009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15785317/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer%20Prevention&amp;title=Resveratrol%20and%20Breast%20Cancer%20Risk&amp;author=F.%20Levi&amp;author=C.%20Pasche&amp;author=F.%20Lucchini&amp;author=R.%20Ghidoni&amp;author=M.%20Ferraroni&amp;volume=14&amp;issue=2&amp;publication_year=2005&amp;pages=139-142&amp;pmid=15785317&amp;doi=10.1097/00008469-200504000-00009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0072">
<cite>

Levis, M.
, Gastino A., de Giorgi G., et al. 2023. “Modern Stereotactic Radiotherapy for Brain Metastases From Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches.” Cancers
15, no. 18: 4622.
</cite> [<a href="https://doi.org/10.3390/cancers15184622" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10526239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37760591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Modern%20Stereotactic%20Radiotherapy%20for%20Brain%20Metastases%20From%20Lung%20Cancer:%20Current%20Trends%20and%20Future%20Perspectives%20Based%20on%20Integrated%20Translational%20Approaches&amp;author=M.%20Levis&amp;author=A.%20Gastino&amp;author=G.%20de%20Giorgi&amp;volume=15&amp;issue=18&amp;publication_year=2023&amp;pages=4622&amp;pmid=37760591&amp;doi=10.3390/cancers15184622&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0073">
<cite>

Li, C.
, Lei S., Ding L., et al. 2023. “Global Burden and Trends of Lung Cancer Incidence and Mortality.” Chinese Medical Journal
136, no. 13: 1583–1590.
</cite> [<a href="https://doi.org/10.1097/CM9.0000000000002529" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10325747/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37027426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chinese%20Medical%20Journal&amp;title=Global%20Burden%20and%20Trends%20of%20Lung%20Cancer%20Incidence%20and%20Mortality&amp;author=C.%20Li&amp;author=S.%20Lei&amp;author=L.%20Ding&amp;volume=136&amp;issue=13&amp;publication_year=2023&amp;pages=1583-1590&amp;pmid=37027426&amp;doi=10.1097/CM9.0000000000002529&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0074">
<cite>

Li, J.
, Yin Z., Huang B., Xu K., and Su J.. 2022. “Stat3 Signaling Pathway: A Future Therapeutic Target for Bone‐Related Diseases.” Frontiers in Pharmacology
13: 897539.
</cite> [<a href="https://doi.org/10.3389/fphar.2022.897539" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9081430/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35548357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Pharmacology&amp;title=Stat3%20Signaling%20Pathway:%20A%20Future%20Therapeutic%20Target%20for%20Bone%E2%80%90Related%20Diseases&amp;author=J.%20Li&amp;author=Z.%20Yin&amp;author=B.%20Huang&amp;author=K.%20Xu&amp;author=J.%20Su&amp;volume=13&amp;publication_year=2022&amp;pages=897539&amp;pmid=35548357&amp;doi=10.3389/fphar.2022.897539&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0075">
<cite>

Li, J.
, Zhong X., Zhao Y., Shen J., Pilapong C., and Xiao Z.. 2022. “Polyphenols as Lung Cancer Chemopreventive Agents by Targeting microRNAs.” Molecules
27, no. 18: 5903.
</cite> [<a href="https://doi.org/10.3390/molecules27185903" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9503430/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36144639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=Polyphenols%20as%20Lung%20Cancer%20Chemopreventive%20Agents%20by%20Targeting%20microRNAs&amp;author=J.%20Li&amp;author=X.%20Zhong&amp;author=Y.%20Zhao&amp;author=J.%20Shen&amp;author=C.%20Pilapong&amp;volume=27&amp;issue=18&amp;publication_year=2022&amp;pages=5903&amp;pmid=36144639&amp;doi=10.3390/molecules27185903&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0076">
<cite>

Li, Q.
, Yuan D., Ma C., et al. 2016. “A New Hope: The Immunotherapy in Small Cell Lung Cancer.” Neoplasma
63, no. 3: 342–350.
</cite> [<a href="https://doi.org/10.4149/302_151001N511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26925794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasma&amp;title=A%20New%20Hope:%20The%20Immunotherapy%20in%20Small%20Cell%20Lung%20Cancer&amp;author=Q.%20Li&amp;author=D.%20Yuan&amp;author=C.%20Ma&amp;volume=63&amp;issue=3&amp;publication_year=2016&amp;pages=342-350&amp;pmid=26925794&amp;doi=10.4149/302_151001N511&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0077">
<cite>

Li, X.
, Wang D., Zhao Q. C., Shi T., and Chen J.. 2016. “Resveratrol Inhibited Non–Small Cell Lung Cancer Through Inhibiting STAT‐3 Signaling.” American Journal of the Medical Sciences
352, no. 5: 524–530.
</cite> [<a href="https://doi.org/10.1016/j.amjms.2016.08.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27865301/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20the%20Medical%20Sciences&amp;title=Resveratrol%20Inhibited%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20Through%20Inhibiting%20STAT%E2%80%903%20Signaling&amp;author=X.%20Li&amp;author=D.%20Wang&amp;author=Q.%20C.%20Zhao&amp;author=T.%20Shi&amp;author=J.%20Chen&amp;volume=352&amp;issue=5&amp;publication_year=2016&amp;pages=524-530&amp;pmid=27865301&amp;doi=10.1016/j.amjms.2016.08.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0078">
<cite>

Liang, G.
, Yang S., Zhou H., et al. 2009. “Synthesis, Crystal Structure and Anti‐Inflammatory Properties of Curcumin Analogues.” European Journal of Medicinal Chemistry
44, no. 2: 915–919.
</cite> [<a href="https://doi.org/10.1016/j.ejmech.2008.01.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18336957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Medicinal%20Chemistry&amp;title=Synthesis,%20Crystal%20Structure%20and%20Anti%E2%80%90Inflammatory%20Properties%20of%20Curcumin%20Analogues&amp;author=G.%20Liang&amp;author=S.%20Yang&amp;author=H.%20Zhou&amp;volume=44&amp;issue=2&amp;publication_year=2009&amp;pages=915-919&amp;pmid=18336957&amp;doi=10.1016/j.ejmech.2008.01.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0079">
<cite>

Liang, Z.
, Wu G., Fan C., et al. 2016. “The Emerging Role of Signal Transducer and Activator of Transcription 3 in Cerebral Ischemic and Hemorrhagic Stroke.” Progress in Neurobiology
137: 1–16.
</cite> [<a href="https://doi.org/10.1016/j.pneurobio.2015.11.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26738445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Progress%20in%20Neurobiology&amp;title=The%20Emerging%20Role%20of%20Signal%20Transducer%20and%20Activator%20of%20Transcription%203%20in%20Cerebral%20Ischemic%20and%20Hemorrhagic%20Stroke&amp;author=Z.%20Liang&amp;author=G.%20Wu&amp;author=C.%20Fan&amp;volume=137&amp;publication_year=2016&amp;pages=1-16&amp;pmid=26738445&amp;doi=10.1016/j.pneurobio.2015.11.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0080">
<cite>

Liu, D.
, He B., Lin L., Malhotra A., and Yuan N.. 2019. “Potential of Curcumin and Resveratrol as Biochemical and Biophysical Modulators During Lung Cancer in Rats.” Drug and Chemical Toxicology
42, no. 3: 328–334.
</cite> [<a href="https://doi.org/10.1080/01480545.2018.1523921" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30484721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20and%20Chemical%20Toxicology&amp;title=Potential%20of%20Curcumin%20and%20Resveratrol%20as%20Biochemical%20and%20Biophysical%20Modulators%20During%20Lung%20Cancer%20in%20Rats&amp;author=D.%20Liu&amp;author=B.%20He&amp;author=L.%20Lin&amp;author=A.%20Malhotra&amp;author=N.%20Yuan&amp;volume=42&amp;issue=3&amp;publication_year=2019&amp;pages=328-334&amp;pmid=30484721&amp;doi=10.1080/01480545.2018.1523921&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0081">
<cite>

Liu, J.
, Chen Z., Li Y., Zhao W., Wu J. B., and Zhang Z.. 2021. “PD‐1/PD‐L1 Checkpoint Inhibitors in Tumor Immunotherapy.” Frontiers in Pharmacology
12: 731798.
</cite> [<a href="https://doi.org/10.3389/fphar.2021.731798" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8440961/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34539412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Pharmacology&amp;title=PD%E2%80%901/PD%E2%80%90L1%20Checkpoint%20Inhibitors%20in%20Tumor%20Immunotherapy&amp;author=J.%20Liu&amp;author=Z.%20Chen&amp;author=Y.%20Li&amp;author=W.%20Zhao&amp;author=J.%20B.%20Wu&amp;volume=12&amp;publication_year=2021&amp;pages=731798&amp;pmid=34539412&amp;doi=10.3389/fphar.2021.731798&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0082">
<cite>

Liu, S.
, Liu J., He L., et al. 2022. “A Comprehensive Review on the Benefits and Problems of Curcumin With Respect to Human Health.” Molecules
27, no. 14: 4400.
</cite> [<a href="https://doi.org/10.3390/molecules27144400" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9319031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35889273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=A%20Comprehensive%20Review%20on%20the%20Benefits%20and%20Problems%20of%20Curcumin%20With%20Respect%20to%20Human%20Health&amp;author=S.%20Liu&amp;author=J.%20Liu&amp;author=L.%20He&amp;volume=27&amp;issue=14&amp;publication_year=2022&amp;pages=4400&amp;pmid=35889273&amp;doi=10.3390/molecules27144400&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0083">
<cite>

Lo Cascio, F.
, Marzullo P., Kayed R., and Palumbo Piccionello A.. 2021. “Curcumin as Scaffold for Drug Discovery Against Neurodegenerative Diseases.” Biomedicine
9, no. 2: 173.</cite> [<a href="https://doi.org/10.3390/biomedicines9020173" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7916200/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33572457/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicine&amp;title=Curcumin%20as%20Scaffold%20for%20Drug%20Discovery%20Against%20Neurodegenerative%20Diseases&amp;author=F.%20Lo%20Cascio&amp;author=P.%20Marzullo&amp;author=R.%20Kayed&amp;author=A.%20Palumbo%20Piccionello&amp;volume=9&amp;issue=2&amp;publication_year=2021&amp;pages=173&amp;pmid=33572457&amp;doi=10.3390/biomedicines9020173&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0084">
<cite>

Lu, K.‐H.
, Wu H. H., Lin R. C., et al. 2020. “Curcumin Analogue l48h37 Suppresses Human Osteosarcoma U2OS and Mg‐63 Cells' Migration and Invasion in Culture by Inhibition of Upa via the Jak/Stat Signaling Pathway.” Molecules
26, no. 1: 30.
</cite> [<a href="https://doi.org/10.3390/molecules26010030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7795127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33374783/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=Curcumin%20Analogue%20l48h37%20Suppresses%20Human%20Osteosarcoma%20U2OS%20and%20Mg%E2%80%9063%20Cells'%20Migration%20and%20Invasion%20in%20Culture%20by%20Inhibition%20of%20Upa%20via%20the%20Jak/Stat%20Signaling%20Pathway&amp;author=K.%E2%80%90H.%20Lu&amp;author=H.%20H.%20Wu&amp;author=R.%20C.%20Lin&amp;volume=26&amp;issue=1&amp;publication_year=2020&amp;pages=30&amp;pmid=33374783&amp;doi=10.3390/molecules26010030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0085">
<cite>

Malysa, A.
, Zhang X. M., and Bepler G.. 2024. “Minichromosome Maintenance Proteins: From DNA Replication to the DNA Damage Response.” Cells
14, no. 1: e12.</cite> [<a href="https://doi.org/10.3390/cells14010012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11719910/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39791713/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Minichromosome%20Maintenance%20Proteins:%20From%20DNA%20Replication%20to%20the%20DNA%20Damage%20Response&amp;author=A.%20Malysa&amp;author=X.%20M.%20Zhang&amp;author=G.%20Bepler&amp;volume=14&amp;issue=1&amp;publication_year=2024&amp;pages=e12&amp;pmid=39791713&amp;doi=10.3390/cells14010012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0086">
<cite>

Man, S.
, Zhang L., Cui J., Yang L., Ma L., and Gao W.. 2018. “Curcumin Enhances the Anti‐Cancer Effects of Paris Saponin II in Lung Cancer Cells.” Cell Proliferation
51, no. 4: e12458.
</cite> [<a href="https://doi.org/10.1111/cpr.12458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6528905/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29608021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Proliferation&amp;title=Curcumin%20Enhances%20the%20Anti%E2%80%90Cancer%20Effects%20of%20Paris%20Saponin%20II%20in%20Lung%20Cancer%20Cells&amp;author=S.%20Man&amp;author=L.%20Zhang&amp;author=J.%20Cui&amp;author=L.%20Yang&amp;author=L.%20Ma&amp;volume=51&amp;issue=4&amp;publication_year=2018&amp;pages=e12458&amp;pmid=29608021&amp;doi=10.1111/cpr.12458&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0087">
<cite>

Mansouri, K.
, Rasoulpoor S., Daneshkhah A., et al. 2020. “Clinical Effects of Curcumin in Enhancing Cancer Therapy: A Systematic Review.” BMC Cancer
20: 1–11.</cite> [<a href="https://doi.org/10.1186/s12885-020-07256-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7446227/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32838749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Clinical%20Effects%20of%20Curcumin%20in%20Enhancing%20Cancer%20Therapy:%20A%20Systematic%20Review&amp;author=K.%20Mansouri&amp;author=S.%20Rasoulpoor&amp;author=A.%20Daneshkhah&amp;volume=20&amp;publication_year=2020&amp;pages=1-11&amp;pmid=32838749&amp;doi=10.1186/s12885-020-07256-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0088">
<cite>

Mccoon, P. E.
, Woessner R., Grosskurth S., et al. 2015. “Abstract CT239: Clinical and Preclinical Evidence of an Immune Modulating Role for the STAT3‐Targeting ASO AZD9150 and Potential to Enhance Clinical Responses to Anti‐PDL1 Therapy.” Cancer Research
75, no. 15_Supplement: CT239.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Abstract%20CT239:%20Clinical%20and%20Preclinical%20Evidence%20of%20an%20Immune%20Modulating%20Role%20for%20the%20STAT3%E2%80%90Targeting%20ASO%20AZD9150%20and%20Potential%20to%20Enhance%20Clinical%20Responses%20to%20Anti%E2%80%90PDL1%20Therapy&amp;author=P.%20E.%20Mccoon&amp;author=R.%20Woessner&amp;author=S.%20Grosskurth&amp;volume=75&amp;issue=15_Supplement&amp;publication_year=2015&amp;pages=CT239&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0089">
<cite>

Meng, X.
, Zhou J., Zhao C. N., Gan R. Y., and Li H. B.. 2020. “Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review.” Food
9, no. 3: 340.</cite> [<a href="https://doi.org/10.3390/foods9030340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7143620/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32183376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Food&amp;title=Health%20Benefits%20and%20Molecular%20Mechanisms%20of%20Resveratrol:%20A%20Narrative%20Review&amp;author=X.%20Meng&amp;author=J.%20Zhou&amp;author=C.%20N.%20Zhao&amp;author=R.%20Y.%20Gan&amp;author=H.%20B.%20Li&amp;volume=9&amp;issue=3&amp;publication_year=2020&amp;pages=340&amp;pmid=32183376&amp;doi=10.3390/foods9030340&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0090">
<cite>

Mizutani, T.
, Masuda M., Nakai E., et al. 2008. “Genuine Functions of P‐Glycoprotein (ABCB1).” Current Drug Metabolism
9, no. 2: 167–174.
</cite> [<a href="https://doi.org/10.2174/138920008783571756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18288958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Drug%20Metabolism&amp;title=Genuine%20Functions%20of%20P%E2%80%90Glycoprotein%20(ABCB1)&amp;author=T.%20Mizutani&amp;author=M.%20Masuda&amp;author=E.%20Nakai&amp;volume=9&amp;issue=2&amp;publication_year=2008&amp;pages=167-174&amp;pmid=18288958&amp;doi=10.2174/138920008783571756&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0091">
<cite>

Mohan, C. D.
, Rangappa S., Preetham H. D., et al. 2022. “Targeting STAT3 Signaling Pathway in Cancer by Agents Derived From Mother Nature.” In Seminars in Cancer Biology, vol. 80, 157–182. Elsevier.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2020.03.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32325172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Seminars%20in%20Cancer%20Biology&amp;author=C.%20D.%20Mohan&amp;author=S.%20Rangappa&amp;author=H.%20D.%20Preetham&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0092">
<cite>

Mohrherr, J.
, Uras I. Z., Moll H. P., and Casanova E.. 2020. “STAT3: Versatile Functions in Non‐Small Cell Lung Cancer.” Cancers
12, no. 5: 1107.
</cite> [<a href="https://doi.org/10.3390/cancers12051107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7281271/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32365499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=STAT3:%20Versatile%20Functions%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer&amp;author=J.%20Mohrherr&amp;author=I.%20Z.%20Uras&amp;author=H.%20P.%20Moll&amp;author=E.%20Casanova&amp;volume=12&amp;issue=5&amp;publication_year=2020&amp;pages=1107&amp;pmid=32365499&amp;doi=10.3390/cancers12051107&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0093">
<cite>

Molenda, S.
, Sikorska A., Florczak A., Lorenc P., and Dams‐Kozlowska H.. 2023. “Oligonucleotide‐Based Therapeutics for STAT3 Targeting in Cancer–Drug Carriers Matter.” Cancers
15, no. 23: 5647.
</cite> [<a href="https://doi.org/10.3390/cancers15235647" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10705165/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38067351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Oligonucleotide%E2%80%90Based%20Therapeutics%20for%20STAT3%20Targeting%20in%20Cancer%E2%80%93Drug%20Carriers%20Matter&amp;author=S.%20Molenda&amp;author=A.%20Sikorska&amp;author=A.%20Florczak&amp;author=P.%20Lorenc&amp;author=H.%20Dams%E2%80%90Kozlowska&amp;volume=15&amp;issue=23&amp;publication_year=2023&amp;pages=5647&amp;pmid=38067351&amp;doi=10.3390/cancers15235647&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0094">
<cite>

Molina, J. R.
, Yang P., Cassivi S. D., Schild S. E., and Adjei A. A.. 2008. “Non‐Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship.” In Mayo Clinic Proceedings. Elsevier.</cite> [<a href="https://doi.org/10.4065/83.5.584" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2718421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18452692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Mayo%20Clinic%20Proceedings&amp;author=J.%20R.%20Molina&amp;author=P.%20Yang&amp;author=S.%20D.%20Cassivi&amp;author=S.%20E.%20Schild&amp;author=A.%20A.%20Adjei&amp;publication_year=2008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0095">
<cite>

Morris, R.
, Kershaw N. J., and Babon J. J.. 2018. “The Molecular Details of Cytokine Signaling via the JAK/STAT Pathway.” Protein Science
27, no. 12: 1984–2009.
</cite> [<a href="https://doi.org/10.1002/pro.3519" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6237706/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30267440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Protein%20Science&amp;title=The%20Molecular%20Details%20of%20Cytokine%20Signaling%20via%20the%20JAK/STAT%20Pathway&amp;author=R.%20Morris&amp;author=N.%20J.%20Kershaw&amp;author=J.%20J.%20Babon&amp;volume=27&amp;issue=12&amp;publication_year=2018&amp;pages=1984-2009&amp;pmid=30267440&amp;doi=10.1002/pro.3519&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0096">
<cite>

Mottaghitalab, F.
, Farokhi M., Fatahi Y., Atyabi F., and Dinarvand R.. 2019. “New Insights Into Designing Hybrid Nanoparticles for Lung Cancer: Diagnosis and Treatment.” Journal of Controlled Release
295: 250–267.
</cite> [<a href="https://doi.org/10.1016/j.jconrel.2019.01.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30639691/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Controlled%20Release&amp;title=New%20Insights%20Into%20Designing%20Hybrid%20Nanoparticles%20for%20Lung%20Cancer:%20Diagnosis%20and%20Treatment&amp;author=F.%20Mottaghitalab&amp;author=M.%20Farokhi&amp;author=Y.%20Fatahi&amp;author=F.%20Atyabi&amp;author=R.%20Dinarvand&amp;volume=295&amp;publication_year=2019&amp;pages=250-267&amp;pmid=30639691&amp;doi=10.1016/j.jconrel.2019.01.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0097">
<cite>

Mukherjee, A.
, and Khuda‐Bukhsh A. R.. 2015. “Quercetin Down‐Regulates IL‐6/STAT‐3 Signals to Induce Mitochondrial‐Mediated Apoptosis in a Nonsmall‐Cell Lung‐Cancer Cell Line, A549.” Journal of Pharmacopuncture
18, no. 1: 19–26.</cite> [<a href="https://doi.org/10.3831/KPI.2015.18.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4379472/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25830055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmacopuncture&amp;title=Quercetin%20Down%E2%80%90Regulates%20IL%E2%80%906/STAT%E2%80%903%20Signals%20to%20Induce%20Mitochondrial%E2%80%90Mediated%20Apoptosis%20in%20a%20Nonsmall%E2%80%90Cell%20Lung%E2%80%90Cancer%20Cell%20Line,%20A549&amp;author=A.%20Mukherjee&amp;author=A.%20R.%20Khuda%E2%80%90Bukhsh&amp;volume=18&amp;issue=1&amp;publication_year=2015&amp;pages=19-26&amp;pmid=25830055&amp;doi=10.3831/KPI.2015.18.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0098">
<cite>

Ostwal, V.
, Ramaswamy A., Bhargava P., et al. 2022. “A Pro‐Oxidant Combination of Resveratrol and Copper Reduces Chemotherapy‐Related Non‐Haematological Toxicities in Advanced Gastric Cancer: Results of a Prospective Open Label Phase II Single‐Arm Study (RESCU III Study).” Medical Oncology
40, no. 1: 17.
</cite> [<a href="https://doi.org/10.1007/s12032-022-01862-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36372825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medical%20Oncology&amp;title=A%20Pro%E2%80%90Oxidant%20Combination%20of%20Resveratrol%20and%20Copper%20Reduces%20Chemotherapy%E2%80%90Related%20Non%E2%80%90Haematological%20Toxicities%20in%20Advanced%20Gastric%20Cancer:%20Results%20of%20a%20Prospective%20Open%20Label%20Phase%20II%20Single%E2%80%90Arm%20Study%20(RESCU%20III%20Study)&amp;author=V.%20Ostwal&amp;author=A.%20Ramaswamy&amp;author=P.%20Bhargava&amp;volume=40&amp;issue=1&amp;publication_year=2022&amp;pages=17&amp;pmid=36372825&amp;doi=10.1007/s12032-022-01862-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0099">
<cite>

Pan, Y.
, Yu Y., Wang X., and Zhang T.. 2020. “Tumor‐Associated Macrophages in Tumor Immunity.” Frontiers in Immunology
11: 583084.
</cite> [<a href="https://doi.org/10.3389/fimmu.2020.583084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7751482/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33365025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Immunology&amp;title=Tumor%E2%80%90Associated%20Macrophages%20in%20Tumor%20Immunity&amp;author=Y.%20Pan&amp;author=Y.%20Yu&amp;author=X.%20Wang&amp;author=T.%20Zhang&amp;volume=11&amp;publication_year=2020&amp;pages=583084&amp;pmid=33365025&amp;doi=10.3389/fimmu.2020.583084&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0100">
<cite>

Panagi, I.
, and Thurston T. L.. 2023. “Ready, STAT3, Go! Bacteria in the Race for M2 Macrophage Polarisation.” Current Opinion in Microbiology
73: 102285.
</cite> [<a href="https://doi.org/10.1016/j.mib.2023.102285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36857844/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Opinion%20in%20Microbiology&amp;title=Ready,%20STAT3,%20Go!%20Bacteria%20in%20the%20Race%20for%20M2%20Macrophage%20Polarisation&amp;author=I.%20Panagi&amp;author=T.%20L.%20Thurston&amp;volume=73&amp;publication_year=2023&amp;pages=102285&amp;pmid=36857844&amp;doi=10.1016/j.mib.2023.102285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0101">
<cite>

Parakh, S.
, Ernst M., and Poh A. R.. 2021. “Multicellular Effects of STAT3 in Non‐Small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.” Cancers
13, no. 24: 6228.
</cite> [<a href="https://doi.org/10.3390/cancers13246228" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8699548/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34944848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Multicellular%20Effects%20of%20STAT3%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer:%20Mechanistic%20Insights%20and%20Therapeutic%20Opportunities&amp;author=S.%20Parakh&amp;author=M.%20Ernst&amp;author=A.%20R.%20Poh&amp;volume=13&amp;issue=24&amp;publication_year=2021&amp;pages=6228&amp;pmid=34944848&amp;doi=10.3390/cancers13246228&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0102">
<cite>

Park, W.
, Amin A. R., Chen Z. G., and Shin D. M.. 2013. “New Perspectives of Curcumin in Cancer Prevention.” Cancer Prevention Research
6, no. 5: 387–400.
</cite> [<a href="https://doi.org/10.1158/1940-6207.CAPR-12-0410" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3693758/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23466484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Prevention%20Research&amp;title=New%20Perspectives%20of%20Curcumin%20in%20Cancer%20Prevention&amp;author=W.%20Park&amp;author=A.%20R.%20Amin&amp;author=Z.%20G.%20Chen&amp;author=D.%20M.%20Shin&amp;volume=6&amp;issue=5&amp;publication_year=2013&amp;pages=387-400&amp;pmid=23466484&amp;doi=10.1158/1940-6207.CAPR-12-0410&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0103">
<cite>

Peng, Y.
, Ao M., Dong B., et al. 2021. “Anti‐Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures.” Drug Design, Development and Therapy
15: 4503–4525.
</cite> [<a href="https://doi.org/10.2147/DDDT.S327378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8572027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34754179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Design,%20Development%20and%20Therapy&amp;title=Anti%E2%80%90Inflammatory%20Effects%20of%20Curcumin%20in%20the%20Inflammatory%20Diseases:%20Status,%20Limitations%20and%20Countermeasures&amp;author=Y.%20Peng&amp;author=M.%20Ao&amp;author=B.%20Dong&amp;volume=15&amp;publication_year=2021&amp;pages=4503-4525&amp;pmid=34754179&amp;doi=10.2147/DDDT.S327378&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0104">
<cite>

Petrella, F.
, Rizzo S., Attili I., et al. 2023. “Stage III Non‐Small‐Cell Lung Cancer: An Overview of Treatment Options.” Current Oncology
30, no. 3: 3160–3175.
</cite> [<a href="https://doi.org/10.3390/curroncol30030239" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10047909/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36975452/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Oncology&amp;title=Stage%20III%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer:%20An%20Overview%20of%20Treatment%20Options&amp;author=F.%20Petrella&amp;author=S.%20Rizzo&amp;author=I.%20Attili&amp;volume=30&amp;issue=3&amp;publication_year=2023&amp;pages=3160-3175&amp;pmid=36975452&amp;doi=10.3390/curroncol30030239&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0105">
<cite>

Philips, R. L.
, Wang Y., Cheon H. J., et al. 2022. “The JAK‐STAT Pathway at 30: Much Learned, Much More to Do.” Cell
185, no. 21: 3857–3876.
</cite> [<a href="https://doi.org/10.1016/j.cell.2022.09.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9815833/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36240739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The%20JAK%E2%80%90STAT%20Pathway%20at%2030:%20Much%20Learned,%20Much%20More%20to%20Do&amp;author=R.%20L.%20Philips&amp;author=Y.%20Wang&amp;author=H.%20J.%20Cheon&amp;volume=185&amp;issue=21&amp;publication_year=2022&amp;pages=3857-3876&amp;pmid=36240739&amp;doi=10.1016/j.cell.2022.09.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0106">
<cite>

Poli, V.
, and Camporeale A.. 2015. “STAT3‐Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance.” Frontiers in Oncology
5: 121.
</cite> [<a href="https://doi.org/10.3389/fonc.2015.00121" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4459099/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26106584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=STAT3%E2%80%90Mediated%20Metabolic%20Reprograming%20in%20Cellular%20Transformation%20and%20Implications%20for%20Drug%20Resistance&amp;author=V.%20Poli&amp;author=A.%20Camporeale&amp;volume=5&amp;publication_year=2015&amp;pages=121&amp;pmid=26106584&amp;doi=10.3389/fonc.2015.00121&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0107">
<cite>

Prasetyanti, P. R.
, and Medema J. P.. 2017. “Intra‐Tumor Heterogeneity From a Cancer Stem Cell Perspective.” Molecular Cancer
16, no. 1: 1–9.
</cite> [<a href="https://doi.org/10.1186/s12943-017-0600-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5314464/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28209166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer&amp;title=Intra%E2%80%90Tumor%20Heterogeneity%20From%20a%20Cancer%20Stem%20Cell%20Perspective&amp;author=P.%20R.%20Prasetyanti&amp;author=J.%20P.%20Medema&amp;volume=16&amp;issue=1&amp;publication_year=2017&amp;pages=1-9&amp;pmid=28209166&amp;doi=10.1186/s12943-017-0600-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0108">
<cite>

Qin, J.‐J.
, Yan L., Zhang J., and Zhang W. D.. 2019. “STAT3 as a Potential Therapeutic Target in Triple Negative Breast Cancer: A Systematic Review.” Journal of Experimental &amp; Clinical Cancer Research
38: 1–16.
</cite> [<a href="https://doi.org/10.1186/s13046-019-1206-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6518732/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31088482/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Experimental%20&amp;%20Clinical%20Cancer%20Research&amp;title=STAT3%20as%20a%20Potential%20Therapeutic%20Target%20in%20Triple%20Negative%20Breast%20Cancer:%20A%20Systematic%20Review&amp;author=J.%E2%80%90J.%20Qin&amp;author=L.%20Yan&amp;author=J.%20Zhang&amp;author=W.%20D.%20Zhang&amp;volume=38&amp;publication_year=2019&amp;pages=1-16&amp;pmid=31088482&amp;doi=10.1186/s13046-019-1206-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0109">
<cite>

Quazi, S.
, and Malik J.. 2022. “Relationship Between Environmental Factors and Cancer: A Systematic Review on Environmental Carcinogens and Lung Cancer.”
10.20944/preprints202202.0162.v1.</cite> [<a href="https://doi.org/10.20944/preprints202202.0162.v1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>]</li>
<li id="fsn370829-bib-0110">
<cite>

Rassu, G.
, Sorrenti M., Catenacci L., et al. 2023. “Conjugation, Prodrug, and Co‐Administration Strategies in Support of Nanotechnologies to Improve the Therapeutic Efficacy of Phytochemicals in the Central Nervous System.” Pharmaceutics
15, no. 6: 1578.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15061578" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10305553/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37376027/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=Conjugation,%20Prodrug,%20and%20Co%E2%80%90Administration%20Strategies%20in%20Support%20of%20Nanotechnologies%20to%20Improve%20the%20Therapeutic%20Efficacy%20of%20Phytochemicals%20in%20the%20Central%20Nervous%20System&amp;author=G.%20Rassu&amp;author=M.%20Sorrenti&amp;author=L.%20Catenacci&amp;volume=15&amp;issue=6&amp;publication_year=2023&amp;pages=1578&amp;pmid=37376027&amp;doi=10.3390/pharmaceutics15061578&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0111">
<cite>

Rivera‐Espinoza, Y.
, and Muriel P.. 2009. “Pharmacological Actions of Curcumin in Liver Diseases or Damage.” Liver International
29, no. 10: 1457–1466.
</cite> [<a href="https://doi.org/10.1111/j.1478-3231.2009.02086.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19811613/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20International&amp;title=Pharmacological%20Actions%20of%20Curcumin%20in%20Liver%20Diseases%20or%20Damage&amp;author=Y.%20Rivera%E2%80%90Espinoza&amp;author=P.%20Muriel&amp;volume=29&amp;issue=10&amp;publication_year=2009&amp;pages=1457-1466&amp;pmid=19811613&amp;doi=10.1111/j.1478-3231.2009.02086.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0112">
<cite>

Robertson, I.
, Wai Hau T., Sami F., et al. 2022. “The Science of Resveratrol, Formulation, Pharmacokinetic Barriers and Its Chemotherapeutic Potential.” International Journal of Pharmaceutics
618: 121605.
</cite> [<a href="https://doi.org/10.1016/j.ijpharm.2022.121605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35227804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Pharmaceutics&amp;title=The%20Science%20of%20Resveratrol,%20Formulation,%20Pharmacokinetic%20Barriers%20and%20Its%20Chemotherapeutic%20Potential&amp;author=I.%20Robertson&amp;author=T.%20Wai%20Hau&amp;author=F.%20Sami&amp;volume=618&amp;publication_year=2022&amp;pages=121605&amp;pmid=35227804&amp;doi=10.1016/j.ijpharm.2022.121605&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0113">
<cite>

Roque, K.
, Ruiz R., Mas L., et al. 2023. “Update in Immunotherapy for Advanced Non‐Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices.” Cancers
15, no. 18: 4547.
</cite> [<a href="https://doi.org/10.3390/cancers15184547" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10526179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37760516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Update%20in%20Immunotherapy%20for%20Advanced%20Non%E2%80%90Small%20Cell%20Lung%20Cancer:%20Optimizing%20Treatment%20Sequencing%20and%20Identifying%20the%20Best%20Choices&amp;author=K.%20Roque&amp;author=R.%20Ruiz&amp;author=L.%20Mas&amp;volume=15&amp;issue=18&amp;publication_year=2023&amp;pages=4547&amp;pmid=37760516&amp;doi=10.3390/cancers15184547&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0114">
<cite>

Sadrkhanloo, M.
, Paskeh M. D. A., Hashemi M., et al. 2023. “STAT3 Signaling in Prostate Cancer Progression and Therapy Resistance: An Oncogenic Pathway With Diverse Functions.” Biomedicine &amp; Pharmacotherapy
158: 114168.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2022.114168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36916439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicine%20&amp;%20Pharmacotherapy&amp;title=STAT3%20Signaling%20in%20Prostate%20Cancer%20Progression%20and%20Therapy%20Resistance:%20An%20Oncogenic%20Pathway%20With%20Diverse%20Functions&amp;author=M.%20Sadrkhanloo&amp;author=M.%20D.%20A.%20Paskeh&amp;author=M.%20Hashemi&amp;volume=158&amp;publication_year=2023&amp;pages=114168&amp;pmid=36916439&amp;doi=10.1016/j.biopha.2022.114168&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0115">
<cite>

Sakwe, A. M.
, Nguyen T., Athanasopoulos V., Shire K., and Frappier L.. 2007. “Identification and Characterization of a Novel Component of the Human Minichromosome Maintenance Complex.” Molecular and Cellular Biology
27, no. 8: 3044–3055.
</cite> [<a href="https://doi.org/10.1128/MCB.02384-06" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1899943/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17296731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20and%20Cellular%20Biology&amp;title=Identification%20and%20Characterization%20of%20a%20Novel%20Component%20of%20the%20Human%20Minichromosome%20Maintenance%20Complex&amp;author=A.%20M.%20Sakwe&amp;author=T.%20Nguyen&amp;author=V.%20Athanasopoulos&amp;author=K.%20Shire&amp;author=L.%20Frappier&amp;volume=27&amp;issue=8&amp;publication_year=2007&amp;pages=3044-3055&amp;pmid=17296731&amp;doi=10.1128/MCB.02384-06&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0116">
<cite>

Saw, S. P.
, Ong B. H., Chua K. L. M., Takano A., and Tan D. S. W.. 2021. “Revisiting Neoadjuvant Therapy in Non‐Small‐Cell Lung Cancer.” Lancet Oncology
22, no. 11: e501–e516.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(21)00383-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34735819/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncology&amp;title=Revisiting%20Neoadjuvant%20Therapy%20in%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer&amp;author=S.%20P.%20Saw&amp;author=B.%20H.%20Ong&amp;author=K.%20L.%20M.%20Chua&amp;author=A.%20Takano&amp;author=D.%20S.%20W.%20Tan&amp;volume=22&amp;issue=11&amp;publication_year=2021&amp;pages=e501-e516&amp;pmid=34735819&amp;doi=10.1016/S1470-2045(21)00383-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0117">
<cite>

Sharma, R.

2022. “Mapping of Global, Regional and National Incidence, Mortality and Mortality‐To‐Incidence Ratio of Lung Cancer in 2020 and 2050.” International Journal of Clinical Oncology
27, no. 4: 665–675.
</cite> [<a href="https://doi.org/10.1007/s10147-021-02108-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8753949/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35020103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Clinical%20Oncology&amp;title=Mapping%20of%20Global,%20Regional%20and%20National%20Incidence,%20Mortality%20and%20Mortality%E2%80%90To%E2%80%90Incidence%20Ratio%20of%20Lung%20Cancer%20in%202020%20and%202050&amp;author=R.%20Sharma&amp;volume=27&amp;issue=4&amp;publication_year=2022&amp;pages=665-675&amp;pmid=35020103&amp;doi=10.1007/s10147-021-02108-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0118">
<cite>

Shen, Y.
, Chen J., and Li X.‐P.. 2023. “Research Advances in Immune Checkpoint Drugs for Non‐Small Cell Lung Cancer.” Journal of Drug Targeting
31, no. 7: 700–713.
</cite> [<a href="https://doi.org/10.1080/1061186X.2023.2235098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37417910/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Drug%20Targeting&amp;title=Research%20Advances%20in%20Immune%20Checkpoint%20Drugs%20for%20Non%E2%80%90Small%20Cell%20Lung%20Cancer&amp;author=Y.%20Shen&amp;author=J.%20Chen&amp;author=X.%E2%80%90P.%20Li&amp;volume=31&amp;issue=7&amp;publication_year=2023&amp;pages=700-713&amp;pmid=37417910&amp;doi=10.1080/1061186X.2023.2235098&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0119">
<cite>

Silva, A. C.
, Costa M. P., Zacaron T. M., et al. 2024. “The Role of Inhaled Chitosan‐Based Nanoparticles in Lung Cancer Therapy.” Pharmaceutics
16, no. 8: 969.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics16080969" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11359377/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39204314/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=The%20Role%20of%20Inhaled%20Chitosan%E2%80%90Based%20Nanoparticles%20in%20Lung%20Cancer%20Therapy&amp;author=A.%20C.%20Silva&amp;author=M.%20P.%20Costa&amp;author=T.%20M.%20Zacaron&amp;volume=16&amp;issue=8&amp;publication_year=2024&amp;pages=969&amp;pmid=39204314&amp;doi=10.3390/pharmaceutics16080969&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0120">
<cite>

Singh, S.
, Gomez H. J., Thakkar S., Singh S. P., and Parihar A. S.. 2023. “Overcoming Acquired Drug Resistance to Cancer Therapies Through Targeted STAT3 Inhibition.” International Journal of Molecular Sciences
24, no. 5: 4722.
</cite> [<a href="https://doi.org/10.3390/ijms24054722" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10002572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36902166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=Overcoming%20Acquired%20Drug%20Resistance%20to%20Cancer%20Therapies%20Through%20Targeted%20STAT3%20Inhibition&amp;author=S.%20Singh&amp;author=H.%20J.%20Gomez&amp;author=S.%20Thakkar&amp;author=S.%20P.%20Singh&amp;author=A.%20S.%20Parihar&amp;volume=24&amp;issue=5&amp;publication_year=2023&amp;pages=4722&amp;pmid=36902166&amp;doi=10.3390/ijms24054722&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0121">
<cite>

Sinn, K.
, Mosleh B., Steindl A., et al. 2022. “Neoadjuvant Chemoradiotherapy Is Superior to Chemotherapy Alone in Surgically Treated Stage III/N2 Non‐Small‐Cell Lung Cancer: A Retrospective Single‐Center Cohort Study.” ESMO Open
7, no. 2: 100466.
</cite> [<a href="https://doi.org/10.1016/j.esmoop.2022.100466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9058885/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35397435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=Neoadjuvant%20Chemoradiotherapy%20Is%20Superior%20to%20Chemotherapy%20Alone%20in%20Surgically%20Treated%20Stage%20III/N2%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer:%20A%20Retrospective%20Single%E2%80%90Center%20Cohort%20Study&amp;author=K.%20Sinn&amp;author=B.%20Mosleh&amp;author=A.%20Steindl&amp;volume=7&amp;issue=2&amp;publication_year=2022&amp;pages=100466&amp;pmid=35397435&amp;doi=10.1016/j.esmoop.2022.100466&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0122">
<cite>

Song, L.
, Xu R., Cai W., et al. 2023. “IL‐6 Upregulates the Expression of IL‐6R Through the JAK2/STAT3 Signalling Pathway to Promote Progression of Hepatocellular Carcinoma.” Scandinavian Journal of Immunology
98, no. 1: e13271.
</cite> [<a href="https://doi.org/10.1111/sji.13271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38441314/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scandinavian%20Journal%20of%20Immunology&amp;title=IL%E2%80%906%20Upregulates%20the%20Expression%20of%20IL%E2%80%906R%20Through%20the%20JAK2/STAT3%20Signalling%20Pathway%20to%20Promote%20Progression%20of%20Hepatocellular%20Carcinoma&amp;author=L.%20Song&amp;author=R.%20Xu&amp;author=W.%20Cai&amp;volume=98&amp;issue=1&amp;publication_year=2023&amp;pages=e13271&amp;pmid=38441314&amp;doi=10.1111/sji.13271&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0123">
<cite>

Sosa Iglesias, V.
, Giuranno L., Dubois L. J., Theys J., and Vooijs M.. 2018. “Drug Resistance in Non‐Small Cell Lung Cancer: A Potential for NOTCH Targeting?” Frontiers in Oncology
8: 267.
</cite> [<a href="https://doi.org/10.3389/fonc.2018.00267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6066509/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30087852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=Drug%20Resistance%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer:%20A%20Potential%20for%20NOTCH%20Targeting?&amp;author=V.%20Sosa%20Iglesias&amp;author=L.%20Giuranno&amp;author=L.%20J.%20Dubois&amp;author=J.%20Theys&amp;author=M.%20Vooijs&amp;volume=8&amp;publication_year=2018&amp;pages=267&amp;pmid=30087852&amp;doi=10.3389/fonc.2018.00267&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0124">
<cite>

Sukprasansap, M.
, and Chanvorachote P.. 2022. “Evidence of Potential Plant‐Derived Compounds With Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches.” Anticancer Research
42, no. 9: 4247–4258.
</cite> [<a href="https://doi.org/10.21873/anticanres.15924" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36039440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Research&amp;title=Evidence%20of%20Potential%20Plant%E2%80%90Derived%20Compounds%20With%20Anticancer%20Effects%20on%20Lung%20Cancer:%20Clinical%20and%20Molecular%20Pharmacology%20Approaches&amp;author=M.%20Sukprasansap&amp;author=P.%20Chanvorachote&amp;volume=42&amp;issue=9&amp;publication_year=2022&amp;pages=4247-4258&amp;pmid=36039440&amp;doi=10.21873/anticanres.15924&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0125">
<cite>

Sun, H.
, Huang W., Luo Z., et al. 2021. “Unraveling the Characterization of Minichromosome Maintenance Complex Component 2 (MCM2) Gene and Its SNPs Associated With Cold‐Tolerance Trait in Pacific White Shrimp (
<em>Litopenaeus vannamei</em>
).” Aquaculture Reports
19: 100610.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Aquaculture%20Reports&amp;title=Unraveling%20the%20Characterization%20of%20Minichromosome%20Maintenance%20Complex%20Component%202%20(MCM2)%20Gene%20and%20Its%20SNPs%20Associated%20With%20Cold%E2%80%90Tolerance%20Trait%20in%20Pacific%20White%20Shrimp%20(%20Litopenaeus%20vannamei%20)&amp;author=H.%20Sun&amp;author=W.%20Huang&amp;author=Z.%20Luo&amp;volume=19&amp;publication_year=2021&amp;pages=100610&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0126">
<cite>

Sun, L.
, Chen B., Jiang R., Li J., and Wang B.. 2017. “Resveratrol Inhibits Lung Cancer Growth by Suppressing M2‐Like Polarization of Tumor Associated Macrophages.” Cellular Immunology
311: 86–93.
</cite> [<a href="https://doi.org/10.1016/j.cellimm.2016.11.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27825563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cellular%20Immunology&amp;title=Resveratrol%20Inhibits%20Lung%20Cancer%20Growth%20by%20Suppressing%20M2%E2%80%90Like%20Polarization%20of%20Tumor%20Associated%20Macrophages&amp;author=L.%20Sun&amp;author=B.%20Chen&amp;author=R.%20Jiang&amp;author=J.%20Li&amp;author=B.%20Wang&amp;volume=311&amp;publication_year=2017&amp;pages=86-93&amp;pmid=27825563&amp;doi=10.1016/j.cellimm.2016.11.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0127">
<cite>

Sung, H.
, Ferlay J., Siegel R. L., et al. 2021. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians
71, no. 3: 209–249.
</cite> [<a href="https://doi.org/10.3322/caac.21660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA:%20A%20Cancer%20Journal%20for%20Clinicians&amp;title=Global%20Cancer%20Statistics%202020:%20GLOBOCAN%20Estimates%20of%20Incidence%20and%20Mortality%20Worldwide%20for%2036%20Cancers%20in%20185%20Countries&amp;author=H.%20Sung&amp;author=J.%20Ferlay&amp;author=R.%20L.%20Siegel&amp;volume=71&amp;issue=3&amp;publication_year=2021&amp;pages=209-249&amp;pmid=33538338&amp;doi=10.3322/caac.21660&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0128">
<cite>

Surh, Y.‐J.
, and Chun K.‐S.. 2007. “Cancer Chemopreventive Effects of Curcumin.” In The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, 149–172. Springer US.</cite> [<a href="https://doi.org/10.1007/978-0-387-46401-5_5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17569209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=The%20Molecular%20Targets%20and%20Therapeutic%20Uses%20of%20Curcumin%20in%20Health%20and%20Disease&amp;author=Y.%E2%80%90J.%20Surh&amp;author=K.%E2%80%90S.%20Chun&amp;publication_year=2007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0129">
<cite>

Suvarna, V.
, Chaubey P., Sangave P. C., and Singh A. K.. 2018. “An Insight of Polyphenols in Lung Cancer Chemoprevention.” In Polyphenols: Prevention and Treatment of Human Disease, 125–136. Elsevier.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Polyphenols:%20Prevention%20and%20Treatment%20of%20Human%20Disease&amp;author=V.%20Suvarna&amp;author=P.%20Chaubey&amp;author=P.%20C.%20Sangave&amp;author=A.%20K.%20Singh&amp;publication_year=2018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0130">
<cite>

Talakesh, T.
, Tabatabaee N., Atoof F., et al. 2022. “Effect of Nano‐Curcumin on Radiotherapy‐Induced Skin Reaction in Breast Cancer Patients: A Randomized, Triple‐Blind, Placebo‐Controlled Trial.” Current Radiopharmaceuticals
15, no. 4: 332–340.
</cite> [<a href="https://doi.org/10.2174/1874471015666220623104316" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35747962/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Radiopharmaceuticals&amp;title=Effect%20of%20Nano%E2%80%90Curcumin%20on%20Radiotherapy%E2%80%90Induced%20Skin%20Reaction%20in%20Breast%20Cancer%20Patients:%20A%20Randomized,%20Triple%E2%80%90Blind,%20Placebo%E2%80%90Controlled%20Trial&amp;author=T.%20Talakesh&amp;author=N.%20Tabatabaee&amp;author=F.%20Atoof&amp;volume=15&amp;issue=4&amp;publication_year=2022&amp;pages=332-340&amp;pmid=35747962&amp;doi=10.2174/1874471015666220623104316&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0131">
<cite>

Tang, L.
, Liu J., Zhu L., et al. 2018. “Curcumin Inhibits Growth of Human NCI‐H292 Lung Squamous Cell Carcinoma Cells by Increasing FOXA2 Expression.” Frontiers in Pharmacology
9: e60.</cite> [<a href="https://doi.org/10.3389/fphar.2018.00060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5801542/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29456509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Pharmacology&amp;title=Curcumin%20Inhibits%20Growth%20of%20Human%20NCI%E2%80%90H292%20Lung%20Squamous%20Cell%20Carcinoma%20Cells%20by%20Increasing%20FOXA2%20Expression&amp;author=L.%20Tang&amp;author=J.%20Liu&amp;author=L.%20Zhu&amp;volume=9&amp;publication_year=2018&amp;pages=e60&amp;pmid=29456509&amp;doi=10.3389/fphar.2018.00060&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0132">
<cite>

Tariq, M.
, Zhang J. Q., Liang G. K., He Q. J., Ding L., and Yang B.. 2017. “Gefitinib Inhibits M2‐Like Polarization of Tumor‐Associated Macrophages in Lewis Lung Cancer by Targeting the STAT6 Signaling Pathway.” Acta Pharmacologica Sinica
38, no. 11: 1501–1511.
</cite> [<a href="https://doi.org/10.1038/aps.2017.124" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5672074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29022575/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Pharmacologica%20Sinica&amp;title=Gefitinib%20Inhibits%20M2%E2%80%90Like%20Polarization%20of%20Tumor%E2%80%90Associated%20Macrophages%20in%20Lewis%20Lung%20Cancer%20by%20Targeting%20the%20STAT6%20Signaling%20Pathway&amp;author=M.%20Tariq&amp;author=J.%20Q.%20Zhang&amp;author=G.%20K.%20Liang&amp;author=Q.%20J.%20He&amp;author=L.%20Ding&amp;volume=38&amp;issue=11&amp;publication_year=2017&amp;pages=1501-1511&amp;pmid=29022575&amp;doi=10.1038/aps.2017.124&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0133">
<cite>

To, S. Q.
, Dmello R. S., Richards A. K., Ernst M., and Chand A. L.. 2022. “STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential.” Cancers
14, no. 2: 429.
</cite> [<a href="https://doi.org/10.3390/cancers14020429" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8773745/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35053592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=STAT3%20Signaling%20in%20Breast%20Cancer:%20Multicellular%20Actions%20and%20Therapeutic%20Potential&amp;author=S.%20Q.%20To&amp;author=R.%20S.%20Dmello&amp;author=A.%20K.%20Richards&amp;author=M.%20Ernst&amp;author=A.%20L.%20Chand&amp;volume=14&amp;issue=2&amp;publication_year=2022&amp;pages=429&amp;pmid=35053592&amp;doi=10.3390/cancers14020429&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0134">
<cite>

Tošić, I.
, and Frank D. A.. 2021. “STAT3 as a Mediator of Oncogenic Cellular Metabolism: Pathogenic and Therapeutic Implications.” Neoplasia
23, no. 12: 1167–1178.
</cite> [<a href="https://doi.org/10.1016/j.neo.2021.10.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8569436/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34731785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasia&amp;title=STAT3%20as%20a%20Mediator%20of%20Oncogenic%20Cellular%20Metabolism:%20Pathogenic%20and%20Therapeutic%20Implications&amp;author=I.%20To%C5%A1i%C4%87&amp;author=D.%20A.%20Frank&amp;volume=23&amp;issue=12&amp;publication_year=2021&amp;pages=1167-1178&amp;pmid=34731785&amp;doi=10.1016/j.neo.2021.10.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0135">
<cite>

Travis, W. D.
, Brambilla E., Nicholson A. G., et al. 2015. “The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.” Journal of Thoracic Oncology
10, no. 9: 1243–1260.
</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000630" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26291008/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Thoracic%20Oncology&amp;title=The%202015%20World%20Health%20Organization%20Classification%20of%20Lung%20Tumors:%20Impact%20of%20Genetic,%20Clinical%20and%20Radiologic%20Advances%20Since%20the%202004%20Classification&amp;author=W.%20D.%20Travis&amp;author=E.%20Brambilla&amp;author=A.%20G.%20Nicholson&amp;volume=10&amp;issue=9&amp;publication_year=2015&amp;pages=1243-1260&amp;pmid=26291008&amp;doi=10.1097/JTO.0000000000000630&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0136">
<cite>

Triller, N.
, Korošec P., Kern I., Košnik M., and Debeljak A.. 2006. “Multidrug Resistance in Small Cell Lung Cancer: Expression of P‐Glycoprotein, Multidrug Resistance Protein 1 and Lung Resistance Protein in Chemo‐Naive Patients and in Relapsed Disease.” Lung Cancer
54, no. 2: 235–240.
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2006.06.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16934363/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Multidrug%20Resistance%20in%20Small%20Cell%20Lung%20Cancer:%20Expression%20of%20P%E2%80%90Glycoprotein,%20Multidrug%20Resistance%20Protein%201%20and%20Lung%20Resistance%20Protein%20in%20Chemo%E2%80%90Naive%20Patients%20and%20in%20Relapsed%20Disease&amp;author=N.%20Triller&amp;author=P.%20Koro%C5%A1ec&amp;author=I.%20Kern&amp;author=M.%20Ko%C5%A1nik&amp;author=A.%20Debeljak&amp;volume=54&amp;issue=2&amp;publication_year=2006&amp;pages=235-240&amp;pmid=16934363&amp;doi=10.1016/j.lungcan.2006.06.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0137">
<cite>
U.S. Food and Drug Administration
. 2018. Notice to US Food and Drug Administration of the Conclusion That the Intended Use of Curcumin Is Generally Recognized as Safe, 822. Food and Drug Administration, GRAS Notice.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Notice%20to%20US%20Food%20and%20Drug%20Administration%20of%20the%20Conclusion%20That%20the%20Intended%20Use%20of%20Curcumin%20Is%20Generally%20Recognized%20as%20Safe&amp;publication_year=2018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0138">
<cite>

Valle‐Mendiola, A.
, and Soto‐Cruz I.. 2020. “Energy Metabolism in Cancer: The Roles of STAT3 and STAT5 in the Regulation of Metabolism‐Related Genes.” Cancers
12, no. 1: 124.
</cite> [<a href="https://doi.org/10.3390/cancers12010124" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7016889/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31947710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Energy%20Metabolism%20in%20Cancer:%20The%20Roles%20of%20STAT3%20and%20STAT5%20in%20the%20Regulation%20of%20Metabolism%E2%80%90Related%20Genes&amp;author=A.%20Valle%E2%80%90Mendiola&amp;author=I.%20Soto%E2%80%90Cruz&amp;volume=12&amp;issue=1&amp;publication_year=2020&amp;pages=124&amp;pmid=31947710&amp;doi=10.3390/cancers12010124&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0139">
<cite>

Vieira, I. R. S.
, Tessaro L., Lima A. K. O., Velloso I. P. S., and Conte‐Junior C. A.. 2023. “Recent Progress in Nanotechnology Improving the Therapeutic Potential of Polyphenols for Cancer.” Nutrients
15, no. 14: 3136.
</cite> [<a href="https://doi.org/10.3390/nu15143136" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10384266/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37513554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrients&amp;title=Recent%20Progress%20in%20Nanotechnology%20Improving%20the%20Therapeutic%20Potential%20of%20Polyphenols%20for%20Cancer&amp;author=I.%20R.%20S.%20Vieira&amp;author=L.%20Tessaro&amp;author=A.%20K.%20O.%20Lima&amp;author=I.%20P.%20S.%20Velloso&amp;author=C.%20A.%20Conte%E2%80%90Junior&amp;volume=15&amp;issue=14&amp;publication_year=2023&amp;pages=3136&amp;pmid=37513554&amp;doi=10.3390/nu15143136&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0140">
<cite>

Wan Mohd Tajuddin, W. N. B.
, Lajis N. H., Abas F., Othman I., and Naidu R.. 2019. “Mechanistic Understanding of Curcumin's Therapeutic Effects in Lung Cancer.” Nutrients
11, no. 12: 2989.
</cite> [<a href="https://doi.org/10.3390/nu11122989" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6950067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31817718/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrients&amp;title=Mechanistic%20Understanding%20of%20Curcumin's%20Therapeutic%20Effects%20in%20Lung%20Cancer&amp;author=W.%20N.%20B.%20Wan%20Mohd%20Tajuddin&amp;author=N.%20H.%20Lajis&amp;author=F.%20Abas&amp;author=I.%20Othman&amp;author=R.%20Naidu&amp;volume=11&amp;issue=12&amp;publication_year=2019&amp;pages=2989&amp;pmid=31817718&amp;doi=10.3390/nu11122989&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0141">
<cite>

Wang, C.
, Yang T., Guo X. F., and Li D.. 2019. “The Associations of Fruit and Vegetable Intake With Lung Cancer Risk in Participants With Different Smoking Status: A Meta‐Analysis of Prospective Cohort Studies.” Nutrients
11, no. 8: 1791.
</cite> [<a href="https://doi.org/10.3390/nu11081791" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6723574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31382476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrients&amp;title=The%20Associations%20of%20Fruit%20and%20Vegetable%20Intake%20With%20Lung%20Cancer%20Risk%20in%20Participants%20With%20Different%20Smoking%20Status:%20A%20Meta%E2%80%90Analysis%20of%20Prospective%20Cohort%20Studies&amp;author=C.%20Wang&amp;author=T.%20Yang&amp;author=X.%20F.%20Guo&amp;author=D.%20Li&amp;volume=11&amp;issue=8&amp;publication_year=2019&amp;pages=1791&amp;pmid=31382476&amp;doi=10.3390/nu11081791&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0142">
<cite>

Wang, H.
, Jia R., Lv T., Wang M., He S., and Zhang X.. 2020. “Resveratrol Suppresses Tumor Progression via Inhibiting STAT3/HIF‐1α/VEGF Pathway in an Orthotopic Rat Model of Non‐Small‐Cell Lung Cancer (NSCLC).” Oncotargets and Therapy
13: 7057–7063.
</cite> [<a href="https://doi.org/10.2147/OTT.S259016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7382608/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32801741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotargets%20and%20Therapy&amp;title=Resveratrol%20Suppresses%20Tumor%20Progression%20via%20Inhibiting%20STAT3/HIF%E2%80%901%CE%B1/VEGF%20Pathway%20in%20an%20Orthotopic%20Rat%20Model%20of%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer%20(NSCLC)&amp;author=H.%20Wang&amp;author=R.%20Jia&amp;author=T.%20Lv&amp;author=M.%20Wang&amp;author=S.%20He&amp;volume=13&amp;publication_year=2020&amp;pages=7057-7063&amp;pmid=32801741&amp;doi=10.2147/OTT.S259016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0143">
<cite>

Wang, J.
, Li D., Cang H., and Guo B.. 2019. “Crosstalk Between Cancer and Immune Cells: Role of Tumor‐Associated Macrophages in the Tumor Microenvironment.” Cancer Medicine
8, no. 10: 4709–4721.
</cite> [<a href="https://doi.org/10.1002/cam4.2327" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6712467/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31222971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Medicine&amp;title=Crosstalk%20Between%20Cancer%20and%20Immune%20Cells:%20Role%20of%20Tumor%E2%80%90Associated%20Macrophages%20in%20the%20Tumor%20Microenvironment&amp;author=J.%20Wang&amp;author=D.%20Li&amp;author=H.%20Cang&amp;author=B.%20Guo&amp;volume=8&amp;issue=10&amp;publication_year=2019&amp;pages=4709-4721&amp;pmid=31222971&amp;doi=10.1002/cam4.2327&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0144">
<cite>

Wang, J.
, Zhou T., Liu Y., Chen S., and Yu Z.. 2022. “Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors.” Frontiers in Pharmacology
12: 781425.
</cite> [<a href="https://doi.org/10.3389/fphar.2021.781425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8785094/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35082668/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Pharmacology&amp;title=Application%20of%20Nanoparticles%20in%20the%20Treatment%20of%20Lung%20Cancer%20With%20Emphasis%20on%20Receptors&amp;author=J.%20Wang&amp;author=T.%20Zhou&amp;author=Y.%20Liu&amp;author=S.%20Chen&amp;author=Z.%20Yu&amp;volume=12&amp;publication_year=2022&amp;pages=781425&amp;pmid=35082668&amp;doi=10.3389/fphar.2021.781425&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0145">
<cite>

Wang, J.‐Y.
, Wang X., Wang X. J., et al. 2018. “Curcumin Inhibits the Growth via Wnt/β‐Catenin Pathway in Non‐Small‐Cell Lung Cancer Cells.” European Review for Medical and Pharmacological Sciences
22, no. 21: 7492–7499.
</cite> [<a href="https://doi.org/10.26355/eurrev_201811_16290" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30468498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Review%20for%20Medical%20and%20Pharmacological%20Sciences&amp;title=Curcumin%20Inhibits%20the%20Growth%20via%20Wnt/%CE%B2%E2%80%90Catenin%20Pathway%20in%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer%20Cells&amp;author=J.%E2%80%90Y.%20Wang&amp;author=X.%20Wang&amp;author=X.%20J.%20Wang&amp;volume=22&amp;issue=21&amp;publication_year=2018&amp;pages=7492-7499&amp;pmid=30468498&amp;doi=10.26355/eurrev_201811_16290&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0146">
<cite>

Wang, T.
, Niu G., Kortylewski M., et al. 2004. “Regulation of the Innate and Adaptive Immune Responses by Stat‐3 Signaling in Tumor Cells.” Nature Medicine
10, no. 1: 48–54.</cite> [<a href="https://doi.org/10.1038/nm976" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14702634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Regulation%20of%20the%20Innate%20and%20Adaptive%20Immune%20Responses%20by%20Stat%E2%80%903%20Signaling%20in%20Tumor%20Cells&amp;author=T.%20Wang&amp;author=G.%20Niu&amp;author=M.%20Kortylewski&amp;volume=10&amp;issue=1&amp;publication_year=2004&amp;pages=48-54&amp;pmid=14702634&amp;doi=10.1038/nm976&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0147">
<cite>

Wang, Y.
, Yuan Y., Wang C., et al. 2022. “Theabrownins Produced via Chemical Oxidation of Tea Polyphenols Inhibit Human Lung Cancer Cells In Vivo and In Vitro by Suppressing the PI3K/AKT/mTOR Pathway Activation and Promoting Autophagy.” Frontiers in Nutrition
9: 858261.
</cite> [<a href="https://doi.org/10.3389/fnut.2022.858261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9070389/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35529455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Nutrition&amp;title=Theabrownins%20Produced%20via%20Chemical%20Oxidation%20of%20Tea%20Polyphenols%20Inhibit%20Human%20Lung%20Cancer%20Cells%20In%C2%A0Vivo%20and%20In%C2%A0Vitro%20by%20Suppressing%20the%20PI3K/AKT/mTOR%20Pathway%20Activation%20and%20Promoting%20Autophagy&amp;author=Y.%20Wang&amp;author=Y.%20Yuan&amp;author=C.%20Wang&amp;volume=9&amp;publication_year=2022&amp;pages=858261&amp;pmid=35529455&amp;doi=10.3389/fnut.2022.858261&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0148">
<cite>

Wong, S. C.
, Kamarudin M. N. A., and Naidu R.. 2021. “Anticancer Mechanism of Curcumin on Human Glioblastoma.” Nutrients
13, no. 3: 950.
</cite> [<a href="https://doi.org/10.3390/nu13030950" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7998496/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33809462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrients&amp;title=Anticancer%20Mechanism%20of%20Curcumin%20on%20Human%20Glioblastoma&amp;author=S.%20C.%20Wong&amp;author=M.%20N.%20A.%20Kamarudin&amp;author=R.%20Naidu&amp;volume=13&amp;issue=3&amp;publication_year=2021&amp;pages=950&amp;pmid=33809462&amp;doi=10.3390/nu13030950&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0149">
<cite>

Woodman, C.
, Vundu G., George A., and Wilson C. M.. 2021. “Applications and Strategies in Nanodiagnosis and Nanotherapy in Lung Cancer.” In Seminars in Cancer Biology, vol. 69, 349–364. Elsevier.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2020.02.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32088362/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Seminars%20in%20Cancer%20Biology&amp;author=C.%20Woodman&amp;author=G.%20Vundu&amp;author=A.%20George&amp;author=C.%20M.%20Wilson&amp;publication_year=2021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0150">
<cite>

Wu, L.
, Guo L., Liang Y., Liu X., Jiang L., and Wang L.. 2015. “Curcumin Suppresses Stem‐Like Traits of Lung Cancer Cells via Inhibiting the JAK2/STAT3 Signaling Pathway.” Oncology Reports
34, no. 6: 3311–3317.
</cite> [<a href="https://doi.org/10.3892/or.2015.4279" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26397387/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncology%20Reports&amp;title=Curcumin%20Suppresses%20Stem%E2%80%90Like%20Traits%20of%20Lung%20Cancer%20Cells%20via%20Inhibiting%20the%20JAK2/STAT3%20Signaling%20Pathway&amp;author=L.%20Wu&amp;author=L.%20Guo&amp;author=Y.%20Liang&amp;author=X.%20Liu&amp;author=L.%20Jiang&amp;volume=34&amp;issue=6&amp;publication_year=2015&amp;pages=3311-3317&amp;pmid=26397387&amp;doi=10.3892/or.2015.4279&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0151">
<cite>

Wu, S.
, Lu J., Zhu H., et al. 2024. “A Novel Axis of circKIF4A‐miR‐637‐STAT3 Promotes Brain Metastasis in Triple‐Negative Breast Cancer.” Cancer Letters
581: 216508.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2023.216508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38029538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Letters&amp;title=A%20Novel%20Axis%20of%20circKIF4A%E2%80%90miR%E2%80%90637%E2%80%90STAT3%20Promotes%20Brain%20Metastasis%20in%20Triple%E2%80%90Negative%20Breast%20Cancer&amp;author=S.%20Wu&amp;author=J.%20Lu&amp;author=H.%20Zhu&amp;volume=581&amp;publication_year=2024&amp;pages=216508&amp;pmid=38029538&amp;doi=10.1016/j.canlet.2023.216508&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0152">
<cite>

Xia, T.
, Zhang M., Lei W., et al. 2023. “Advances in the Role of STAT3 in Macrophage Polarization.” Frontiers in Immunology
14: 1160719.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1160719" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10110879/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37081874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Immunology&amp;title=Advances%20in%20the%20Role%20of%20STAT3%20in%20Macrophage%20Polarization&amp;author=T.%20Xia&amp;author=M.%20Zhang&amp;author=W.%20Lei&amp;volume=14&amp;publication_year=2023&amp;pages=1160719&amp;pmid=37081874&amp;doi=10.3389/fimmu.2023.1160719&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0153">
<cite>

Xin, W.
, and Zhang Y.. 2024. “Curcumin Activates the JNK Signaling Pathway to Promote Ferroptosis in Colon Cancer Cells.” Chemical Biology &amp; Drug Design
103, no. 3: e14468.
</cite> [<a href="https://doi.org/10.1111/cbdd.14468" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38443754/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chemical%20Biology%20&amp;%20Drug%20Design&amp;title=Curcumin%20Activates%20the%20JNK%20Signaling%20Pathway%20to%20Promote%20Ferroptosis%20in%20Colon%20Cancer%20Cells&amp;author=W.%20Xin&amp;author=Y.%20Zhang&amp;volume=103&amp;issue=3&amp;publication_year=2024&amp;pages=e14468&amp;pmid=38443754&amp;doi=10.1111/cbdd.14468&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0154">
<cite>

Xu, H.
, Tong X., Mugundu G., et al. 2019. “Population Pharmacokinetic Analysis of Danvatirsen Supporting Flat Dosing Switch.” Journal of Pharmacokinetics and Pharmacodynamics
46: 65–74.
</cite> [<a href="https://doi.org/10.1007/s10928-019-09619-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30661177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmacokinetics%20and%20Pharmacodynamics&amp;title=Population%20Pharmacokinetic%20Analysis%20of%20Danvatirsen%20Supporting%20Flat%20Dosing%20Switch&amp;author=H.%20Xu&amp;author=X.%20Tong&amp;author=G.%20Mugundu&amp;volume=46&amp;publication_year=2019&amp;pages=65-74&amp;pmid=30661177&amp;doi=10.1007/s10928-019-09619-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0155">
<cite>

Xu, J.
, Lin H., Wu G., Zhu M., and Li M.. 2021. “IL‐6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.” Frontiers in Oncology
11: 760971.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.760971" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8714735/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34976809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=IL%E2%80%906/STAT3%20Is%20a%20Promising%20Therapeutic%20Target%20for%20Hepatocellular%20Carcinoma&amp;author=J.%20Xu&amp;author=H.%20Lin&amp;author=G.%20Wu&amp;author=M.%20Zhu&amp;author=M.%20Li&amp;volume=11&amp;publication_year=2021&amp;pages=760971&amp;pmid=34976809&amp;doi=10.3389/fonc.2021.760971&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0156">
<cite>

Xu, J.
, Liu C., Wu X., and Ma J.. 2023. “Current Immune Therapeutic Strategies in Advanced or Metastatic Non‐Small Cell Lung Cancer.” Chinese Medical Journal
136, no. 15: 1765–1782.
</cite> [<a href="https://doi.org/10.1097/CM9.0000000000002536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10405997/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37257112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chinese%20Medical%20Journal&amp;title=Current%20Immune%20Therapeutic%20Strategies%20in%20Advanced%20or%20Metastatic%20Non%E2%80%90Small%20Cell%20Lung%20Cancer&amp;author=J.%20Xu&amp;author=C.%20Liu&amp;author=X.%20Wu&amp;author=J.%20Ma&amp;volume=136&amp;issue=15&amp;publication_year=2023&amp;pages=1765-1782&amp;pmid=37257112&amp;doi=10.1097/CM9.0000000000002536&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0157">
<cite>

Xu, X.
, and Zhu Y.. 2017. “Curcumin Inhibits Human Non‐Small Cell Lung Cancer Xenografts by Targeting STAT3 Pathway.” American Journal of Translational Research
9, no. 8: 3633–3641.
</cite> [<a href="/articles/PMC5575177/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28861154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Translational%20Research&amp;title=Curcumin%20Inhibits%20Human%20Non%E2%80%90Small%20Cell%20Lung%20Cancer%20Xenografts%20by%20Targeting%20STAT3%20Pathway&amp;author=X.%20Xu&amp;author=Y.%20Zhu&amp;volume=9&amp;issue=8&amp;publication_year=2017&amp;pages=3633-3641&amp;pmid=28861154&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0158">
<cite>

Xu, X.‐L.
, Deng S. L., Lian Z. X., and Yu K.. 2021. “Resveratrol Targets a Variety of Oncogenic and Oncosuppressive Signaling for Ovarian Cancer Prevention and Treatment.” Antioxidants
10, no. 11: 1718.
</cite> [<a href="https://doi.org/10.3390/antiox10111718" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8614917/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34829589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antioxidants&amp;title=Resveratrol%20Targets%20a%20Variety%20of%20Oncogenic%20and%20Oncosuppressive%20Signaling%20for%20Ovarian%20Cancer%20Prevention%20and%20Treatment&amp;author=X.%E2%80%90L.%20Xu&amp;author=S.%20L.%20Deng&amp;author=Z.%20X.%20Lian&amp;author=K.%20Yu&amp;volume=10&amp;issue=11&amp;publication_year=2021&amp;pages=1718&amp;pmid=34829589&amp;doi=10.3390/antiox10111718&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0159">
<cite>

Yang, C.‐L.
, Liu Y. Y., Ma Y. G., et al. 2012. “Curcumin Blocks Small Cell Lung Cancer Cells Migration, Invasion, Angiogenesis, Cell Cycle and Neoplasia Through Janus Kinase‐STAT3 Signalling Pathway.” PLoS One
7, no. 5: e37960.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0037960" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3360669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22662257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Curcumin%20Blocks%20Small%20Cell%20Lung%20Cancer%20Cells%20Migration,%20Invasion,%20Angiogenesis,%20Cell%20Cycle%20and%20Neoplasia%20Through%20Janus%20Kinase%E2%80%90STAT3%20Signalling%20Pathway&amp;author=C.%E2%80%90L.%20Yang&amp;author=Y.%20Y.%20Liu&amp;author=Y.%20G.%20Ma&amp;volume=7&amp;issue=5&amp;publication_year=2012&amp;pages=e37960&amp;pmid=22662257&amp;doi=10.1371/journal.pone.0037960&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0160">
<cite>

Yang, S.‐M.
, Hsu H.‐H., and Chen J.‐S.. 2017. “Recent Advances in Surgical Management of Early Lung Cancer.” Journal of the Formosan Medical Association
116, no. 12: 917–923.
</cite> [<a href="https://doi.org/10.1016/j.jfma.2017.07.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28781098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20Formosan%20Medical%20Association&amp;title=Recent%20Advances%20in%20Surgical%20Management%20of%20Early%20Lung%20Cancer&amp;author=S.%E2%80%90M.%20Yang&amp;author=H.%E2%80%90H.%20Hsu&amp;author=J.%E2%80%90S.%20Chen&amp;volume=116&amp;issue=12&amp;publication_year=2017&amp;pages=917-923&amp;pmid=28781098&amp;doi=10.1016/j.jfma.2017.07.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0161">
<cite>

Yasumoto, K.
, Hanagiri T., and Takenoyama M.. 2009. “Lung Cancer‐Associated Tumor Antigens and the Present Status of Immunotherapy Against Non‐Small‐Cell Lung Cancer.” General Thoracic and Cardiovascular Surgery
57: 449–457.
</cite> [<a href="https://doi.org/10.1007/s11748-008-0433-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19756930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=General%20Thoracic%20and%20Cardiovascular%20Surgery&amp;title=Lung%20Cancer%E2%80%90Associated%20Tumor%20Antigens%20and%20the%20Present%20Status%20of%20Immunotherapy%20Against%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer&amp;author=K.%20Yasumoto&amp;author=T.%20Hanagiri&amp;author=M.%20Takenoyama&amp;volume=57&amp;publication_year=2009&amp;pages=449-457&amp;pmid=19756930&amp;doi=10.1007/s11748-008-0433-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0162">
<cite>

Yousef, E. M.
, Furrer D., Laperriere D. L., et al. 2017. “MCM2: An Alternative to Ki‐67 for Measuring Breast Cancer Cell Proliferation.” Modern Pathology
30, no. 5: 682–697.
</cite> [<a href="https://doi.org/10.1038/modpathol.2016.231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28084344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Modern%20Pathology&amp;title=MCM2:%20An%20Alternative%20to%20Ki%E2%80%9067%20for%20Measuring%20Breast%20Cancer%20Cell%20Proliferation&amp;author=E.%20M.%20Yousef&amp;author=D.%20Furrer&amp;author=D.%20L.%20Laperriere&amp;volume=30&amp;issue=5&amp;publication_year=2017&amp;pages=682-697&amp;pmid=28084344&amp;doi=10.1038/modpathol.2016.231&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0163">
<cite>

Yousef, M.
, Vlachogiannis I. A., and Tsiani E.. 2017. “Effects of Resveratrol Against Lung Cancer: In Vitro and In Vivo Studies.” Nutrients
9, no. 11: 1231.
</cite> [<a href="https://doi.org/10.3390/nu9111231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5707703/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29125563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrients&amp;title=Effects%20of%20Resveratrol%20Against%20Lung%20Cancer:%20In%C2%A0Vitro%20and%20In%C2%A0Vivo%20Studies&amp;author=M.%20Yousef&amp;author=I.%20A.%20Vlachogiannis&amp;author=E.%20Tsiani&amp;volume=9&amp;issue=11&amp;publication_year=2017&amp;pages=1231&amp;pmid=29125563&amp;doi=10.3390/nu9111231&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0164">
<cite>

Yu, H.
, Lee H., Herrmann A., Buettner R., and Jove R.. 2014. “Revisiting STAT3 Signalling in Cancer: New and Unexpected Biological Functions.” Nature Reviews Cancer
14, no. 11: 736–746.
</cite> [<a href="https://doi.org/10.1038/nrc3818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25342631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Cancer&amp;title=Revisiting%20STAT3%20Signalling%20in%20Cancer:%20New%20and%20Unexpected%20Biological%20Functions&amp;author=H.%20Yu&amp;author=H.%20Lee&amp;author=A.%20Herrmann&amp;author=R.%20Buettner&amp;author=R.%20Jove&amp;volume=14&amp;issue=11&amp;publication_year=2014&amp;pages=736-746&amp;pmid=25342631&amp;doi=10.1038/nrc3818&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0165">
<cite>

Yu, H.
, Pardoll D., and Jove R.. 2009. “STATs in Cancer Inflammation and Immunity: A Leading Role for STAT3.” Nature Reviews Cancer
9, no. 11: 798–809.
</cite> [<a href="https://doi.org/10.1038/nrc2734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4856025/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19851315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Cancer&amp;title=STATs%20in%20Cancer%20Inflammation%20and%20Immunity:%20A%20Leading%20Role%20for%20STAT3&amp;author=H.%20Yu&amp;author=D.%20Pardoll&amp;author=R.%20Jove&amp;volume=9&amp;issue=11&amp;publication_year=2009&amp;pages=798-809&amp;pmid=19851315&amp;doi=10.1038/nrc2734&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0166">
<cite>

Yu, X.
, Zhang Y., Luo F., Zhou Q., and Zhu L.. 2024. “The Role of microRNAs in the Gastric Cancer Tumor Microenvironment.” Molecular Cancer
23, no. 1: 170.
</cite> [<a href="https://doi.org/10.1186/s12943-024-02084-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11334576/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39164671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer&amp;title=The%20Role%20of%20microRNAs%20in%20the%20Gastric%20Cancer%20Tumor%20Microenvironment&amp;author=X.%20Yu&amp;author=Y.%20Zhang&amp;author=F.%20Luo&amp;author=Q.%20Zhou&amp;author=L.%20Zhu&amp;volume=23&amp;issue=1&amp;publication_year=2024&amp;pages=170&amp;pmid=39164671&amp;doi=10.1186/s12943-024-02084-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0167">
<cite>

Zhang, L.‐X.
, Li C. X., Kakar M. U., et al. 2021. “Resveratrol (RV): A Pharmacological Review and Call for Further Research.” Biomedicine &amp; Pharmacotherapy
143: 112164.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2021.112164" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34649335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicine%20&amp;%20Pharmacotherapy&amp;title=Resveratrol%20(RV):%20A%20Pharmacological%20Review%20and%20Call%20for%20Further%20Research&amp;author=L.%E2%80%90X.%20Zhang&amp;author=C.%20X.%20Li&amp;author=M.%20U.%20Kakar&amp;volume=143&amp;publication_year=2021&amp;pages=112164&amp;pmid=34649335&amp;doi=10.1016/j.biopha.2021.112164&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0168">
<cite>

Zhang, Y.
, Yuan F., Li P., et al. 2022. “Resveratrol Inhibits HeLa Cell Proliferation by Regulating Mitochondrial Function.” Ecotoxicology and Environmental Safety
241: 113788.
</cite> [<a href="https://doi.org/10.1016/j.ecoenv.2022.113788" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35738103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ecotoxicology%20and%20Environmental%20Safety&amp;title=Resveratrol%20Inhibits%20HeLa%20Cell%20Proliferation%20by%20Regulating%20Mitochondrial%20Function&amp;author=Y.%20Zhang&amp;author=F.%20Yuan&amp;author=P.%20Li&amp;volume=241&amp;publication_year=2022&amp;pages=113788&amp;pmid=35738103&amp;doi=10.1016/j.ecoenv.2022.113788&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0169">
<cite>

Zhao, T.
, Karki N., Zoltowski B. D., and Matthews D. A.. 2022. “Allosteric Regulation in STAT3 Interdomains Is Mediated by a Rigid Core: SH2 Domain Regulation by CCD in D170A Variant.” PLoS Computational Biology
18, no. 12: e1010794.
</cite> [<a href="https://doi.org/10.1371/journal.pcbi.1010794" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9815575/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36542668/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20Computational%20Biology&amp;title=Allosteric%20Regulation%20in%20STAT3%20Interdomains%20Is%20Mediated%20by%20a%20Rigid%20Core:%20SH2%20Domain%20Regulation%20by%20CCD%20in%20D170A%20Variant&amp;author=T.%20Zhao&amp;author=N.%20Karki&amp;author=B.%20D.%20Zoltowski&amp;author=D.%20A.%20Matthews&amp;volume=18&amp;issue=12&amp;publication_year=2022&amp;pages=e1010794&amp;pmid=36542668&amp;doi=10.1371/journal.pcbi.1010794&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0170">
<cite>

Zhi, T. X.
, Liu K. Q., Cai K. Y., et al. 2022. “Anti‐Lung Cancer Activities of 1, 2, 3‐Triazole Curcumin Derivatives via Regulation of the MAPK/NF‐κB/STAT3 Signaling Pathways.” ChemMedChem
17, no. 3: e202100676.
</cite> [<a href="https://doi.org/10.1002/cmdc.202100676" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34773680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ChemMedChem&amp;title=Anti%E2%80%90Lung%20Cancer%20Activities%20of%201,%202,%203%E2%80%90Triazole%20Curcumin%20Derivatives%20via%20Regulation%20of%20the%20MAPK/NF%E2%80%90%CE%BAB/STAT3%20Signaling%20Pathways&amp;author=T.%20X.%20Zhi&amp;author=K.%20Q.%20Liu&amp;author=K.%20Y.%20Cai&amp;volume=17&amp;issue=3&amp;publication_year=2022&amp;pages=e202100676&amp;pmid=34773680&amp;doi=10.1002/cmdc.202100676&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0171">
<cite>

Zhou, F.
, Qiao M., and Zhou C.. 2021. “The Cutting‐Edge Progress of Immune‐Checkpoint Blockade in Lung Cancer.” Cellular &amp; Molecular Immunology
18, no. 2: 279–293.
</cite> [<a href="https://doi.org/10.1038/s41423-020-00577-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8027847/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33177696/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cellular%20&amp;%20Molecular%20Immunology&amp;title=The%20Cutting%E2%80%90Edge%20Progress%20of%20Immune%E2%80%90Checkpoint%20Blockade%20in%20Lung%20Cancer&amp;author=F.%20Zhou&amp;author=M.%20Qiao&amp;author=C.%20Zhou&amp;volume=18&amp;issue=2&amp;publication_year=2021&amp;pages=279-293&amp;pmid=33177696&amp;doi=10.1038/s41423-020-00577-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0172">
<cite>

Zhou, H.
, Zheng B., and McClements D. J.. 2021. “In Vitro Gastrointestinal Stability of Lipophilic Polyphenols Is Dependent on Their Oil–Water Partitioning in Emulsions: Studies on Curcumin, Resveratrol, and Quercetin.” Journal of Agricultural and Food Chemistry
69, no. 11: 3340–3350.
</cite> [<a href="https://doi.org/10.1021/acs.jafc.0c07578" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33689331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Agricultural%20and%20Food%20Chemistry&amp;title=In%20Vitro%20Gastrointestinal%20Stability%20of%20Lipophilic%20Polyphenols%20Is%20Dependent%20on%20Their%20Oil%E2%80%93Water%20Partitioning%20in%20Emulsions:%20Studies%20on%20Curcumin,%20Resveratrol,%20and%20Quercetin&amp;author=H.%20Zhou&amp;author=B.%20Zheng&amp;author=D.%20J.%20McClements&amp;volume=69&amp;issue=11&amp;publication_year=2021&amp;pages=3340-3350&amp;pmid=33689331&amp;doi=10.1021/acs.jafc.0c07578&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0173">
<cite>

Zhu, B.‐H.
, Chen H. Y., Zhan W. H., et al. 2011. “(−)‐Epigallocatechin‐3‐Gallate Inhibits VEGF Expression Induced by IL‐6 via Stat3 in Gastric Cancer.” World Journal of Gastroenterology: WJG
17, no. 18: 2315.
</cite> [<a href="https://doi.org/10.3748/wjg.v17.i18.2315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3098399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21633597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20Journal%20of%20Gastroenterology:%20WJG&amp;title=(%E2%88%92)%E2%80%90Epigallocatechin%E2%80%903%E2%80%90Gallate%20Inhibits%20VEGF%20Expression%20Induced%20by%20IL%E2%80%906%20via%20Stat3%20in%20Gastric%20Cancer&amp;author=B.%E2%80%90H.%20Zhu&amp;author=H.%20Y.%20Chen&amp;author=W.%20H.%20Zhan&amp;volume=17&amp;issue=18&amp;publication_year=2011&amp;pages=2315&amp;pmid=21633597&amp;doi=10.3748/wjg.v17.i18.2315&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0174">
<cite>

Zhu, L.
, and Chen L.. 2019. “Progress in Research on Paclitaxel and Tumor Immunotherapy.” Cellular &amp; Molecular Biology Letters
24: 1–11.
</cite> [<a href="https://doi.org/10.1186/s11658-019-0164-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6567594/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31223315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cellular%20&amp;%20Molecular%20Biology%20Letters&amp;title=Progress%20in%20Research%20on%20Paclitaxel%20and%20Tumor%20Immunotherapy&amp;author=L.%20Zhu&amp;author=L.%20Chen&amp;volume=24&amp;publication_year=2019&amp;pages=1-11&amp;pmid=31223315&amp;doi=10.1186/s11658-019-0164-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0175">
<cite>

Zhu, W.
, Qin W., Zhang K., et al. 2012. “Trans‐Resveratrol Alters Mammary Promoter Hypermethylation in Women at Increased Risk for Breast Cancer.” Nutrition and Cancer
64, no. 3: 393–400.
</cite> [<a href="https://doi.org/10.1080/01635581.2012.654926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3392022/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22332908/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrition%20and%20Cancer&amp;title=Trans%E2%80%90Resveratrol%20Alters%20Mammary%20Promoter%20Hypermethylation%20in%20Women%20at%20Increased%20Risk%20for%20Breast%20Cancer&amp;author=W.%20Zhu&amp;author=W.%20Qin&amp;author=K.%20Zhang&amp;volume=64&amp;issue=3&amp;publication_year=2012&amp;pages=393-400&amp;pmid=22332908&amp;doi=10.1080/01635581.2012.654926&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fsn370829-bib-0176">
<cite>

Zimna, A.
, and Kurpisz M.. 2015. “Hypoxia‐Inducible Factor‐1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies.” BioMed Research International
2015: 549412.
</cite> [<a href="https://doi.org/10.1155/2015/549412" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4471260/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26146622/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BioMed%20Research%20International&amp;title=Hypoxia%E2%80%90Inducible%20Factor%E2%80%901%20in%20Physiological%20and%20Pathophysiological%20Angiogenesis:%20Applications%20and%20Therapies&amp;author=A.%20Zimna&amp;author=M.%20Kurpisz&amp;volume=2015&amp;publication_year=2015&amp;pages=549412&amp;pmid=26146622&amp;doi=10.1155/2015/549412&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data used to support the findings of this study are available from the corresponding author upon request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Food Science &amp; Nutrition are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/fsn3.70829"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/FSN3-13-e70829.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12376182/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12376182/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12376182%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12376182/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12376182/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12376182/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12376182/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12376182/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="ZskhDNzwAE4tr6JHRZNgjnqWJBb7EsOURETnRqe19UzX7byDonHXww964SC8xL2L">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
